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General introduction 
 
 
“From a historical perspective, the plastic surgeon has been characterized as an innovator 
who is willing and ready to both introduce and to accept new ideas.” Stephen J. Mathes 
 
Plastic surgery restores form and function 
Plastic surgery is a unique problem-solving specialty, which, not limited by anatomical 
boundaries, performs surgery from head to toe.1 Historically, plastic surgery has mostly 
focused on form, as implied by the term “plastic”. Since the early writings of Sushruta, dating 
back to 600BC and considered by many to be the father of plastic surgery for his description 
of nose reconstruction using a cheek flap, surgeons have come a long way to restore or 
improve form in congenital and acquired defects.2 Reconstructive options include the use of 
autologous tissue or synthetic materials. While having the advantage of endless of-the-shelf 
supply and being relatively easy to place, synthetic implants also have some major 
drawbacks, such as suboptimal biocompatibility, poor integration with native tissue, rupture, 
leakage, capsular contraction, lack of natural feel and an unnatural appearance.3 Due to 
these shortcomings, there is a great demand for reconstruction of soft tissue defects using 
autologous tissue.  
 
Through persistent anatomical research a deep knowledge of the vascular system has been 
developed, and with modern day technological advancements and the advent of (super) 
microsurgery, the array of surgical options has never been greater. While numerous 
different approaches have been tested and introduced, the basic principle remains the 
same. A flap consisting of skin, fat and sometimes muscle is carefully dissected from the 
donor site and transferred locally, leaving the blood supply intact or completely freed from 
the surrounding tissue, enabling the surgeon to transfer it to a distant recipient site. In the 
latter procedure (so-called free flaps) the native vascular supply is cut, allowing the flap to 
be lifted. Once relocated the flap’s vascular pedicle is microsurgically attached to the artery 
and vein of the recipient site to restore blood flow through the tissue. If sensation or 
movement is required in free flaps, plastic surgeons are able to reconnect nerve stomps 
directly or through the use of an interposition graft. Regaining these functions leads to a 
significant improvement of the reported quality of life.4 An example of this is a recently 
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described method of DIEP flap neurotization that showed promising results.5,6 In other forms 
of breast reconstruction, particularly in autologous fat transfer, surgical neurotization is not 
possible. However, reinnervation might be obtained in a different way.   
 
Autologous fat transfer 
In spite of the benefits, free flaps have certain disadvantages. Relative to implant-based 
reconstruction, the procedure is long and difficult, there is an increased risk of donor site 
morbidities and tissue necrosis, with a longer recovery period (up to six weeks to be able to 
perform normal physical activities) and more elaborate scars. In cases where there is merely 
a volume deficit, and not skin, autologous fat transfer (AFT) or autologous fat grafting aims 
to overcome the drawbacks of free flaps.7 It entails harvesting adipose tissue through 
liposuction, processing of the lipoaspirate and subsequently injecting it back into the 
recipient site. The whole process is less time consuming and carries relatively low risks. 
Instead of introducing a foreign body such as an implant to create volume, a patient’s own 
fat is used as a filler material. Compared to other materials autologous adipose tissue is easy 
to access, harvest and work with, shows excellent biocompatibility and is increasingly 
abundant in most individuals.8 This way AFT provides form, but it has also proven to provide 
a functional effect in indications such as neuropathic pain caused by neuromas9, burns10, 
scars11,12 and post mastectomy pain syndrome.13,14 However, a major issue in AFT is that 
once grafted a substantial portion of the graft is  resorbed. This causes the volume of the 
grafted fat to decrease over time, most prominently during the first 3-6 months after the 
procedure. Retained volumes range between 40 and 80%.15-17 As a consequence final 
volume and shape are difficult to predict. Often multiple procedures are needed in order to 
achieve and maintain the desired end result. A generally accepted cause for the volume 
decrease is the lack of vascularization in the graft during the first days after fat transfer. 
 
Advanced solutions in regenerative medicine 
In order to overcome major issues such as a lack of vascularization and innervation, 
advanced solutions are investigated. Approaches include increasing the vascularization of 
the recipient site pre- and post-operatively18,19 or modifying the pro-angiogenic potential of 
a given therapy by adding single or multiple growth factors20-22, platelet-rich plasma23,24, 
regenerative cells from stromal vascular fractions16,17 or by adding isolated stem cells.25,26 
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Others have combined cell-based therapy and biomaterials through tissue engineering 
leading to interesting concepts so far. Yet, despite the initial development of scaffolds for 
reconstructing soft tissue defects27, nobody has been able to create adequately vascularized 
(and innervated) constructs of relevant size.28 While major advances have been made, and 
the idea is enticing that one day we might have off-the-shelf customizable tissue constructs, 
there is still much to be learned from harnessing the body’s own regenerative capabilities 
and technology that is able to modulate these processes. Stem cells hold the promise to help 
in extreme cases where angiogenesis may be severely impaired after prolonged ischemia or 
where central/peripheral nervous injury or neurodegeneration occurred. All biological 
examples correspond to clinical diseases like hind limb ischemia or spinal cord injury, where 
pharmacological and surgical help do not address the cause of the problem nor adequately 
modulate the microenvironment. Since the basic problem of inflammation, angiogenesis and 
regeneration is the same in plastic surgery or in any other healing process, stem cells offer 
the opportunity to explore a possible role in the restoration of form and function in plastic 
surgery.  
 
Stem cells  
In regeneration, stem cells, which are undifferentiated cells present during all stages of life, 
play a crucial role. Not only are they the predecessors of all cells in the body, they also have 
an intricate role in all major processes during the healing phase after a surgical procedure, 
such as inflammation and angiogenesis. The ability to differentiate varies between stem cells 
depending on their origin and their derivation.29 The differentiation potential can vary from 
totipotent to unipotent cells, and the origin varies from embryonic stem cells to adult stem 
cells, including tissue-resident stem cells (see figure 1). The next section will focus on 
multipotent adult (tissue-resident) stem cells: mesenchymal and hematopoietic stem cells.  
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Figure 1. Stem cell hierarchy.30 ICM = Inner Cell Mass. ESC = Embryonic Stem Cell. PGC = Primordial 
Germ Cell. EGC = Embryonic Germ Cell. FSC = Follicle Stem Cell. MSC = Mesenchynal stem cell. HSC = 
Hematopoietic Stem cell. NSC = Nerve Stem Cell. iPSC = induced Pluripotent Stem Cell.
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Bone marrow-derived mesenchymal stem cells  
Bone marrow is located within the spongy or cancellous portions of bone and is composed of 
hematopoietic cells (myeloid and lymphoid), marrow adipose tissue and supportive stromal 
cells. The stroma is heterogenic in nature and contains fibroblasts, macrophages, 
osteoblasts, osteoclasts and endothelial (stem) cells as well as mesenchymal stem cells. 
Friedenstein et al. were the first the point out a subset of precursor cells for osteoblast and 
fibrous tissue in the late 60’s.31 These cells were adherent to plastic in culture and could 
form colonies of fibroblastoid cells and were initially dubbed colony-forming-unit-fibroblasts 
(CFU-f). Later studies confirmed and extended these findings by delineating the 
multipotency and ascertain the distinction from endothelial and hematopoietic cells.32-34 
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are fibroblast-like cells which 
comprise less than 0.1% of the total population of adult bone marrow cells.35 Caplan coined 
the term mesenchymal stem cells (MSCs) to indicate the ability to differentiate into cells 
within the mesenchymal lineage36, although later studies showed they are capable of 
forming cell types outside the mesenchymal lineage such as vascular smooth muscle cells.37 
Next to their differentiation capacity, noted attributes of BM-MSCs are migration to sites of 
injury or inflammation after intravenous infusion, their ability to influence other resident 
progenitor cells, and promote recovery of damaged tissues through secretion of a variety of 
cytokines and chemokines.38,39 It is not surprising that BM-MSC have already been used 
clinically to treat a wide range of conditions and diseases, like myocardial infarction40, 
stroke41, amyotrophic lateral sclerosis42, Graft-Versus-Host-Disease after bone marrow 
transplantation43,  chronic wounds44 and several others.   
 
Hematopoietic stem cells 
Hematopoietic stem cells (HSCs) give rise to myeloid and lymphoid lineages leading to the 
production of red blood cells, white blood cells and platelets in a process called 
hematopoiesis which forms approximately 1010 cells daily.45 They were first described by Till 
and McCulloch in 1961, yet their exact definition has changed over time.46 An extraordinary 
feature of these cells is their ability to self-renew, even at extremely high turnover rates. 
Two types of HSC have been described: long-term CD34+ repopulating cells (1/100.000 cells 
in marrow) which remain active and functional throughout life, and short-term repopulating 
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cells that remain for about 6 weeks.47 Another feature of HSC is that they too are able to 
across lineages when exposed to specific stimuli.48 HSCs reside in two distinct immune-
privileged niches or locations in the bone marrow and are heavily influenced by the 
microenvironment surrounding them.49 Both the sympathetic nervous system and 
neighboring cells such as MSC play a role in regulation.50 Beside their clinical use in 
hematopoietic cell transplantation, HSC are widely investigated for their regenerative 
characteristics.45  
 
Adipose derived (mesenchymal) stem cells 
Adipose tissue contains a heterogeneous collection of cells organized in a structured mesh of 
connective tissue that is highly vascularized (see figure 2). It has the highest tissue partial 
oxygen tension of any organ.51 Adipocytes make up more than 90 percent of the volume due 
to their enormous size of 50 to 130 µm. However, they only represent 20 percent or less in 
total number of cells.52 The other cells present in fat, called stromal vascular fraction (SVF), 
comprise primarily of pre-adipocytes/adipose-derived stromal/stem cells, immune cells 
(macrophages, granulocytes and lymphocytes), endothelial (progenitor) cells, pericytes 
(progenitor) cells and fibroblasts.52,53  
 
Figure 2. Structure of human adipose tissue. Immunohistologic image on the left, further detailed by 
the electromicroscopic images on the right.51 
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Adipose-derived stem cells are adult stem cells of mesenchymal origin native to adipose 
tissue. While described as pre-adipocytes in several papers 4 decades ago54,55, the term 
“adipose-derived stromal cells (ADSC)” was coined in several pioneering studies in the early 
2000’s.56-58 Later, due to confusion over the number of different names to identify the same 
adipose tissue cell population, the International Fat Applied Technology Society reached a 
consensus to adopt the term “adipose-derived stem cell (ASC)” for further use in literature.59 
ASC are classically described to be able to differentiate into cells of the adipogenic, 
osteogenic, and chondrogenic lineages, while for example also myogenic and neural 
differentiation have been described.60,61 Although different techniques are available to 
isolate ASC, adipose tissue is generally harvested through liposuction or excision, and 
enzymatically digested to isolate the SVF. The SVF is then sorted by flow cytometry or 
directly plated in culture flasks, making use of the characteristic of ASC to adhere to plastic, 
while other cells from the SVF are washed away in subsequent medium changes. Human ASC 
have a typical fibroblast-like appearance in culture and can be phenotypically characterized 
by the following markers: CD45‒ CD235a‒ CD31‒ CD34+ with added markers in vitro of CD13, 
CD73, CD90 and CD105.62 They can be distinctly separated from endothelial (CD31+) and 
hematopoietic (CD45+) cells in the SVF. Furthermore, ASC lack expression of HLA-DR and co-
stimulatory molecules, leading them to be immune privileged. Benefits of ASC over their 
mesenchymal counterpart the “bone marrow-derived MSC (BM-MSC)” include ease of 
isolation, higher abundance of tissue itself and higher cell yields as 1 gram of adipose tissue 
yields approximately 5000 stem cells, which is a factor of 100-500 higher than MSCs from 
bone marrow.63,64 The exact location of the ASC within non-disturbed fat remains highly 
debated, but multiple studies have shown that ASC may reside within the perivascular 
tissue.65,66 ASC have been shown to function in a dual way: by transdifferentiation into 
mature cells and via paracrine mechanisms involving neighboring cells. While the first 
hypotheses on the mechanism of action of ASC focused towards differentiation, secretion of 
a myriad of cytokines and growth factors may be more important than previously thought.67 
Numerous studies have investigated the secretome of ASC, and found amongst others that 
they possess robust pro-angiogenic characteristics and immunomodulatory properties.57,60,62  
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What happens in the graft after fat transfer? 
The moment the adipose tissue is removed from the donor site it becomes ischemic. The 
liposuction process itself causes injury to the donor tissue as well as the recipient site. A 
cocktail of injury related cytokines, such as basic fibroblast growth factor and vascular 
endothelial growth factor, are released triggering a cascade of healing processes.51 
Meanwhile, inflammatory cells such as M1 macrophages and lymphocytes home in on the 
grafted area and release pro-inflammatory cytokines. M1 (or “classically activated) 
macrophages are formed in response to several inflammatory mediators such as IFN-γ and 
LPS and in turn produce a high level of pro-inflammatory cytokines such as TNF-α and IL-
6.68,69 In this time the adipocytes struggle to survive, and the way they do this is described by 
two general theories. The cell survival theory was the first one published by Peer in the 
1950’s.70 This theory states that adipocytes in grafts of certain size survive directly by 
plasmatic diffusion and early revascularization. In physiological conditions each individual fat 
cell is no more than 200-300 µm away from the nearest capillary, enabling oxygen and 
nutrients to reach the cell through diffusion. If the limit is exceeded, for example when 
grafting larger volumes of fat, the core of the graft is deprived of oxygen and nutrients 
leading to cell death. Later studies by the Yoshimura group with the use of more 
sophisticated technology, showed that actually most adipocytes in the fat graft die within 24 
hours.71,72 The authors describe three distinguishable zones in fat grafts: the outer surviving 
zone in which all of the cells survive through diffusion, the middle “regenerating” zone in 
which only the subset of cells that are most resistant to hypoxia survive (i.e. ASC) and 
provide new adipocytes to replace the dead ones, and the central or “necrotic” zone in 
which all cells perish (see figure 3). After the initial inflammatory response, both resident 
ASC and infiltrated stem cells from bone marrow spin the micro environment more towards 
pro regeneration. M2 macrophages appear and surround the oil droplets that remain after 
adipocyte death. M2 (or “alternatively activated”) macrophages show anti-
inflammatory/regenerative properties, are induced through IL-4 and IL-13 and are 
characterized by for example  increased production of IL-10.69 In the following time period 
new adipocytes mature and vascular networks are reestablished. If the oil droplets are not 
successfully phagocytized by the macrophages, M2 macrophages will either form fibrotic 
tissue or encapsulate the oil, forming a cyst.73  
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Figure 3. The three zones in fat grafts and an overview of the events in the graft following fat 
transfer.51 
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Angiogenesis 
Angiogenesis describes the chain of events leading to the formation of new capillary 
networks and is key in development and regeneration after injury. It is the focus of 
treatments of ischemia-related illnesses and (chronic) wounds. Therapies aim to 
revascularize a certain area of tissue by sprouting capillaries of existing collateral bloods 
vessels. This applies certainly to fat grafts, in which an avascular graft has to be 
revascularized to maintain the tissue long term. Three pioneering studies from separate 
groups in 2004 sparked interest in the pro-angiogenic effect of ASC. Rehman et al showed 
that ASC reacted to hypoxia in cell culture with increased levels of secreted VEGF by 5 fold, 
and that conditioned medium (CM) of hypoxic ASC had a beneficial effect on the growth and 
apoptosis rate of endothelial cells (EC).74 In the same year it was shown that human ASC 
assumed endothelial-like functionality in vitro and in vivo by using hind limb ischemia 
models.75,76 The hind limb ischemia model was later also used in a comparative study of 
murine ASC vs BM-MSC, adipocytes and PBS.77 Herein, injection of ASC after vessel ligation 
proved to promote angiogenesis from collateral vessels, enabling better tissue perfusion and 
increasing capillary density. Although some level of transdifferentiation towards adipocytes 
was observed more emphasis was placed on the increased expression of VEGF. While VEGF 
is a key pro-angiogenic factor, it is unlikely to be the only factor of importance. Exploratory 
studies into the secretome of ASC revealed a plethora of other angiogenesis related factors 
such as hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF/FGF-2), 
transforming growth factor β2 (TGF-β2), placental growth factor (PGF) and angiopoietins 1 
and 2 (Ang-1 and Ang-2).78 Interestingly the secretion of these factors varied after 
supplementation of different additives to the culture medium, hinting at an adaptive 
secretory profile based on the current state of the local tissue environment at any given 
time. Equally interesting was the fact that neutralizing VEGF and HGF in the CM led to 
decreased viability and migration of endothelial cells (EC). Similar effects have been seen 
after silencing expression of for example HGF. Cai et al found that this lead to a decreased 
ability to promote survival, proliferation and migration of both mature and progenitor EC in 
vitro and decreased reperfusion in the ischemic hind limb model in vivo.79  
 
More specifically in fat grafting, ASC have been shown to promote angiogenesis during the 
acute phase after surgery and form microtubules within 24hr of ischemia and capillary 
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networks within 3 days.80,81 Suga and colleagues performed an insightful study in which ASC 
were injected into inguinal fat pads of mice.82 The fluorescently labeled ASC were tracked 
through bioluminescence in the first 28 days after surgery, and although more ASC were 
present in ischemic fat pads at day 7 versus normal fat pads, very little luminescent cells 
were traced after 28 days indicating cell death.  However, proliferating EC were seen 
adjacent to the graft, which lead to the hypothesis that paracrine mechanisms might play a 
role. This hypothesis was confirmed by the finding of elevated levels of VEGF and HGF in the 
tissue lysates after 7 days, and in vitro data that revealed a stimulatory effect of ASC in EC 
proliferation and network assays, which was inhibited when neutralizing antibodies against 
VEGF or HGF were added.  
 
ASC have also been incorporated into tissue engineering, a relatively new field in which cell 
therapy is often combined with biomaterials. Yet, despite the initial development of 
scaffolds for reconstructing soft tissue defects27, so far it is impossible to create adequately 
vascularized constructs of relevant size28. The resulting lack of oxygen and nutrients prevents 
formation of a habitable environment for cells to reside in. While a multitude of techniques 
have been employed in the past to vascularize scaffolds83-85, a truly successful method for 
large volume constructs has yet to be developed.  
 
Immunomodulation by MSCs 
MSCs have been praised for their ability to influence the immune system and have therefore 
been widely used as therapeutic agents for the treatment of autoimmune diseases. 
However, MSCs are not constitutively immunosuppressive. The immunomodulatory 
characteristics are strongly influenced by signals from the surrounding microenvironment. 
MSCs need ‘priming’ by specific cytokines such as TNF-α to become immunosuppressive and 
the level of inflammation and concentration of these cytokines in the local 
microenvironment at the time of administration plays a critical role in determining the final 
outcome.86,87  
There are several ways for MSCs to mediate their effect on the immune system, ranging 
from cell to cell contact to the production of paracrine factors such as cytokines and growth 
factors88. Moreover, MSCs regulate proliferation, activation and effector functions of 
GENERAL INTRODUCTION 19
1
 
 
 
immune cells (macrophages, dendritic cells (DCs), natural killer (NK) and natural killer T (NKT) 
cells, neutrophils, basophils, eosinophils, mast cells, T and B lymphocytes), indicating their 
therapeutic potential in the treatment of autoimmune and inflammatory diseases.88  
During the early phase of inflammation MSCs promote recruitment of neutrophils to the site 
of inflammation, protect them from apoptosis and may supercharge their ability to 
phagocytize bacteria.89,90 This process is sustained by several factors that are release upon 
recognition of microbial antibodies by (tissue-resident) MSCs, such as IL-8 and macrophage 
migration inhibitory factor (MIF).91 However, during the late stage of the immune response 
even in the presence of high levels of TNF-α and IFN-γ, MSCs may induce the production of 
anti-inflammatory cytokines in monocytes/macrophages such as IL-10, inhibiting neutrophil 
migration and consequent oxidative damage.92 These findings suggest a direct regulatory 
role, in which MSCs serve to promote host defense on one hand, and at the same time 
prevent tissue damage by an excessive immune response, and focus on tissue 
regeneration.93  
 
Electrical stimulation 
In the human body various biochemical and biophysical cues are responsible for the creation 
and maintenance of tissues and organs.94 Among these are endogenous electric fields (EFs), 
which are naturally present in living organisms. Besides the well-known role of electricity in 
generating action potentials in nerves, EFs also play an important role in physiological 
processes such as embryonic development, regeneration and wound healing.95,96 EFs are 
generated through constant movement of negatively and positively charged ions across 
channels in the membrane of individual cells leading to a membrane potential. Analogous to 
the membrane potential on cell level is the macro-equivalent that occurs when cells are 
together in a continuous layer, establishing a tissue-level electric gradient across the cellular 
interface.97 An example of this is the trans-epithelial potential found in skin, lens and 
cornea.98  In case of a breach of the epithelium, such as in wounds, the potential difference 
between the two sides of the epithelium short circuits, generating an EF that is responsible 
for cell migration towards the injury site and controls cellular actions like spatial orientation 
and cell division rate.99-102   
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Building upon this knowledge, previous in vitro and in vivo studies have applied some form 
of electrical stimulation (ES), not only to accelerate wound healing but also to influence a 
variety of cells and signaling cascades. There are many types of electrical stimulation, varying 
from applied direct current (DC) to more complex stimuli (either using direct or alternating 
current) in various wave forms and stimuli patterns, generated by a multitude of chips, 
generators or therapeutic systems.94 There are also several ways to deliver the electrical 
stimulus, ranging from direct stimulation/coupling to indirect stimulation/coupling 
(capacitive coupling, inductive coupling such as pulsed electromagnetic fields (PEMF), or a 
combination of both).  
Studies so far have shown impressive results in topics such as wound healing103, bone 
healing104 and angiogenesis105. Sheikh et al demonstrated for example that ES of ischemic 
rabbit hind limbs significantly induced both arteriogenesis and angiogenesis106. The exact 
mechanisms remain to be elucidated, although in endothelial cells the enhanced release of 
VEGF and activation of VEGF receptors (VEGFRs), phosphatidylinositol-3-kinase (PI3K)-Akt 
and Rho-ROCK elements of the VEGFR signaling pathway play a significant role.107 That same 
VEGF upregulation after ES was found in BM-MSCs108 and ASCs.109 Clinical applications of ES, 
focusing specifically on modifying or amplifying the regenerative effects of stem cells could 
be a useful add-on therapy to existing treatment regimens. 
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Aim of this thesis 
 
The aim of this thesis was to investigate the effect of stem cells on the two most important 
processes that play a role in regeneration after (surgical) tissue trauma: inflammation and 
angiogenesis. A deeper understanding of the intricate sequence of events and the role of 
stem cells herein can lead to new surgical approaches and/or post-operation management. 
Grafting of autologous fat is an important tool in the plastic surgeon’s armamentarium, 
however a partial resorption of the graft remains a problem. The safety and effectiveness of 
stem cells as well as a clinical example of the regenerative effects of adipose tissue in 
neuropathic pain were studied. In the end of this thesis we performed a proof of principle 
study with the aim to develop a non-invasive, safe and low-cost technique to modify the 
behavior of adipose-derived stem cells with electrical stimulation, specifically focused 
towards improving autologous fat transfer.  
 
Outline of this thesis 
 
Chapter 2. Efficacy and Safety of Autologous Fat Transfer in Facial Reconstructive Surgery: 
A Systematic Review and Meta-analysis. 
In chapter 2, we focused specifically on autologous fat transfer thorough analysis of the 
efficacy and safety of performing autologous fat transfer in plastic surgery. We compiled the 
available clinical data in a systematic review and meta-analysis.  
Chapter 3. Autologous Fat Transfer as a Treatment for Peripheral Neuropathic Pain 
without Apparent Cause. 
In chapter 3, we tested in a clinical trial whether patients in a chronic neuropathic pain 
setting would benefit from autologous fat transfer with respect to their pain perception, 
possibly through the regenerative capabilities of cells within the transplant.  
Chapter 4. Standardized Human Bone Marrow-derived Stem Cells Infusion Improves 
Survival and Recovery in a Rat Model of Spinal Cord Injury. 
In chapter 4, we set out to investigate the immunomodulatory properties of a refined bone-
marrow derived stem cell preparation of MSCs and HSCs in an acute model of spinal cord 
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injury.  Our focus lay towards researching the anti-inflammatory properties and the effect on 
nerve regeneration in the context of improved functional outcome.  
Chapter 5. Efficacy of Different Doses of Human Autologous Adult Bone Marrow Stem Cell 
Transplantation on Angiogenesis in a Rat Model With Hind Limb Ischemia. 
In chapter 5, we administered bone marrow-derived stem cells intramuscularly and intra-
arterially in a rat hind limb ischemia model in order to stimulate angiogenesis. The surgical 
ligation of arterial blood vessels lead to an acute-onset traumatic ischemia, which enabled us 
to directly visualize the angiogenic effects of the administered stem cells.  
Chapter 6. Electrical Stimulation Promotes the Angiogenic Potential of Adipose-derived 
Stem Cells. 
In chapter 6, we electrically stimulated adipose tissue-derived stem cells in vitro to 
determine the angiogenic effect of the conditioned medium in an in vivo animal model. This 
pilot study lays the foundation for further translational studies.  
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ABSTRACT 
 
Importance:  
The use of autologous fat transfer (AFT) or lipofilling for correcting contour deformities is 
seen as one of the major breakthroughs in reconstructive plastic surgery. Its applications in 
facial reconstructive surgery have been of particular interest owing to the prospect of 
achieving autologous reconstruction by a minimally invasive approach. However, its 
unpredictability and variable degree of resorption have limited its utility and much 
scepticism still exists regarding its efficacy. Furthermore, more than 2 decades of clinical 
research have produced a highly fragmented body of evidence that has not been able to 
provide definite answers. 
Objective:  
To investigate the safety and efficacy of AFT in facial reconstruction through a systematic 
review and meta-analysis. 
Data sources:  
A literature search was performed in PubMed, Embase, and the Cochrane Library from 
inception to October 11, 2017. 
Study selection:  
All published studies investigating the efficacy and safety of AFT in facial reconstructive 
surgery. 
Data extraction and synthesis:  
Two independent reviewers performed data extraction systematically, adhering to the 
PRISMA guidelines. Summary measures were pooled in a random-effects model meta-
analysis. 
Main outcomes and measures:  
The patient and surgeon satisfaction, graft survival, number of AFT sessions, and the 
incidence of AFT-related complications were the main outcomes of interest in this meta-
analysis. 
 
AFT & FACIAL RECONSTRUCTION 33
2
 
 
 
Results:  
This systematic review resulted in the inclusion 52 relevant studies consisting of 1568 unique 
patients. These included 4 randomized clinical trials, 11 cohort studies, and 37 case series. 
The overall follow-up averaged 1.3 years after AFT. Meta-analysis revealed a very high 
overall patient satisfaction rate of 91.1% (95% CI, 85.1%-94.8%) and overall surgeon 
satisfaction rate of 88.6% (95% CI, 83.4%-92.4%). The number of AFT sessions required to 
achieve the desired result was 1.5 (95% CI, 1.3-1.7) and 50% to 60% of the injected volume 
was retained at 1 year. Only 4.8% (95% CI, 3.3%-6.9%) of procedures resulted in clinical 
complications. 
Conclusions and relevance:  
To our knowledge, this study provides the first overview of the current knowledge about AFT 
in facial reconstructive surgery. Our results confirm that AFT is an effective technique for 
treating soft-tissue deformities in the head and neck, with low rate of minor complications. 
 
 
KEY POINTS 
Question: Is autologous fat transfer (lipofilling) an effective treatment for soft tissue 
deformities in the face? 
Findings: This meta-analysis of 52 studies found AFT to be associated with a high patient 
(91%) and surgeon (89%) satisfaction after 1.5 AFT sessions. Volume retention stabilized 
at 50-60% at one year only 5% of procedures resulted in clinical complications.   
Meaning: This thorough analysis of the combined data from all published studies 
confirms that AFT is a safe and effective treatment in facial reconstructive surgery. 
 
 Introduction 1.1
Autologous fat transfer (AFT), also known as lipofilling, is regarded as an elegant technique 
that excels in correcting soft-tissue contour deformities and volume deficits in almost any 
body part. Its application in the face has always been of particular interest as it allows for 
precise titration and injection of patient’s own fat by means of a minimally invasive 
approach. AFT can play an important role in the treatment of disfiguring congenital 
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syndromes such as progressive hemifacial atrophy (Parry-Romberg Syndrome) or hemifacial 
(craniofacial) microsomia. For these disorders, the only viable alternative for correcting 
volume deficits remains the free flap transfer, which often leads to disappointing results in 
the long term due to sagging and disruption of facial musculature. Another disorder that can 
greatly benefit from AFT is HIV-associated lipodystrophy, where antiretroviral therapy can 
lead to devastating facial wasting. The prospect of restoring facial volume without relying on 
allogenic fillers of implants makes AFT a promising solution in these patients. Due to these 
properties, fat transfer has also been increasingly applied in the treatment of acquired soft-
tissue defects in the face such as adhesive scars and even burns (Figure 1).
Figure 1: Indications of AFT in the face: A) Parry-Romberg Syndrome, B) HIV-associated lipodystrophy, 
C) Acquired facial scar deformity.
However, the unpredictability of long-term graft retention has hampered the widespread 
acceptance and application of AFT in reconstructive plastic surgery. The loss of a significant 
portion of the grafted volume seems to be an inherent limitation with AFT, which has been 
the main criticism with this technique. This has engendered divergent and even polarized 
opinions among plastic surgeons worldwide with respect to whether AFT offers a reliable 
solution for correcting soft-tissue deformities in facial reconstructive surgery. Unfortunately, 
more than two decades of clinical research have failed to provide convincing evidence on 
this matter. The reason is that published literature comprises of a large number of small 
studies investigating a diversity of outcome measures in different patient populations, 
producing a body of evidence that is highly fragmented and difficult to analyze. 
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This has inspired us to perform the first systematic review and meta-analysis on the subject, 
aimed to facilitate interpretation of the evidence on the efficacy and safety of AFT in facial 
reconstructive surgery by clinicians, guideline committees and policy-makers.  
 Patients and methods 1.2
This systematic review adhered to the standards of the Cochrane Handbook of Systematic 
Reviews of Interventions1 and the Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE)2 and was written in the format provided by the Preferred Reporting Items of 
Systematic Reviews and Meta-Analyses (PRISMA) statement3 (eTable 6 - Online supplement). 
A comprehensive, reproducible electronic search was conducted in PubMed, EMBASE and 
the Cochrane Library to identify all published studies with human subjects receiving the 
intervention autologous fat transfer for facial reconstruction (eTable 1,2 – Online 
supplement). The search was performed on October 11th 2017. Eligibility assessment was 
performed in a standardized manner. The retrieved hits were screened and reviewed by two 
independent reviewers (T.K and J.B.) based on the title and abstract using predefined 
inclusion and exclusion criteria. Disagreements were solved through discussion until 
consensus was reached.  An additional assessment was performed based on the full-text 
versions of all selected papers and those with insufficient information in the title and 
abstract. All references were stored in Endnote Reference Management Tool, (version X7.3.1, 
Thomson Reuters).   
To be able to conduct a meta-analysis, a thorough extraction of all relevant data was 
performed (eTable 3 – Online supplement). In some occasions, authors were contacted to 
send additional data. In cases when key data was reported only in graphs or figures, it was 
extracted using the WebPlotDigitizer software4. Whenever necessary, units were 
transformed to a standard format to ensure comparability and allow pooling of data. 
Continuous variables reported in the form of median ± range were transformed into mean ± 
standard deviations (SD) using the standard estimating equations used for meta-analyses5. 
Custom outcome measurement scales and scores were also standardized accordingly. 
Finally, if studies from the same author or institution conducted in the same time period and 
reporting the same outcomes were suspected for overlap of more than 25% of the sample 
size, only the largest or most relevant study was included.  Meta-analysis was performed 
using the “metafor” package6 of the R-software7. Summary measures were pooled in a 
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standard random-effects model and presented as forest plots. Heterogeneity was assessed 
using the I2-statistic, which was tolerable if below 40%. Publication bias considered 
acceptable if upon visual inspection, the distribution of studies was approximately 
symmetrical. 
 Results 1.3
1.3.1 Study selection 
The electronic search yielded a total of 370 unique hits (eFigure 1– Online supplement). 
Screening of the title and abstract lead to the inclusion of 102 studies for further evaluation. 
A total of 43 clinical trials were selected through further screening of the full-text. Reasons 
for exclusion consisted of the unavailability of the full-text, secondary sources (reviews, 
commentaries), the use of AFT for cosmetic indications, enhancement with supplements 
(such as platelet rich plasma, PRP or stromal-vascular fraction, SVF). Case reports (defined as 
reports of five cases or less) were also not considered for inclusion. Screening of the 
citations, references and related articles of the 43 selected trials yielded nine additional hits. 
It should be noted that some cohort studies consisting of one or more treatment arms, 
which did not meet the inclusion criteria of the predefined PICO (such as use of supplements 
or combination treatments), were not included in the analysis. This was also the case 
whenever outcomes of interest were only relevant or measured in one of the treatment 
groups. 
 Study characteristics 1.4
Fifty-two clinical trials were identified for inclusion8-59(eTable 4). They consisted of 37 case-
series, eleven cohort studies and four randomized-controlled trials. The majority of these 
had a retrospective design (n= 44) and all studies were conducted between 1986 and 2016.  
1.4.1 Population 
From the 52 included studies (1,549 patients), only one study was suspected of significant 
overlap in patient populations45, resulting in 51 studies with a total of 1,533 unique patients. 
Most commonly, a study would include patients of a specific diagnosis. In fourteen studies 
11,12,17,19,20,23,33,35,37,38,44,45,49,54, it involved patients with HIV-associated lipodystrophy, 
comprising of 650 patients, thus representing the most common indication for which AFT is 
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described in published literature. The majority (76.9%) were males and the mean age at the 
time of the first AFT session was 42.6 years (95%CI 34.4 – 46.7). Furthermore, sixteen studies 
10,14-16,25,26,28,32,43,47,50,52,53,57-59 consisting of 409 patients evaluated AFT in patients with 
congenital disorders. From this group, 201 (49.1%) patients suffered from Parry-Romberg 
syndrome, 181 (44.3%) from craniofacial microsomia and the remaining 27 patients (6.6%) 
represent a mixed group of craniofacial microsomia, Goldenhar syndrome and Treacher 
Collins from a single study32. The mean age at the time of treatment with AFT was 23.8 years 
(95%CI 19.8 – 27.8) in this group. Another seventeen studies8,9,13,18,21,22,24,27,29,30,39-41,46,48,55,56 
formed a more heterogeneous group consisting 326 patients with a mean age of 36.8 years 
(95%CI 31.5 – 42.1) treated with AFT for a variety of acquired facial deformities such. In 
seven studies it was applied for treating small contour deformities such as facial scars (e.g. 
traumatic, thermal injury) and in another two AFT was performed for lip contouring after 
resection of epithelial cancer or cleft-lip surgery. Five studies involved the restoration of 
contour deformities after maxillofacial reconstruction after trauma and two – after 
autologous reconstruction of irradiated head and heck cancer. Finally, one study performed 
facial contouring with AFT in addition to conventional surgical treatment for facial burns 
involving large areas of the face.  
Each of the remaining four studies31,34,42,51(148 patients) involved a mixed group of patients 
from any of the abovementioned indications. 
1.4.2 Intervention 
From the included trials, the vast majority adhered to the principles of AFT as described by 
Coleman60, with the occasional minor variation in the surgical instruments used.  
1.4.3 Control group 
Only sixteen studies examining AFT included a control group, which most often involved 
patients receiving AFT with supplements (n=9) such as PRP19,21, SVF14,21,51,52,59, bone-marrow 
derived mesenchymal stem-cells26 or cultured adipose-derived stem cells28. As the scope of 
this paper is limited to the use of AFT without supplements, treatment arms that involved 
enhancement of AFT with the abovementioned supplements were excluded from the 
analysis. Another four studies involved additional treatment arms receiving (semi-) 
permanent fillers36-38,44, two studies compared AFT to autologous flaps47,53 and the last study 
– with dermis-fat grafts33.  
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1.4.4 Outcome measures 
1.4.4.1 Patient satisfaction:  
The satisfaction of the patient with respect to the result of the AFT reconstruction was 
measured in 30 trials. Twelve of these studies presented the result using categorical or 
“Likert scores” and reported the number of patients with a certain score (category) at the 
end of the treatment. The Likert scales consisted of a scale with two to five categories 
corresponding to degrees of satisfaction with the outcome (e.g. very dissatisfied, 
dissatisfied, satisfied, very satisfied) or opinion about the rate of improvement (e.g. very 
poor, poor, fair, good, excellent). To standardize the scales, scores were dichotomized into 
two distinct categories - satisfied versus dissatisfied. For all studies, such a cut-off point 
between the positive and negative categories was easily identifiable. Furthermore, 22 
studies presented satisfaction scores in the form of custom-made visual analogue scales 
(VAS), ranging from 4 to 50 levels, which were transformed into a standard 10-point VAS 
scale (0=maximum dissatisfaction, 10=maximum satisfaction).  
1.4.4.2 Surgeon satisfaction/evaluation:  
Twenty-nine studies reported the surgeon’s satisfaction, which typically consisted of visual 
evaluation of pre- and postoperative photographs to determine the rate of success of the 
AFT treatment. Sixteen studies reported surgeon’s evaluation using Likert scales with two to 
five categories describing the effect of AFT on the clinical result, which were subsequently 
dichotomized into good versus poor. Ten studies reported mean VAS scores (range 0-3 to 0-
20) and these were also transformed to a standard 0-10 scale (0=very poor result, 
10=excellent result).   
1.4.4.3 Volume measurements:  
From sixteen studies addressing fat resorption through volume measurements, three of 
them attempted to estimate volume changes by evaluating tissue thickness using ultrasound 
or CT-scan and were excluded from the analysis8,16,48. The remaining thirteen studies that 
utilized appropriate imaging techniques such as 3D image capture devices 25,28,36,50,53,58,  or 
Computed Tomography (CT) 14,19,20,43,52. Eight of these investigated volume retention in 
exclusively congenital patients (Parry-Romberg and craniofacial microsomia), while the 
remaining five involved HIV-associated lipodystrophy patients. The percentage graft 
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retention represents the fraction of the measured gain in volume, relative to the total 
volume of injected fat, as shown in the following formula: 
 
 
 
The relationship between the graft retention with time was investigated by means of a 
meta-regression.  
 
1.4.4.4 AFT-related complications:  
Forty-five studies evaluated the safety of AFT in terms of immediate and late AFT-related 
complications. A total of 65 complications were documented in 1,755 AFT procedures 
(3.7%), with the majority consisting of irregularities or asymmetry post-AFT (chiefly in HIV-
patients). Only two infections (0.1%), two cases of fat necrosis (0.1%) and ten hematomas 
(0.6%) were reported and these represent the only true complications encountered in this 
vast cohort. Additional meta-analysis was performed to derive the proportion of 
complications per AFT procedure. 
1.4.5 Time frame 
The average clinical follow-up after AFT was 1.3 (95%CI 0.9 – 1.6) years. 
 Meta-analysis results 1.5
Results of individual studies are presented in eTable 4. A random-effects model meta-
analysis was performed with pooled data of each outcome. Categorical data was 
dichotomized and presented as a meta-analysis of proportions, which can be treated as 
percentages. 
1.5.1 Patient satisfaction 
Meta-analysis of categorical data revealed an overall proportion of satisfied patients of 0.91 
(95%CI 0.85-0.95), after a mean follow-up of 2.0 years (Figure 2). It was highest in studies 
with mixed patients (96%), followed by HIV-lipodystrophy (94%), congenital deformities 
(92%) and lowest in studies investigating patients with acquired deformities (82%). Meta-
analysis of reported VAS-scores resulted in an average score of 7.9 (95% CI 7.5-8.3), with 
little variation between the mean scores of individual studies or subgroups (Figure 3).  
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1.5.2 Surgeon satisfaction/evaluation 
As with patient satisfaction, a very high proportion of the plastic surgeons were satisfied 
with the result ‒ 0.89 (95% CI 0.83-0.92) after a mean follow-up of 1.2 years (Figure 2). The 
highest overall satisfaction rate was noted in congenital deformities (95%), followed by HIV-
lipodystrophy (90%) and acquired deformities (87%). The mixed patients displayed the 
lowest surgeon satisfaction rate (78%), though this subgroup consisted of a single study with 
only 27 patients. Subsequent meta-analysis of VAS-scores led to an overall score of 7.8 (95% 
CI 7.3-8.4) and similarly to the scores reported by patients, surgeon scores varied little 
between relevant subgroups (Figure 3). 
1.5.3 Volume measurements  
Twelve studies provided data on volume retention, which was plotted against time in a 
meta-regression model. Patients with congenital deformities displayed a trend toward 
gradual decrease, stabilizing at 59% (95%CI 45-72) after one year of follow-up (Figure 4a). On 
the contrary, conflicting patterns of volume changes were seen in HIV-associated 
lipodystrophy patients, where volume retention decreased to 51% (95%CI 37-66) in some 
studies and or increased drastically to 238% (95%CI 201-274) in others (see Figure 4b). 
1.5.4 Number of AFT sessions 
Meta-analysis of pooled data from 50 studies (1,525 patients) showed that a mean of 1.5 
sessions (95%CI 1.3 – 1.7) were needed to achieve the desired result and on average 27 ml 
of fat was injected per procedure (eFigure 5 – Online supplement). Subgroup analysis 
revealed some variation between indications with the highest number of procedures being 
performed for the correction of congenital deformities (1.8 sessions) and the lowest in HIV-
associated facial lipodystrophy (1.1 sessions). 
1.5.5 Complications 
The incidence of AFT-related clinical complications based on our meta-analysis was low - 
0.05 (95%CI 0.03-0.07), or equivalent to 5% of the AFT procedures (eFigure 6 – Online 
supplement). Only in HIV-associated lipodystrophy patients, a higher rate of complications 
was reported (7%), however these were not commonly encountered AFT-related 
complications as in other indications but consisted mainly of asymmetry or overcorrection 
due to lipohypertrophy.  
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Figure 2: Patient and surgeon satisfaction (categorical data). Legend: AFT=autologous fat transfer, 
P=patient, S=surgeon.
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Figure 3: Patient and surgeon satisfaction (continuous data). Legend: AFT=autologous fat transfer, 
P=patient, S=surgeon.
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Figure 4: Meta-regression of graft retention over time for patients who underwent facial 
reconstruction (A) Volume retention in congenital patients (blue circles). (B) Volume retention in HIV-
associated lipodystrophy patients. Studies were categorised based on whether patients experienced a 
normal (expected) rate of resorption (red circles) or extreme hypertrophy (green circles).  Legend: size 
of the circles corresponds to sample size, thick lines represent meta-regression effect estimates and 
their respective 95% CI (gray dotted lines). The total number of patients with volume measurements 
at each time-point in the follow-up is shown below (N. patients). Legend: HIV= human 
immunodeficiency virus, Hyperfr. =fat hypertrophy group, Normal=normal resorption pattern group. 
 
 Discussion 1.6
This meta-analysis aims to provide a clinically relevant, quantifiable measure on the overall 
efficacy of autologous fat transfer in facial reconstructive surgery. Our results demonstrate a 
clear trend toward a very high rate of patient (91%) and surgeon (89%) satisfaction after a 
mean of 1.5 procedures and a low rate (5%) of minor complications. The volume retention in 
patients with congenital facial deformities showed a wide variation between studies, ranging 
between 40% to over 80% with pooled effect estimate of 59% at one year. In HIV-
lipodystrophy patients, deviations were even more extreme and two distinct patterns of 
volume changes were observed. The former resembled the resorption pattern of congenital 
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patients, gradually decreasing to 51% at one year. The latter, on the other hand, led to a 
spontaneous increase in volume to more than 238% at one year. This could, in theory, be 
attributed to extreme lipohypertrophy of grafted fat, which has been commonly reported as 
an adverse event in studies with HIV-patients. Whether this effect is the result of the choice 
of a donor site affected by lipohypertrophy (cervical hump, abdomen or breast area), 
metabolic (medication) or iatrogenic stimuli, must be evaluated in future studies.  
By a thorough examination of the totality of the evidence, it can be deduced that AFT seems 
to be an effective procedure that leaves the vast majority of patients and surgeons satisfied 
with the result after about a year of clinical follow-up. It is clear that future studies will play a 
crucial role in providing higher quality evidence that would allow for more nuanced 
recommendations regarding specific subgroups or indications, evaluating factors influencing 
the (long-term) volume retention, as well as the added value of supplements. As setting up 
randomized-controlled trials (RCTs) in some of these areas can be difficult, they should be 
evaluated whenever possible by prospective study design with the use of control groups and 
validated outcome measurement instruments such as 3D volume assessments and quality of 
life scales (See Table 5 – Online supplement).   
 Limitations 1.7
The main limitation of this meta-analysis as well as the accumulated body of knowledge on 
AFT in general, remains the low level-of-evidence of published studies. Unlike the widely 
accepted approach, where the adoption of a new therapy is based on the achievement of 
statistical significance for the primary outcome from well-executed RCTs or large cohorts, 
this has not been possible in the case of AFT. Its unique properties that give it competitive 
edge above conventional techniques, have also robbed it of an alternative treatment to 
perform in a control group. Setting up randomized trials with AFT has therefore been 
difficult due to practical and ethical challenges. Non-randomized cohorts, on the other hand 
could potentially introduce bias by allocating the treatment based on the indication, severity 
or the patient/surgeon’s preference. Inevitably, this would produce groups that are not 
comparable, thereby reducing the methodological quality of the study. Nevertheless, studies 
involving control groups not treated with AFT are scarce, and the few such trials that have 
been conducted only compare different AFT techniques (with or without supplements) with 
each other. More than two decades after the popularization of AFT by Coleman60, clinical 
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research on the topic has not been successful in providing convincing evidence on its efficacy 
and safety.  
Another important obstacle that hinders progress in the field of autologous fat transfer, is 
the lack of practical and reliable instruments to quantify the absolute effect of treatment. 
For many years, plastic surgeons have relied on non-validated, custom-made questionnaires 
to measure patient satisfaction, routinely use pre- and postoperative photographs for a 
slightly more objective confirmation of the findings. These outcomes have been reported as 
either continuous (means ± SD) or categorical (frequencies) variables, based on the type of 
questionnaire or scale. Each of these presents with its own advantages and limitations. As 
most retrospective studies rarely measured outcomes preoperatively, determining of the 
absolute effect of AFT becomes difficult in the absence of baseline values. In addition, the 
use of a continuous scale is of limited value when attempting to quantify the effect of AFT 
with different baseline scores. It is arguable that the same in change in different satisfaction 
scores can have different clinical significance. For example, an increase in a satisfaction from 
1– 4 out of 10 can be classified as an unsatisfactory result, while the same increase in 
another patient from a score of 4 – 7 out of 10 would be seen as successful. When dealing 
with studies reporting of nominal (categorical) data, outcomes such as the rate of 
satisfaction are often reported as frequencies of patients falling in each category (e.g. 
dissatisfied, satisfied, very satisfied). As such an approach does not rely on baseline values, it 
can more accurately reflect the absolute effect of AFT, though it lacks the precision of 
continuous data. 
For the abovementioned reasons, performing a meta-analysis on this topic is highly 
challenging as the paucity of relevant control groups and pre- versus postoperative data 
prevents applying widely accepted statistical measures of effect such as the relative risk or 
odds ratios. Therefore, this meta-analysis focused on providing pooled effect estimates that 
indicate the size, direction and confidence intervals for each outcome. 
Dealing with heterogeneity is another major challenge with meta-analyses. Pooling a large 
number of studies with potentially different patient demographics, indications and outcome 
measurements can result in important heterogeneity that could reduce the validity of the 
effect estimates. To correct for this, a random-effects model was applied to all cases and 
whenever possible, subgroup meta-analyses were performed by pooling studies with similar 
indications together. It is important to note that despite the potential differences between 
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included studies, the pooled effect estimates demonstrate a clear convergence toward a 
very high rate of satisfaction with the procedure and a low rate of clinical complications. As 
the indications of AFT in facial reconstructive surgery consists of a heterogeneous group of 
indications and patients, it can be argued that such a general approach delivers evidence on 
precisely the population this meta-analysis aims to draw conclusions about.  
 Conclusion 1.8
Autologous fat transfer seems to be an effective treatment for contour deformities in facial 
reconstruction, as reflected by the high patient satisfaction (91%) and surgeon satisfaction 
(89%), achieved after a mean of 1.5 procedures. Volume retention was observed to decrease 
to 50-60% after one year but needs further investigation, especially in HIV-associated facial 
lipodystrophy patients. Autologous fat transfer can be considered a safe treatment, with 
only 5% of procedures resulting in minor complications. 
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1.12.1 E-figures
eFigure 1: Flowchart of the search strategy. Legend: n= number of studies; P= Population, I= 
Intervention, O= Outcome, suppl.=supplements (e.g. PRP, stromal-vascular fraction enrichment)
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eFigure 2: Meta-analysis of the number of AFT sessions needed to achieve the desired result. Legend: 
VOL=mean injected volume. N=total number of patients.
52 CHAPTER 2
eFigure 3: Meta-analysis of the rate of AFT-related complications per procedure. Legend: FU=follow-
up, VOL=mean injected volume, n=total number of complications, N=total number of procedures.
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1.12.2 E-tables 
 
eTable 1: PICO design 
PICO Description 
Population Patients with craniofacial soft-tissue deformities  
Intervention Autologous Fat Transfer (without the use of supplements such as PRP, SVF)  
Controls Conventional reconstructive techniques, fillers or no treatment 
Outcomes Crucial outcome measures: 
• Patient satisfaction  
• Surgeon satisfaction/evaluation 
• Quality of life 
• Postoperative complications 
Important outcome measures: 
• Number of AFT sessions 
• Volume retention (degree of resorption) 
 
 
 
 
eTable 2: Search syntax 
Database Search syntax 
PubMed (craniofacial[tiab] OR cranio-facial[tiab] OR cranio[tiab] OR cranial[tiab] OR facial[tiab] OR 
hemifacial[tiab] OR face[tiab]) AND (atroph*[tiab] OR lipoatroph*[tiab] OR hypoplas*[tiab] OR 
aplas*[tiab] OR defect[tiab] OR deformit*[tiab] OR deficienc*[tiab] OR malformation[tiab] OR 
disorder[tiab] OR congenital[tiab] OR hereditary[tiab] OR syndrome[tiab] OR Parry[tiab] OR 
Romberg[tiab] OR Treacher[tiab] OR microsomia[tiab] OR atroph*[tiab] OR lipoatroph*[tiab] OR 
lipodystrophy*[tiab] OR deficienc*[tiab] OR HIV[tiab] OR immuno-defficiency[tiab] OR AIDS[tiab]) AND 
(("fat graft"[tiab] OR "fat grafts"[tiab] OR "fat grafting"[tiab]) OR "fat injection"[tiab] OR 
lipoaspirate*[tiab] OR “fat transfer"[tiab] OR lipofilling[tiab] OR liposculptur*[tiab] OR 
lipostructur*[tiab] OR lipo-injection[tiab] OR lipoinjection[tiab] OR lipotransfer[tiab] OR lipo-
transfer[tiab] OR "fat transplant"[tiab] OR lipomodelling[tiab] OR lipomodeling[tiab] OR 
lipografting[tiab] OR lipo-grafting[tiab] OR microlipoinjection[tiab] OR "adipose tissue grafting"[tiab] 
OR "adipose tissue transfer"[tiab] OR "adipose tissue transplant"[tiab] OR lipotransplant[tiab] OR lipo-
transplant[tiab] OR microlipofilling[tiab] OR micro-lipofilling[tiab] OR "grafting of fatty tissue"[tiab] OR 
"transfer of fatty tissue"[tiab] OR "injection of fatty tissue"[tiab] OR "fatty tissue grafting"[tiab] OR 
"fatty tissue transfer"[tiab] OR "fatty tissue injection"[tiab] OR "autologous fat transplant"[tiab] OR 
"autologous fat transplants"[tiab]) NOT ("dermal"[tiab] OR derma-fat[tiab] OR derma[tiab]) 
Embase (craniofacial:ti:ab OR cranio-facial:ti:ab … OR derma:ti:ab) AND [embase]/lim NOT [medline]/lim 
Cochrane (craniofacial OR cranio-facial … OR derma) in Abstract, Title and Keywords 
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eTable 3: Data extraction sheet 
Database Search syntax 
Study design characteristics Assessment of: 
• Author (year) overlap studies 
• Study period (start date – end date) overlap studies 
• Type of trial (RCT, cohort, case-series, case-report) study design 
• Design (prospective, retrospective) study design 
Evaluation of the risk of bias  
• Randomization (if non-RCT, use of consecutive patients)? Selection bias 
• Blinding of participants and personnel (if applicable)? Performance bias 
• Blinding of outcome assessment (if applicable)? Detection bias 
• Incomplete outcome data (loss to follow up >15%?) Attrition bias 
• Selective reporting of outcomes? Reporting bias 
• Suspicion of funding by industry, conflict of interests? Publication bias 
Study population characteristics  
• Number of treated patients, total number of interventions  Important outcome 
• Age, BMI Demographics 
• Diagnosis, indication, previous procedures Demographics 
• Surgical technique, type of anaesthesia, donor sites Important outcome 
• Number of AFT sessions, Important outcome 
• Mean injected volume per session, per location Important outcome 
Time factor  
• Time between AFT sessions Important outcome 
• Length of follow-up Important outcome 
Volume assessment  
- Type of imaging used, volume measurements Important outcome 
Patient and surgeon satisfaction  
• Type of measurement tool/scale/score used, timing evaluation Crucial outcome 
Quality of life  
• Type of scoring system used, time evaluation Crucial outcome 
Number of sessions  
• Number of AFT procedures per patient needed for successful reconstruction Important outcome 
Complications  
• Type and total number of AFT-related complications Crucial outcome 
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eTable 4: Baseline table of all studies 
 Study characteristics Demographics Intervention Reported outcomes  
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1 Agrawal (2016) CS no 25 acq. 30 AFT 1.1 28 1.0       4 
2 Arcuri (2013) CS no 19 acq. 30 AFT 1.2 22 1.0       4 
3 Benchamkha (2012) CS no 12 PRS 32 AFT 1.7 20 1.5       4 
4 Burnouf (2005) CS no 33 HIV 45 AFT 1.0 33 1.0       4 
5 Caye (2003) CS no 29 HIV 43 AFT 1.1 29 0.9       4 
6 Cervelli (2016) CS no 43 acq. 30 AFT 2.1 69 0.8       4 
7 Chang (2013) CH no 10 PRS 28 AFT+SVF 1.7 17 1.0       2 
    10 PRS 28 AFT 1.7 17 1.0        
8 Denadai (2016) CS no 11 CM 6 AFT 1.4 15 1.0       4 
9 Denadai (2017) CS no 142 CM 22 AFT 1.4 205 0.0       4 
10 Dollfus (2009) CS no 6 HIV 17 AFT 1.2 6 2.0       4 
11 Ducic (2003) CS no 20 acq.  AFT 1.4 25 1.0       4 
12 Fontdevila (2008) CS no 26 HIV 45 AFT 1.0 26 1.0       4 
13 Fontdevila (2014) RCT no 29 HIV 46 AFT 1.0 29 1.0       1 
    20 HIV 47 AFT+PRP 1.0 20 1.0        
14 Gentile (2014) CH no 10 acq. 45 AFT+SVF 1.4 14 5.0       2 
    10 acq. 45 AFT+PRP 1.4 14 5.0        
    10 acq. 45 AFT 1.4 14 5.0        
15 Gutierres (2017) CS no 12 acq. 60 AFT 1.0 12 1.0       4 
16 Gu (2017) CS no 20 acq. 38 AFT 1.3 26 0.0       4 
17 Guaraldi (2005) CS no 41 HIV  AFT 1.0 41 1.5       4 
18 Jiang (2016)  CS no 26 PRS 27 AFT 2.0 52 -       4 
19 Jianhui (2014) CH no 26 PRS 24 AFT 1.4 37 1.2       3 
    10 PRS 25 AFT+BMSC 1.0 10 1.2        
20 Jones (2017) CS no 18 acq. 16 AFT 1.1 20 1.0       4 
21 Koh (2012) RCT no 5 PRS 28 AFT 1.0 5 1.5       1 
    5 PRS 28 AFT+SVF 1.0 5 1.5        
22 Laurent (2006) CS no 9 acq. 16 AFT 1.9 17 1.3       4 
23 Lei (2016) CS no 18 acq. 37 AFT 2.2 39 1.5       4 
24 Li (2015) CS no 6 mix 47 AFT 2.2 13 0.3       4 
25 Lim (2012) CS no 27 CM 17 AFT 2.1 56 2.2       4 
Continued on next page… 
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eTable 4: Baseline table of all studies … Continued 
 Study characteristics Demographics Intervention Reported outcomes  
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26 Martins (2016) CH no 18 HIV 51 AFT 1.0 18 0.5       3 
    6 HIV 49 DFG 1.0 6 0.0        
27 Mojallal (2009) CS no 100 mix 42 AFT 1.6 160 1.9       4 
28 Mori (2006) CH no 8 HIV - AFT - 8 -       3 
    4 HIV - Impl. - 4 -        
29 Nelson (2008) CH no 26 HIV - AFT 1.1 26 -       2 
    10 HIV - PLA - 10 -        
    8 HIV - Bio-A - 8 -        
30 Nelson (2012) CH no 12 HIV 43 AFT 1.0 12 -       2 
    16 HIV 45 Bio-A - 16 -        
    20 HIV 46 PLA - 20 -        
31 Orlando (2007) CH no 54 HIV 45 AFT 1.2 65 0.9       2 
    24 HIV 47 AFT 1.0 24 0.9        
    91 HIV 46 PLA - 91 -        
    130 HIV 46 PAcr - 130 -        
32 Pallua (2014) CS no 26 acq. 46 AFT 1.0 35 1.9       4 
33 Phulpin (2009) CS no 11 acq. 48 AFT 2.2 17 3.3       4 
34 Pinksi (1992) CS no 43 acq. 35 AFT 1.0 43 2.2       4 
35 Piombino (2015) CS no 32 mix 24 AFT 1.2 33 1.1       4 
36 Qiao (2017) CS no 7 PRS 22 AFT 1.9 11 0.5       4 
37 Rauso (2010) CS 38 16 HIV - AFT - 16 1.2       4 
38 Rauso (2011) CH 37 14 HIV 44 AFT 1.0 14 1.0       2 
    9 HIV 45 Bio-A - 9 1.0        
39 Sardesai (2007) CS no 14 acq. 48 AFT 1.0 - -       4 
40 Schmitz (2008) CH no 12 PRS - AFT 2.0 24 -       3 
    7 PRS - flap - 7 -        
41 Scotto (2016) CS no 18 acq. 38 AFT 1.0 18 1.0       4 
42 Serra-Renom (2004) CS no 38 HIV 42 AFT 1.3 50 1.0       4 
43 Slack (2014) CH no 42 PRS - AFT 3.3 139 -       3 
    35 cosm. - AFT 1.7 60 -        
Continued on next page… 
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eTable 4: Baseline table of all studies … Continued 
 Study characteristics Demographics Intervention Reported outcomes  
 Study 
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44 Sterodimas (2011) RCT no 10 mix 46 AFT 2.1 21 1.5       1 
    10 mix 44 AFT+SVF 1.0 10 1.5        
45 Tanikawa (2013) RCT no 7 CM 19 AFT 1.0 7 0.5       1 
    7 CM 12 AFT+SVF 1.0 7 0.5        
46 Tanna (2011) CH no 21 CM - AFT 4.3 91 1.0       3 
    10 CM - flap - 22 -        
47 Uzzan (2012) CS no 317 HIV 44 AFT 2.0 391 1.0       4 
48 Viard (2012) CS no 15 acq. 38 AFT 2.3 40 5.5       4 
49 Vitagliano (2016) CS no 5 acq. - AFT 1.0 5 -       4 
50 Xie (2007) CS no 31 PRS 24 AFT 1.6 50 3.0       4 
51 Yang (2016) CS no 31 PRS 22 AFT 3.1 96 1.1       4 
52 Yoshimura (2008) CH no 3 PRS 46 AFT 1.0 3 0.8       3 
    3 PRS 39 AFT+SVF 1.0 3 0.9        
Legend: RCT= Randomized Controlled Trial, CH= cohort, CS= case-series, ‘-‘.=data not available/reported, mix= 
mixed population, PRS= Parry Romberg Syndrome, CM= Craniofacial Microsomia, acq= patients with acquired 
facial deformities, HIV=patients with HIV-associated lipodystrophy. AFT=Autologous Fat Transfer only. PRP= 
Platelet-Rich Plasma enrichment. SVF= Stromal-Vascular Fraction enrichment, BMSC= Bone-Marrow Stem Cell 
enrichment. Impl= silicone implant. In outcomes:  ‘’=outcome measured, ‘blank cell’=outcome not measured in 
the particular study. Level of evidence: 1=RCT, 2=prospective cohort, 3=retrospective cohort, 4=case series, 
5=case-report. 
 
eTable 5: Recommendations for focus of future research on AFT in craniofacial reconstruction 
Research topic Proposed study design 
1. Factors determining the (long-term) volume retention Prospective 3D imaging studies 
2. Most optimal timing AFT (congenital disorders) RCTs, prospective cohort studies 
3. Added value of supplements (PRP, SVF) RCTs, prospective cohort studies 
4. Improvements in the AFT technique (instruments, systems) RCTs, prospective cohort studies 
5. Regenerative effects of AFT (skin quality, vascularisation, elasticity) RCTs, prospective cohort studies 
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eTable 6. Prisma checklist 
Section/Topic # Checklist item page # 
Title    
Title 1 Identify the report as a systematic review, meta-analysis, or both.    
Abstract    
Structured summary        2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number. 
3 
Introduction    
Rationale 3 Describe the rationale for the review in the context of what is already known. 4 
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS). 
4 
Methods    
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including 
registration number. 
N.A. 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale 
5 
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched. 
4 
Search 8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated. 
5 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).   
5 
Data collection 
process 
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators. 
5 
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.   
5 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and 
how this information is to be used in any data synthesis.   
5 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).   5 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.   
5 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).   
5 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified. 
5 
Results    
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.   
5 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.   
6 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).   
6 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.   
8-9 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.   
8-9 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see Item 15).   9-10 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 8-9 
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analyses, meta-regression [see Item 16]). 
Discussion    
Summary of 
evidence 
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).   
9 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting bias).   
10 
Conclusions 26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research. 
11 
Funding    
Funding 27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.   
11 
From:   Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  For more information, visit: www.prisma-statement.org. 
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Summary  
Neuropathic pain has a far-reaching effect on the daily lives of patients. Recently, autologous 
fat transfer (AFT) has demonstrated promising results in patients with painful scars or after 
neuroma excision. However, there is a subgroup of patients who do not show any apparent 
cause for the pain. We hypothesized that in these patients, AFT alone in the area around the 
affected nerve might lead to beneficial results. Patients with clearly demarcated neuropathic 
pain and who had exhausted all other treatment options were referred by a pain specialist. 
Fourteen patients who met the inclusion criteria received AFT in the area of the affected 
nerve. Pain scored on the VAS, patient satisfaction and quality of sleep were recorded before 
and after surgery. To investigate long-term effects, a second follow-up was planned at least 
one year later. Patient satisfaction was 93% after the first follow-up and 86% after more 
than one year. The mean VAS score was 7.4 before surgery and significantly decreased to 3.8 
after autologous fat grafting (p<0.0001) and 4.3 (p=0.0017) at long-term follow-up. The 
quality of sleep improved in 50% of the patients, whereas the remainder indicated no 
difference. No complications were registered. The results show that AFT alone, even over a 
longer period of time and in patients refractory to multiple treatment modalities, could be 
useful to treat peripheral neuropathic pain without apparent cause. For definitive evidence 
prospective controlled studies with a larger study population and control/sham groups are 
warranted. 
 
Introduction 
Neuropathic pain, estimated to occur in 1-8% of the general population, is a challenge in 
daily practice with a profound influence on daily life.1 Treatment modalities are diverse and 
include various forms of pharmacotherapy, electrical stimulation and surgical interventions.2-
4 Pharmacotherapy and other non-surgical treatments lead to a clinically meaningful pain 
reduction in less than 50% and 30% of the cases, respectively.5,6 Patients with refractory pain 
often undergo surgery, which traditionally was mostly performed by resection and 
relocation of the affected nerve into muscle, vein or bone.7-9 In recent years autologous fat 
transfer (AFT) has been introduced into the arsenal of surgical techniques to treat 
neuropathic pain caused by neuromas, burns and scars  and post mastectomy pain 
syndrome (PMPS).10-16 Acknowledging the beneficial effect of AFT found for these 
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indications, our aim was to investigate whether autologous fat transfer can be an effective 
treatment for peripheral neuropathic pain when there is no clear cause in the form of a 
neuroma or scar.  
 
Methods 
A retrospective cohort study was conducted among patients with neuropathic pain confined 
to a specific location without apparent cause who were treated with autologous fat transfer 
between December 2011 and August 2014.  
 
Patient inclusion 
All patients were referred by a pain specialist and were diagnosed with neuropathic pain 
that was refractory to multiple treatment modalities. The majority of the patients presented 
with a history of trauma or a surgical procedure in the area before the onset of the pain. Pre-
operative examination included Tinel’s sign and completion of the Visual Analog Scale (VAS) 
as an assessment of pain intensity. Inclusion criteria were: a clearly demarcated area of pain 
and positive Tinel’s sign in the absence of an underlying cause such as a painful scar or 
neuroma as validated by means of high-resolution ultrasonography.17  
 
Surgical procedure 
Surgery was performed under general anesthesia. The donor site (usually abdomen) was 
infiltrated with saline (NaCl 0.9%) and 0.001 mg adrenaline / ml before adipose tissue was 
harvested through a 3 mm blunt Mercedes tip cannula, at low suction settings using a Cytori 
pure graft system (Cytori Therapeutics Inc., San Diego, CA, USA). The lipoaspirate was then 
re-injected subcutaneously in the pre-operatively marked area using a fanning technique.  
 
Outcome measures 
Baseline characteristics were recorded. Primary outcome measures were patient satisfaction 
(yes or no) and pain scores pre- and post-operatively on the visual analogue scale (VAS) 
ranging from 0 ‘no pain at all’, to 10 ‘unbearable pain’. A long-term follow-up was planned 
after a minimum of one year after surgery to evaluate changes in pain experience. Quality of 
sleep and safety of the procedure were also evaluated.  
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Statistical analysis 
Statistical comparison of the pre- and postoperative VAS scores was performed by paired 
Student’s t-test. A p-value < 0,05 was considered to be statistically significant. 
 
Results 
Fourteen individual patients were included. Their baseline characteristics can be found in 
table 1. Thirteen patients (93%) were satisfied with the treatment results at the first post-
operative follow-up, while 11 patients (86%) remained satisfied after more than one year 
follow-up. The mean VAS score was 7.4 before surgery (range 6-10)  and significantly 
decreased to 3.8 after autologous fat grafting (p<0.0001; range 0-8; see figure 1) at 8 weeks 
follow-up and 4.3 (p=0.0017; range 0-10) at long-term follow-up (on average 28 months). In 
3 patients the VAS increased between the first and second follow-up, but was still below the 
pre-operative value. The quality of sleep improved in 50% of the patients, whereas the 
remainder indicated no difference. No complications were registered. 
 
Characteristics (n=14) Mean (+ range) 
Age  51 (17-78) 
Gender (male/female) 6/8 
BMI 24.9 (18.0-29.1) 
Smoking status (yes/no) 4/10 
Duration of first follow-up 8 weeks (2-20) 
Duration of second follow-up 28 months (15-49) 
Total volume of fat injected 21.8 ml (2-70) 
Treated areas 
Calcaneus 
Achilles tendon 
Malleolus 
Patella 
Upper leg 
Dig IV 
MCP 
Infraorbital 
 
1 
1 
1 
4 
4 
1 
1 
1 
 
Table 1. Patient Demographics 
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Fig 1. VAS score before surgery and at the two follow-ups. The mean VAS score significantly 
decreased from 7.4 (range 6-10) before surgery to 3.8 (range 0-8) after autologous fat grafting at 8 
weeks follow-up and 4.3 (range 0-10) at the follow-up of more than one year. The VAS increased in 3 
cases between the first and second follow-up, but was still below the pre-operative value. 
Discussion
The study results revealed that the vast majority of patients (86%) were satisfied with the 
pain relief after more than 1 year follow-up  and 50% of the patients reported improved 
quality of sleep. In the literature, a pain reduction of at least 30% is generally regarded as 
being clinically relevant.3 This effect was reached in 9/14 patients (64%), while 5/14 patients 
(36%) reported a pain reduction of at least 50%. The meaningful effect of the procedure was 
corroborated by the fact that previous “standard care” pain treatments had either no or 
short-lasting effects, while the effect of autologous fat transfer lasted much longer. 
The significant decrease in pain reflects the results from studies wherein cause of the pain 
was known. Vaienti et al reported a reduction of 23.2% in the mean disabilities of the arm, 
shoulder and hand (DASH) scores and an improvement in the VAS score of 22% (although 
not statistically significant) after perineural fat grafting in eight patients for the treatment of 
painful end-neuromas of the upper limb.10 Fredman et al noted a pain reduction in 6 out of 7 
patients with burn scars.14 Huang et al reported a significant decrease in VAS score of 4.38 
after one week, 5.38 after 4 weeks and 5.62 after 24 weeks of treatment, and a likewise 
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decrease in the Neuropathic Pain Symptom Inventory  in 13 patients with painful scars.16 In 
patients with PMPS several studies revealed that AFT significantly decreased the VAS score 
versus non-operated controls, with a mean decrease of >3 points.11,12,18 
Interestingly, all fourteen patients reported pain relief in the first weeks after surgery. 
However, two patients indicated recurrence of pain after two months with an increased VAS 
score compared to pre-operative. Another patient reported at the long term follow-up that 
the VAS had been rising slightly after a few months, but was still at acceptable levels at the 
last  follow-up. Although Huang et al found no recurrence of pain in patients responding to 
treatment, Vaienti et al described a similar deterioration of the pain relief over time in some 
patients.10,16 We hypothesize that graft volume loss, in literature described to be between 
40-80% in the first months post-operative, may be responsible for the recurrence of pain.19-
21 If that is the case, treatments or methods, which improve graft volume retention, may also 
improve the long term effects on pain.  
 
Conclusions 
This study shows that AFT might be a useful alternative in treating localized peripheral 
neuropathic pain. However, prospective controlled studies with larger study populations and 
control/sham groups are required to provide definitive evidence. 
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Abstract 
Spinal cord injury (SCI) is an incurable disorder with an unmet need of an effective 
treatment. Recently, autologous human bone marrow-derived stem cells have shown to 
promote functional improvement, due to their anti-inflammatory and regenerative/apocrine 
properties. In this study, the primary objective was to test whether a single intrathecal 
injection with a 100µL suspension of 400,000 fresh human bone marrow-derived CD34+ and 
an equal number of CD105+ stem cells (Neuro-Cells (NC)), one day after balloon-compression 
of the spinal cord, improves motor function and reduces secondary damage in 
immunodeficient rats. During the first 5 weeks after this intervention, NC significantly 
improved locomotor recovery and induced less injury-associated adverse events compared 
to vehicle-treated rats.  
Histological analysis showed that NC reduced astrogliosis, and apoptosis early after 
administration (day 4), but not at a later stage (day 56) after SCI. Proteomic studies (at day 
56) pointed to the release of paracrine factors and identified proteins involved in 
regenerative processes. As stem cells seem to reach their effects in acute lesions by mainly 
suppressing (secondary) inflammation, it is thus realistic to expect a lower magnitude of 
their eventual beneficial effect in T-cell deficient rats, a fact reinforcing the robustness of 
Neuro-Cells efficacy. Taken together, this study indicates that an intrathecal instillation of 
Neuro-Cells holds great promise as a neuro-regenerative intervention in a clinical setting 
with acute SCI patients. 
 
Introduction 
The prevalence of spinal cord injury (SCI) worldwide is estimated at 2.5 million cases and the 
financial burden per case is calculated to be between 200,000 - 260,000 Euros/year (1). 
Pending severity of the injury, SCIs may cause an (in)complete loss of sensory, motor and 
vegetative functions under the level of the spinal cord involved: in legs (paraplegia) or in 
arms and in legs (tetraplegia). Traditionally, in 60% of the cases, traumatic spinal cord injury 
is caused by falls and by motor vehicle accidents (2), but recently more and more combat-
wounded soldiers are affected (3). Due to the lack of disease-modifying interventions, life 
expectancy in SCI patients is impaired (4) and the quality of their lives is poor (5,6).  
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As a small functional improvement in SCI patients might come with a major increase in 
quality of life and daily independency, recently, much attention is given to control and 
reduce collateral damage of neural tissue by inhibiting the posttraumatic inflammatory 
cascades (7-10). Less than 10% of functional long-tract connections is needed to enable 
locomotion (11). Although this level of connectivity often remains after the injury, axons 
might become non-functional because of collateral damage resulting in neurodegeneration 
at a later stage (12). Therefore, prevention of secondary damage in the acute phase of spinal 
cord injury is of utmost importance, which offers the opportunity of functional improvement 
by disease-modifying interventions (7,13).  
Until the recent past, steroids were applied for this purpose (14), although wide spread use 
has stopped due to limited effects and severe adverse effects (15,16). In SCI, a therapeutic 
intervention combining both anti-inflammatory and regenerative properties is an unmet 
need. Hypothetically, stem cells may be such an intervention, as one of the characteristics of 
adult stem cells (both hematopoietic and mesenchymal stem cells) is the ability to both 
inhibit inflammation and to mediate regeneration by increasing neuroplasticity in 
neurodegenerative processes (8,17-25). Recent studies suggested that not only the site of 
the lesion, but also the timing of the administration of stem cells after the lesion are crucial 
for their beneficial effects in the context of the evolving post-traumatic inflammatory 
response (9,10,23-29).  Dose and number of cells administrated appear to be of less 
importance (30).     
The objective of this study was to investigate whether a single intrathecal administration 
with ‘Neuro-Cells’ (a not substantial manipulated low immunogenic, fresh human bone 
marrow-derived stem cell preparation, depleted of erythrocytes and the majority of the 
lymphocytes according to the manufacturing standard operating procedures of Neuroplast 
BV) provided a better survival and functional recovery in T-cell deficient rats after spinal cord 
injury. 
In this study, a moderate grade SCI was applied in rats by a moderate balloon compression 
of a spinal thoracic (Th 9) segment. Unfortunately, treatment of these animals with 
autologous stem cells or with a low-immunogenic rat stem cell preparation (following the 
manufacturing procedure of Neuro-Cells) is not realistic due to the limited volume of rat 
bone marrow, and the invasiveness of the cell collection procedure itself in rats. Thus, T-cell 
deficient rats were selected to avoid both rejection of human stem cells and the use of 
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immune suppressive drugs. Immune suppressive drugs are considered major confounders as 
they not only interfere with stem cells but also offer a cell protective effect to local neurons 
(31-34). They can substantially influence the outcome in experimental studies after the 
effects of stem cell interventions in favour of the vehicle treated animals. Therefore, these 
drugs dampen neuro-inflammation following acute spinal cord injury and thus final damage, 
with consequent less sensorimotor and neurovegetative symptoms (35). In comparison to 
normal, immune competent rats, the higher liability to infections may also have a significant 
effect on survival of the experimental animals (35). 
We hypothesized that infusion with Neuro-Cells 24 h after SCI will improve locomotor 
recovery by reducing secondary damage. Functional behavioral recovery was monitored 
weekly using the Basso, Beattie, Bresnahan (BBB) open field test (36). Histological studies 
were performed 4 and 56 days post-surgery to determine the number of apoptotic cells, 
reactive astrocytes, and microglia infiltration in both vehicle and Neuro-Cells-treated 
animals. Moreover, we used mass-spectrometry technology to screen for and identify 
peptides in each site relative to the spinal lesion (rostral, lesion, caudal) obtained in vivo. We 
hypothesized that Neuro-Cells changes the composition of local peptides by down regulation 
of pro-inflammatory proteins as compared to the vehicle treated animals. This effect is 
expected to be the strongest in the lesion site as compared to the rostral and caudal sites 
 
Methods 
Animals and experimental Design 
Adult male T-cell deficient A-thymic RH-Foxn1rnu (260-310 g) purchased from Harlan (Harlan 
laboratories, the Netherlands) were housed in pairs during the acclimatization period, for 
post-operative care and throughout the rest of the experiments. Rats were maintained in an 
isolated part of the animal facility apart from immune competent animals and under 
standard housing conditions (12 h light/dark cycle, lights on at 8:00 a.m., humidity 40–60%, 
temperature 22 ± 1 °C) with ad libitum access to food and water. The Animal Care and Use 
Committee of the University of Maastricht reviewed and approved all animal surgeries, 
procedures, and post-operational care (permit number DEC2013-013). Laboratory personnel 
managed animals following the National Institute of Health Guide for the Care and Use of 
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Laboratory Animals. A total number of 62 rats underwent surgical procedures for inclusion in 
this study (Figure 1).
Figure 1: Experimental design. At day 0 (d0), spinal cord injury (SCI) or a sham lesion was induced in 
T-cell deficient rats. Rats were injected intrathecal with vehicle or Neuro-Cells, caudal to the lesion at 
day 1. Immunohistochemistry (IHC) was performed at day 4 and day 56 after administration. 
Proteomic studies were performed at day 56. Throughout the study, Basso-Beattie-Bresnahan (BBB) 
measurements for assessing locomotor behaviour (36) were performed on a weekly base.
 
Spinal Cord Balloon Compression
After a subcutaneous injection of buprenorphine (0.05 mg/kg), animals were anaesthetized 
(3-4% Isoflurane) and maintained (1.5–2.5% Isoflurane, Sigma-Aldrich) in anesthesia with a 
stable body temperature of 37°C. Having removed the spinal processes T10–T11 after a 2-cm 
midline incision at T10-L1, a small hole (1.5 mm diameter) was drilled in the vertebral arch 
T10, using a surgical microscope (37). After opening the periosteal membrane in order to 
allow direct visualization of the spinal cord with intact dura mater, a groove was drilled in 
the midline on the dorsal surface of the vertebral T11 lamina. Then, an epidural inserted 
French Fogarty catheter (Baxter Healthcare Corporation, Irvine, CA) filled with saline and 
connected to an airtight 50 µL Hamilton syringe type 1705, cranially for 1 cm, was guided 
through this groove, thus positioning the center of the balloon at T8–T9. In case of SCI-
lesioning, but not in sham-lesioning, the balloon was then rapidly inflated with 15 µL saline 
and held in situ during 5 minutes before deflating and removal of the catheter, closing the 
wound and terminating anesthesia. Post-operative care included subcutaneous application 
of buprenorphine 0.05 mg/kg during 4 days to relief the pain. 
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Neuro-Cells  
Neuro-Cells is the working name (patent WO2015/059300A1) of a fresh, standardized 
human bone marrow derived stem cells containing product, that is produced under good 
manufacturing practices (GMPs) without expansion and/or labeling (or other major 
manipulation) of the stem cells. Neuro-Cells comprises of hematopoietic stem cells and their 
progenitors (HSCs), mesenchymal stem cells and their progenitors (MSCs) and other 
mononuclear cells.  Four healthy male volunteer donors were recruited with informed 
consent for collection of 50-75 mL bone marrow from their iliac crest under local anesthesia, 
following standard operating procedures. Neuro-Cells was depleted from erythrocytes by 
Ficoll (GE Healthcare, Chicago, Ill.) density gradient centrifugation (at 400g, at room 
temperature) and the number of lymphocytes was substantially reduced (table 1) by positive 
selection between 95-97%, and resuspending the remaining cells in Ringer-lactate. MSCs and 
HSCs were characterized by flow cytometry (Miltenyi, Germany). The group of MSCs were 
identify by being positive for CD73, or CD90, or CD105 and negative for CD34 and CD45 and 
CD14 (38). HSCs were positive for CD34, and CD38. Every Neuro-Cells batch fulfilled the GMP 
release criteria of at least 4 million HSCs and an equal number of MSCs suspended in 10 mL 
Ringer-lactate for intrathecal application. Besides the intra-donor variation, the intrathecal 
treatment of the SCI-rats was calibrated to 4.0x105 CD34+ cells in vials of 100 µL. However, 
due to the fresh nature of the cells and the calibration based on the number of CD34+ cells, 
the individual number of MSCs will differ per used donor. Table 1 gives an overview of the 
number of cells applied to the individual rats. 
 
Cell population in Neuro-Cells Mean absolute number of cells injected in each animal  
(in 100 µl) 
Total nucleated cells 1.2 x 107 
HSC: total CD34+ cells 4.0 x 105 
MSC:  CD271+ cells 7.8 x 104 ± 2.6 x 104  
MSC:  CD133+ cells 1.5 x 104 ± 0.5 x 104  
MSC:  CD90+ cells 3.7 x 103± 1.3 x 103 
MSC:  CD105+ cells 3.5 x 105± 2.0 x 105 
MSC:  CD73+ cells 4.5 x 103± 2.1 x 103 
Table 1: Characterization of cell population in ‘Neuro-Cells’.  
 
Intrathecal Infusion 
At day 1 post-surgery, we subcutaneously injected the rats with 0.05 mg/kg buprenorphine 
(AST Farma B.V., The Netherlands) and further anaesthetized them with isoflurane 
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(induction phase with 3-4% isoflurane and maintenance phase with 1.5–2.5% isoflurane), 
keeping the rats’ body temperature at 37°C using heating pads. The wound of the first 
operation was reopened in order to visualize the dura. Then the dura was punctured and, 
after collection of a drop of cerebrospinal fluid (CSF), a syringe, either filled with Neuro-Cells 
or vehicle (Ringer lactate), was connected and emptied, caudally of the lesion, through a 
microliter pump over a time period of 5 minutes. We infused SCI-treated rats with 100 µL 
Neuro-Cells or 100 µL vehicle. Post-operative treatment and care were identical to those 
after the lesioning. Local pressure at the puncture hole and applying some drops of the 
animal’s blood on the puncture hole prevented for CSF leakage. 
 
 
Post-operative Care 
Animals’ wellbeing, general health condition, urodynamic and body weights were assessed 
twice per day until day 35. The bladder was emptied manually twice a day until the rats were 
able to spontaneously empty their bladder again, usually within 14 days after the lesion. 
During the period of manual bladder emptying, the urine was routinely checked for bacteria 
growth using a urine dipstick.  
 
Functional Evaluation 
Rats were assessed for locomotor behavior with the Basso-Beattie-Bresnahan (BBB) open 
field test (36). Locomotor recovery was tested pre-SCI (baseline) and at days 1, 7, 14, 21, 28 
and 35 post-lesion. At post-surgery day 1, SCI-lesioned rats had to display a flaccid paraplegia 
(BBB score 0) before the application of Neuro-Cells or vehicle. Based on the established 
natural recovery, SCI-lesioned animals were also excluded when scoring was below 4 
(protracted recovery) and/or above 8 (partial lesion) at day 7 (37). The exclusion parameters 
of animals were established before the execution of the experiment. Open field locomotor 
function was assessed by two independent researchers, evaluating videotapes not aware of 
the treatment. 
 
Immunohistochemical Analyses 
At days 4 and 56, four rats out of the NC- and Veh.-treated SCI animals and three out of the 
NC- and Veh.-treated Sham animals were anesthetized with isoflurane (induction phase with 
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3-4% isoflurane and maintenance phase with 1.5–2.5% isoflurane) and sacrificed by 
transcardial perfusion with Ringer lactate (Baxter, pH 7.4). The spinal cord tissue of the 
entire affected area was positioned into cryo-molds in a longitudinal orientation and 
embedded in optimal cutting temperature compound (OCT, VWR, The Netherlands; for rats 
sacrificed 4 days post SCI) or porcine gelatin (10%, Sigma Aldrich; for rats sacrificed 56 days 
post SCI). Subsequently, the spinal cord tissue was snap frozen in liquid nitrogen and stored 
at -80°C until further processing. To assess the presence of human-derived transplanted 
cells, as well as astrogliosis, inflammation and apoptosis of the infused cells, serial 
longitudinal cryosections of the spinal cord (10 μm) were cut through the areas of interest: 
the rostral part of the lesion (RO), the center of the lesion (CE), and the caudal part of the 
lesion (CA), using a cryostat (Leica Biosystems), and then stored at -20°C until further 
processing. To identify human stem cells transplanted into the rat spinal cord at day 4 after 
infusion caudally to the lesion, antibodies directed against human mitochondrial 
(MAB1273C3, 1:100, clone 113-1, Millipore) were used. To study the early- and late-effects 
of Neuro-Cells in inflammation, astrogliosis and apoptosis, sections were incubated 
overnight at 4°C with the following primary antibodies:  rabbit anti-CD68 (Abcam, 1:500, 
ab125212), rabbit anti-GFAP (Abcam; 1:500, ab7260), and rabbit anti-cleaved caspase-3 (Cell 
signaling, 1:500, [Asp175] 9661). Sections were washed with 1 x PBS and incubated with 
secondary antibodies [(donkey anti-rabbit Alexa 488 (Invitrogen, 1:100) or donkey anti-
mouse Alexa 488 (Invitrogen, 1:100)] in 0,1% blocking buffer for 1 hour at room 
temperature. Cell nuclei were stained for 10 minutes with 4′,6-diamidino-2-phenylindole 
(DAPI, Thermofisher).  
For quantitation, two sections per rat were visualized with a confocal microscope (DSU, 
Olympus® BX51W1; 20x objective) and StereoInvestigator software (MicroBrightField, 
Williston, VT) and ImageJ programs (NIH, Bethesda, MD) were used for analysis. Image J was 
used to calculate the area of each anatomical region (rostral, lesion and caudal) and 
integrated mean density. The corrected total cell fluorescence (CTCF) of GFAP+ and CD68+ 
was calculated as integrated density – (area of selected region x mean fluorescent intensity 
of background reading). For the CA and RO sites of the lesion, fluorescence intensity was 
measured at the outer surface of the spinal cord and at the middle part of the section (2 
points at each part of the lesion (S1, Figure 1). For the CE part, fluorescence intensity was 
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measured at the border of the center lesion. The average values of fluorescence intensities 
from 2 images were used as the reference for comparisons within each group.  
Serum of the rats sacrificed at day 4 was taken for ELISA testing to determine the 
concentration of interleukins and compare the concentrations of the vehicle and Neuro-Cells 
treated SCI-lesioned animals with the sham lesioned animals. To study the concentrations of 
IL-1β, IL-6 and TNFα in a blood plasma, rat enzyme-linked immunosorbent assay (ELISA) was 
performed using Rat Interleukin 1 beta (Rt IL-1β) ELISA kit (ThermoFisher Scientific, 
Waltham, MA, USA), IL-6 Rat ELISA Kit (ThermoFisher Scientific, Waltham, MA, USA) and 
TNFα (Rt TNFα) Rat ELISA Kit (ThermoFisher Scientific, Waltham, MA, USA) according to the 
manufacturer's instructions. The microwell absorbance was measured at 450 nm with 
Promega microplate reader for all cytokines (Promega, Madison, WI, USA). 
 
Statistical Analysis 
Analyses were performed using statistical package SPSS 17.0 for Windows XP. Data were 
normally distributed as determined by Shapiro-Wilk tests for normality and we therefore 
performed parametrical statistical analyses on datasets. We performed a two-way ANOVA 
(with ‘group’ as the predicting factor and ‘lesion site’ as the moderating factor) to assess the 
data obtained from the histology study. If a group effect, level on spinal cord effect or an 
interaction effect (group x lesion site) was significant a post hoc Fishers Least Significant 
Difference (LSD) test was performed, after determining equality of variances using Levene’s 
test (which was the case unless stated otherwise). Repeated measures ANOVA was used to 
analyze the BBB score and the bladder recovery function over the different days with within-
subjects factor “testing day”, and “group” as fixed between-subject factors. Huynh-Feldt 
correction was used to correct for violations of sphericity. Rat survival as a function of 
treatment was determined as Kaplan-Meier estimates, and differences in the survival curves 
were evaluated with this method. There were no censored data. A p value ≤ 0.05 was 
considered significant. Data are presented as mean with standard error of the mean (SEM). 
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Proteomics  
 
Materials 
For proteomic studies in NC-treated and Veh-treated rats, sacrificed at day 56, ammonium 
bicarbonate, dithiothreitol, iodoacetamide and trifluoroacetic acid (ULC grade) were 
purchased from Sigma-Aldrich, urea from GE Healthcare, the enzyme mix trypsin/lysC (mass 
spec grade) from Promega, and water, acetonitrile, formic acid, all ULC grade, from Biosolve. 
Sample Preparation 
Gelatin was removed from the spinal cords by 3 washes in warm (30-35°C) 50 mM 
Ammonium bicarbonate (ABC). After washing, 5M Urea in 50mM ABC was added to the 
spinal cord tissues. Tissue disruption and lysis was performed by three freeze-thaw cycles 
using a warm water bath and liquid nitrogen. During 45 minutes, the lysate then was 
reduced with 20mM Dithiothreitol (DTT) before being alkylated with 40mM Iodoacetamide 
(IAM) for another 45 minutes in the darkness. The alkylation was terminated by 20mM DTT 
to consume any excess IAM. Digestion was performed with a mixture of LysC and Trypsin, 
which was added at a ratio of 1:25 (enzyme to protein). After two hours of digestion at 37°C 
in a water bath, the lysate was diluted with 50mM ABC to 1M Urea and further digested at 
37°C overnight. The digestion was terminated by addition of formic acid (FA) to a total of 1%.  
Biognosys iRT’s were added to each peptide sample according to manufacturer’s instructions 
(required for the DIA analysis using Spectronaut X software, Biognosys Inc., Beverly, MA, 
USA). 
 
Liquid Chromatography – Mass Spectrometry 
Peptide separation was performed on a Thermo Scientific (Dionex) Ultimate 3000 Rapid 
Separation UHPLC system equipped with an Acclaim PepMap C18 analytical column (2 µm, 
100Å, 75 µm x 150 mm). Peptide samples were first desalted on an online installed C18 
trapping column. Desalted peptides were then separated on the analytical column with a 90 
minutes linear gradient from 5% to 35% Acetonitrile (ACN) with 0.1% FA at 300 nL/min flow 
rate. The UHPLC system was coupled to a Q Exactive HF mass spectrometer (Thermo 
Scientific). DDA settings were as follows. Full MS scan between 375 – 1,500 m/z at resolution 
of 120,000 followed by MS/MS scans of the top 15 most intense ions at a resolution of 
15,000. The HRM DIA (data-independent acquisition) method consisted of a survey full MS 
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scan at 120,000 resolution at 350 – 1,650 m/z. Then 58 DIA windows were acquired at 
30,000 resolution (S2, Table 1). 
 
Data Analyses 
For protein identification the DDA spectra were analyzed with Proteome Discoverer (PD) 
version 2.1.1.21. Within the PD software, the search engine Sequest was used with the 
SwissProt Human (Homo sapiens (TaxID=9606) (v2016-11-30)) and Rat (Rattus norvegicus 
(TaxID=10116) (v2016-11-30) databases and the Biognosys iRT peptide sequences (supplied 
by Biognosys). The database search was performed with the following settings: enzyme was 
trypsin, a maximum of 2 missed cleavages, minimum peptide length of 6, precursor mass 
tolerance of 10 ppm, fragment mass tolerance of 0.02 Da, dynamic modifications of 
methionine oxidation and protein N-terminus acetylation, static modification of cysteine 
carbamidomethylation. The DDA measurements were used to create a spectral library using 
spectral library generation in Spectronaut 9 (39) (Biognosys). Only identifications with FDR of 
maximum 1% at peptide and protein level were taken into account for spectral library 
generation. For protein quantitation, the DIA data were analyzed with Spectronaut 9, with 
the manufacturer’s recommended default settings. 
 
Differential abundance testing 
Within each site of the lesion (RO, CE, CA), differential protein abundance between Neuro-
Cells- and vehicle-treated conditions was tested using Spectonaut’s built-in algorithm. 
Abundance data for proteins found differentially abundant with q-value below 0.05 was 
submitted to downstream functional analysis.  
 
Representations of biological functionality 
The following complementary knowledge-based classifications of protein functionality were 
used in combination, to create biological interpretation of the detected lists of differentially 
abundant proteins: i) Gene Ontology (including Biological Process and Cellular Component 
branches of the hierarchy) were adopted from GSEA website of Broad Institute (40) ii) 
regulons, generated by collecting the known transcription-target relationships from HTRIdb 
(41) and CellNet  (42) and iii) Reactome pathways (43). For all the functionality 
representations, members of the gene ID-based categories were remapped to protein IDs 
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with Bioconductor’s biomaRt package (44). The sets of protein IDs were restricted to 
proteins actually detected in the experiment (at any lesion site and condition).  
 
Protein set enrichment analysis 
Functionality enrichment tests with lists of responsive proteins (40) in context of the 3 
functionality representations described above, were performed with goseq package (45) 
using Wallenius approximation and correction for protein length. Statistical significance of 
the enrichment tests was estimated with 100,000 data permutations.  
 
Protein-sharing networks 
To identify response patterns at a general level rather than individual functional categories, 
we generated protein-sharing networks. For this purpose, we collected respective category-
protein relationships (e.g. Reactome pathways) and restricted them to proteins that were 
called responsive to Neuro-Cells in at least one of the three sites. Subsequently, for each pair 
of the categories (network nodes), the number of shared proteins was recorded and used to 
map to the width of the edge connecting those two nodes. The analysis was performed with 
a combination of R programming language (R core team, 2014) and Cytoscape network 
analysis platform (46) version 3.6.1.  
Results 
Animals  
During the quarantine period, 66 rats were randomized into two groups: group 1 (N = 49) for 
SCI-lesioning, and group 2 (N = 17) for sham-lesioning. Before this lesioning, though, one 
animal belonging to group 2 was lost because of intercurrent health problems, and during 
the SCI-lesioning another one (out of group 1), because of anaesthesia-related death. The 48 
surviving SCI-lesioned animals in group 1 were further randomized in 24 rats for treatment 
with Neuro-Cells (SCI-NC animals) and 24 rats for treatment with the Vehicle (SCI-Veh 
animals). The 16 surviving sham-lesioned rats were randomized into 7 animals for a 
treatment with Neuro-Cells (Sham-NC animals) and 9 animals for the intervention with the 
Vehicle (Sham-Veh animals). All SCI-lesioned animals had a BBB score of 0 points before the 
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application of their treatment. Day 4 of the study, 4 SCI-NC and 4 SCI-Veh as well as 3 Sham-
NC and 3 Sham-Veh. animals were sacrificed for immunohistochemistry. Within the first 
week after the SCI-lesioning, 13 animals had to be excluded from the experimental design: 2 
SCI-NC animals (due to direct perilesional surgical complications and shock) and 3 SCI-Veh 
animals (due to direct post-lesional convulsions, shock, and artificial-induced bladder 
rupture). Conform the protocol, another 4 SCI-NC rats had to be excluded because of a BBB-
score at day 7 < 4 (probably because of a histological confirmed increase of the SCI-lesion 
due to the intrathecal injection of the viscous Neuro-Cells preparation), and 4 SCI-Veh rats 
because of a BBB-score >8 (probably because of an impartial SCI lesion). During the study, 1 
SCI-NC rat and 5 SCI-Veh animals reached a humane endpoint due to SCI-surgery-induced 
complications. The 9 Sham-Veh and 7 Sham-NC treated animals, during the study, did not 
suffer any surgery-related complication, nor did they reach any humane endpoint. So, in the 
end 13 SCI-NC, 8 SCI-Veh, 9 Sham-Veh, and 7 Sham-NC treated rats completed the study, 
and were sacrificed at day 56. An overview of the study is displayed in Fig. 2.
Figure 2: Flowchart with the number of rats used in this study. Red squares represent animals 
excluded from the study as described in the text.
 
Survival
There were no mortalities in the 16 sham-lesioned animals. In the SCI-lesioned animals, 
apart from the 5 peri-lesional direct SCI-surgery related deaths, during the 56 days following 
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lesioning, 5 out of 13 Vehicle-treated animals reached a humane endpoint, due to 
development of ascites (n=3; day4, day5, day6), kidney failure (n=1; day18) and severe body 
weight loss (n=1; day38). In Neuro-Cells treated rats only 1 out of 14 animals reached a 
humane endpoint at day 10 post-surgery, due to severe body weight loss (Figure 2).  The SCI-
lesioned rats treated with Neuro-Cells appear to survive longer, as group differences 
reached significance (p≤0.05). A plot of the survival function is shown in Figure 3.
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Kaplan-Meier estimates of postoperative survival (adverse events reaching human end 
point) stratified by treatment with either vehicle or Neuro-Cells. Rats of the SCI-Neuro-Cells group 
survive longer (p≤0.05).
 
Adverse events, general health conditions, body weight and urodynamic functions
There were no mortalities in the 16 sham-lesioned animals. During the 56 days following 
lesioning, 5 out of 13 Vehicle-treated animals reached serious adverse events (SAEs) with a 
humane endpoint, due to development of ascites (n=3; day4, day5, day6), kidney failure 
(n=1; day18) and severe body weight loss (n=1; day38). In Neuro-Cells treated rats only 1 out 
of 14 animals reached such SAE at day 10 post-surgery, due to severe body weight loss 
(Figure 2).  The SCI-lesioned rats treated with Neuro-Cells appear to suffer significant less 
SAEs (p≤0.05). A plot of the survival function is shown in Figure 3. Apart from these SAEs, 
surviving animals, suffered a higher incidence in the NC-treated group (p = 0.12) of a 
temporary cystitis, favorably reacting to a treatment with Baycal.
All surviving animals, after a modest loss of body weight during the first week after surgery, 
did gain body weight during the following weeks of the study period. Animals that 
underwent spinal cord injury and that were treated with Neuro-Cells did not differ in body 
weight compared to vehicle-treated group at day 1 and day 35 post-surgery (S5, table 4). 
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Sham-lesioned animals, whether treated with Neuro-Cells or Vehicle, did not suffer any 
adverse event, loss of body weight, or any loss of urodynamic functions.  
Regarding the SCI-related loss of urodynamic functions, after surgery, all animals needed 
assistance with bladder voiding. Measuring manually expelled urine, NC-treatment did not 
affect the recovery of bladder control throughout a 14 day observation period (repeated-
measurement ANOVA, p = 0.916) as compared to the Vehicle-treated animals (see S6, Figure 
3). 
BBB Score
On day 1, the sham-lesioned groups received the highest BBB score possible, whereas both 
the SCI-treated groups scored the lowest possible (0 points), demonstrating the validity of 
this rat model of SCI. The scores increased in both SCI-vehicle and SCI-Neuro-Cells groups 
over time (repeated measure ANOVA, F (6,114) = 2.72, p<0.032). However, by 14 days and 
35 days post-surgery, there was a statistically significant difference in BBB scores between 
the Neuro-Cells- and vehicle-treated rats (p<0.01; p<0.008 respectively; Figure 4). These 
results indicated that Neuro-Cells induced functional improvement after SCI in rats.
 
 
 
 
 
 
 
 
 
Figure 4:  Effects of Neuro-Cells and Vehicle (placebo) on locomotor function in rats after SCI-surgery 
and sham SCI surgery. The first BBB evaluation took place at day 0, before surgery. At that time, no 
statistically significant differences in BBB scores were found between NC and Veh treated SCI-rats, 
whereas the BBB scores in the sham-operated rats during the whole study were   different from SCI-
operated rats (p<0.001). During the whole study, BBB scores in NC-treated SCI-rats were higher as 
those in Veh-treated SCI-rats, differences reaching significance at days 14 and 35 (*p<0.01). 
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ELISA-serum
The concentration of serum interleukin-1b, 6 and TNF-a were measured by ELISA. Figure 5 
compared the mean differences between the vehicle respectively Neuro-Cells treated 
animals with the Vehicle and Neuro-Cells treated sham lesioned animals. 
 
Figure 5:  Differences in serum concentration between the Veh.- and NC-treated SCI-lesioned and 
sham-lesioned animals at day 4. At that time, there was a significant increase of serum Interleukin-1β 
and serum TNF-α in the Veh.-treated SCI-lesioned animals compared to the Veh.- and NC-treated 
sham-lesioned animals, but not for the NC-treated groups (*p<0.05). The serum Interleukin-6 was 
lower in the NC treated SCI lesioned animals as compared to the Veh.-treated SCI-lesioned animals 
but both were significantly higher as compared to their sham-lesioned counterpart.
 
Immunohistochemistry
The survival of human transplanted stem cells was evaluated 3 days post-implantation of 
Neuro-Cells. Human positive cells were found partially attached to the spinal cord surface, 
which were identified by human mitochondrial epitopes (Figure 6B and 6C).
 
Figure 6: Presence of human cells at CA (and less in CE) in NC-treated SCI rats detected by human 
mitochondrial epitopes, displayed in representative images at CA, 3 days after the treatment.  A) 
DAPI, B) Human mt, C) Overlay. Scale bars represents 50 µm.
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Early effects (day 4) on post-injury cellular responses 
Monocytes and macrophages are key players of the inflammatory modulation and of the 
resolution of inflammation after SCI (47,48). In comparison to sham lesioned, vehicle or NC-
treated animals, we observed a significant effect at the SCI-induced lesion site (F (1, 
42)=56.02, p<0.001) in CD68+ expression at day 4, with an increase at the central part of the 
lesion. Post hoc analysis showed that the CD68+ expression was significantly increased 
(p<0.008) at the CA in the Neuro-Cells-treated rats compared to vehicle-treated rats (Figure 
7B). No differences were found in the CD68+ expression at the RO between the two treated 
groups (Figure 7B).   
SCI-induced astrogliosis is an important process in glial scar tissue formation, as reactive 
astrocytes increase their expression of GFAP. In order to assess astrogliosis in SCI rats 
(vehicle vs. Neuro-Cells) 4 days post-injury, we examined the GFAP expression at the RO, CE 
and CA site of the lesion, in relation to those in the sham lesioned, vehicle or NC-treated 
animals (Figures 6C and 7D). Analysis showed a significant main effect of the SCI-induced 
lesion site in GFAP expression (F (1,42)=29.05, p<0.001) with an increase in GFAP+ expression 
at the central part of the lesion. There was also a significant main effect of the group (F 
(1,42)=4.61, p<0.038), as Neuro-Cells treated rats had an overall lower number of GFAP+ 
expression as compared to the vehicle-treated group of rats. Post hoc analysis revealed a 
significant decrease in GFAP+ expression at the CE in the Neuro-Cells-treated rats (p<0.042; 
Figure 7D) when compared to vehicle-treated rats. No differences were found in the GFAP+ 
expression between the Neuro-Cells- and vehicle-treated groups at the RO or the CA site of 
the lesion (Figure 7D). 
Components of the caspase-3 apoptotic pathway are activated after traumatic SCI in rats 
and occur early in neurons at the injury site and hours to days later in oligodendroglia 
adjacent to and distant from the injury site (49,50). To examine the effects of vehicle and 
Neuro-Cells on apoptotic cell death after SCI, we quantified the expression of cleaved 
caspase-3+ at day 4 post-injury in relation to those in sham-lesioned, vehicle or NC-treated 
rats (Figures 7E and 7F). We found a significant effect in the SCI-lesion site (F (1,42)=9.30, 
p<0.001), namely an increased number of cleaved caspase-3+ cells at the lesion site and a 
significant main group effect (F (1,42)=6.13, p<0.017). Interestingly, a significant interaction 
effect (F (1,42)=4.45, p<0.018) was observed, suggesting that the pattern of cleaved caspase-
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3+ expression differs along the sites of the lesion depending on the group (vehicle versus
Neuro-Cells). Post hoc analysis revealed a significant decrease in cleaved caspase-3+ cells in 
rats treated with Neuro-Cells at the CA (p<0.003; Figure 7E and 7F) and at the CE (p<0.012), 
suggesting a decreased apoptosis in both segments. The number of cleaved caspase-3+ cells 
did not differ between Neuro-Cells and vehicle-treated rats at the RO site of the lesion 
(Figure 7E and 7F).
Figure 7: CD68+, GFAP+ and cleaved caspase-3+ cells in Veh.- and NC-treated rats across the RO, CE 
and CA sites (Lesion = CE) relative to the lesion at day 4 post-injury. Panels show representative 
examples of fluorescent labeling of CD68+ (A), GFAP+ (C) and caspase-3+ cells (E). For the caspase-3+
cells we quantify the total number of positive cells (E). Magnification bar represents 50 μm. The 
effects of NC in CD68+, GFAP+ and caspase-3+ at the RO, CE and CA sites are shown (B, D, F). The data 
are expressed as mean ± SEM. n = 7-8 sections per animal in each group. *: significant, p≤0.05.
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Late effects (day 56) on cellular responses
At day 56, we found a significant effect of the SCI-lesion site (F(1,40)=54.72, p<0.001) with a 
significant increase in CD68+ expression at the CE site but no significant differences were ob-
served between Neuro-Cells- and vehicle-treated rats at the RO, CE and CA sites (Figure 8A 
and 8B). A significant main effect of the lesion site (F (1,41)=6.56, p<0.003) with an increase 
in GFAP+ expression was also found at the CE site (Figure 8C). Post hoc analysis revealed no 
differences in GFAP+ expression between Neuro-Cells- and vehicle-treated rats at any site of 
the lesion (Figure 8D). A significant main effect of the lesion site (F (1,42)=8.67, p<0.001) was 
found in the number of cleaved caspase-3+ cells but post hoc comparisons between Neuro-
Cells and vehicle-treated rats did not reach significance, suggesting that the number of cells 
that are undergoing apoptosis was not different between both groups 56 days post-injury 
(Figure 8E and 8F).
Figure 8: CD68+, GFAP+ and cleaved caspase-3+ cells in Veh.- and NC-treated rats across the RO, CE 
and CA sites (Lesion = CE)  relative to the lesion at day 56 post-injury. Panels show representative 
examples of fluorescent labeling of CD68+ (A), GFAP+ (C) and caspase-3+ cells (E). For the caspase-3+
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cells we quantify the total number of positive cells (E). Magnification bar represents 50 μm. The 
effects of NC in CD68+, GFAP+ and caspase-3+ at the RO, CE and CA sites are shown (B, D, F). The Data 
are expressed as mean ± SEM. n = 7-8 sections per animal in each group. *: significant, p<0.05. 
 
Proteomic Studies 
Differential protein expression 
We quantified 573 protein abundances in SCI rats that were injected with Neuro-Cells and in 
SCI rats that were injected with vehicle at day 56 after administration. For this purpose, we 
used tissues from the three different anatomical sites of the lesion: i) rostral (RO), ii) center 
(CE), and iii) caudal (CA). We compared the functional analyses of the differentially abundant 
proteins with alternative functional classifications to assess the biological functionality 
relevant to the Neuro-Cells effects (see Methods). The most relevant representations 
appeared to be Regulons, Gene Ontology Cellular Component and Reactome pathways taken 
in a gene-sharing network context. 
 
Network of the functional responses: Reactome pathways 
Analysis of the sets of proteins that significantly changed their abundance in response to 
Neuro-Cells (with q-value below 0.05) in context of Reactome pathways, and limiting the 
search to pathways affected in either direction with p < 0.001, revealed 17 responsive 
pathways at RO, 33 at CE and 17 at CA. The total number of pathways that responded in any 
direction at any of the 3 levels of the lesion was 60. In order to reveal more general 
functional patterns that transcend categories of individual pathways, we constructed a 
protein-sharing urine network. Out of 60 responsive pathways, 55 (~92%) shared the 
underlying responsive proteins with at least one another pathway. Overall, all the 55 
pathways were found in 3 densely connected clusters and 2 outlier clusters of 2-3 pathways 
(Figure 9). While those clusters were identified on the basis of connectivity only, irrespective 
to the sign of response of their members to Neuro-Cells, subsequent visualization of the 
directions of the effect of Neuro-Cells on expression of the 55 pathways at every level of the 
lesion revealed that the highly connected clusters also showed a trend to consistent sign of 
response at a particular level, despite the much less consistent responses at pathway (and 
especially – individual protein) levels between the site of the lesion. Hence, by generalizing 
the considered biological entity from protein to pathway and then to network of pathways, 
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we found a progressively more consistent response to Neuro-Cells-treated rats at the 
different levels.   
In particular, the first cluster from the left was enriched in glycosylation, extracellular matrix, 
scavenger receptors, keratan and collagen metabolism related proteins. This cluster showed 
a clear trend to be impaired at the RO and CE sites, and to be upregulated at the CA site, 
although this last trend was no longer present after multiple testing correction.  The second 
cluster, in the middle of the network, was enriched in generally defined functional pattern of 
ion movements across membrane (including such categories as cardiac construction, ion 
homeostasis, ion transport, reduction of cytosolic Ca2+ levels, ion transport-by-type-ATPases) 
and semaphorins. This middle cluster had a trend to be upregulated by Neuro-Cells at all the 
3 sites of the lesion. The rightmost smaller cluster of 10 pathways was not connected in as 
dense manner as the major 2 clusters, and the response pattern of the pathways comprising 
it, was more site-dependent. Interestingly, “metabolism of carbohydrates” operated as a link 
between the two highly connected clusters with opposite trend of response to Neuro-Cells. 
“Extracellular matrix organization” also provided some protein-sharing links between the 
two clusters. 
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Figure 9: Protein-sharing network of the 55 responsive Reactome pathways that share proteins 
assigned to them. Significance of the pathway enrichment among proteins overexpressed with 
Neuro-Cells is mapped to red color, while pathway enrichment among lower expressed proteins is 
mapped to blue color. A, Rostral part of the lesion; B, Central part of the lesion; C, Caudal part of the 
lesion; D, Color map showing the range of -log10(FDR) values. Numerical pathway IDs: 1, Platelet 
activation, signaling and aggregation; 2, Respiratory electron transport, ATP synthesis by 
chemiosmotic coupling, and heat production by uncoupling proteins; 3, Advanced glycosylation end 
product receptor signaling; 4, Binding and Uptake of Ligands by Scavenger Receptors; 5, Cardiac 
conduction; 6, Chondroitin sulfate/dermatan sulfate metabolism; 7, Collagen biosynthesis and 
modifying enzymes; 8, Collagen formation; 9, Complex I biogenesis; 10, COPII (Coat Protein 2) 
Mediated Vesicle Transport; 11, Cristae formation; 12, CS/DS degradation; 13, Defective B4GALT1 
causes B4GALT1-CDG (CDG-2d); 14, Defective CHST6 causes MCDC1; 15,  Defective ST3GAL3 causes 
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MCT12 and EIEE15; 16,  Diseases associated with glycosaminoglycan metabolism; 17, Diseases of 
glycosylation; 18,  ECM proteoglycans; 19, Extracellular matrix organization; 20, Formation of ATP by 
chemiosmotic coupling; 21,  G alpha (12/13) signaling events; 22, Gluconeogenesis; 23, Glucose 
metabolism; 24,  Glycolysis; 25,  Glycosaminoglycan metabolism; 26,  Hemostasis; 27, HuR (ELAVL1) 
binds and stabilizes mRNA; 28,  Integrin cell surface interactions; 29, Ion homeostasis; 30, Ion 
transport by P-type ATPases; 31, Keratan sulfate/keratin metabolism; 32, Keratan sulfate 
biosynthesis; 33, Keratan sulfate degradation; 34,  Metabolism of carbohydrates; 35, Metabolism of 
fat-soluble vitamins; 36, Metabolism of RNA; 37,  Metallothioneins bind metals; 38, Netrin-1 
signaling; 39, Neurotransmitter receptors and postsynaptic signal transmission; 40, Neutrophil 
degranulation; 41, RA biosynthesis pathway; 42, Recycling pathway of L1 R-HSA-437239; 43, 
Reduction of cytosolic Ca++ levels; 44,  Respiratory electron transport; 45, Response to metal ions; 
46, Retinoid metabolism and transport; 47,  Retrograde transport at the Trans-Golgi-Network; 48, 
Scavenging by Class A Receptors; 49, Sema4D in semaphorin signaling; 50, Sema4D induced cell 
migration and growth-cone collapse; 51, Semaphorin interactions; 52, Smooth Muscle Contraction; 
53, SRP-dependent cotranslational protein targeting to membrane; 54, Transport of Mature mRNA 
derived from an Intron-Containing Transcript; 55, Transport of Mature Transcript to Cytoplasm. 
 
Insights on the upstream transcriptional regulatory events from proteomics 
Besides functional summarization of the observed protein-level changes, we also leveraged 
the known transcription factor – target gene relationships to gain preliminary insights on the 
possible upstream gene regulatory events mediating the observed responses to Neuro-Cells. 
While transcriptome data is required to draw this level of conclusions more directly and 
accurately and post-transcriptional and post-translational events alter the gene expression-
based signatures. We used backward projection of the en masse protein level changes, in 
order to map them to known sets of transcription factor targets to identify the responsible 
upstream transcriptional regulators. With this approach, 33 regulons were identified to be 
upregulated in Neuro-Cells injected rats compared to vehicle-treated SCI rats at the CE, 17 
regulons at the RO and 21 regulons at the CA respectively (S3, Table 2). When we examined 
the functions of the candidate regulons of the 3 areas, we found that the regulons identified 
at the CA and CE level had an identical reported function. In those regions 13 upregulated 
regulons involved in differentiation could be identified, though none at RO. These CA and CE 
situated regulons play a role in spinal cord motor neuron differentiation (LMO4), neuron 
differentiation (NLX2-2, RUNX2), astrocyte differentiation (NKX2-2, PAX6) and 
oligodendrocyte differentiation (OLIG1, OLIG2, SOX10). GOCC analysis revealed that in the 
actin cytoskeleton and actin filament the regulons identified at the CE were mainly located in 
the plasma membrane, whereas the regulons identified at the CA and at the RO were 
located in the mitochondrial membrane (Table 3, S4).  
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Discussion 
A large body of literature provides evidence for the beneficial effects of cell-based therapies 
in patients with SCI (51). Many studies have investigated the effects of stem cells as a 
potential treatment for SCI, however most of the studies failed to demonstrate safety and 
substantial functional improvement, after the use of manipulated stem cells (52). 
Manipulation of stem cells before administration leads to proliferation and/or to 
differentiation in a disease-free signalling environment that is not relevant to the initial aim 
of the transplantation. Without exposure to signalling proteins in the direct disease 
environment, active labelling and/or expanding will change the phenotype and function of 
the stem cells, and will bring these cells into the next stage of differentiation in which they 
are able to expand and/or to exert only basic functions. The latter, however, is key to the 
working mechanism in neurodegenerative disorders (30). Mesenchymal stem cells (MSCs) 
and Hematopoietic Stem Cells (HSCs) are not able to pass the blood-brain and central 
nervous system (CNS)-CSF barrier and after intrathecal application float in the CSF (53-55). 
However, signalling proteins are able to freely trespass these barriers and thus interact with 
these cells (56,57). We have developed therefore a standardized bone marrow fraction of 
not- or marginally-manipulated MSCs and HSCs (Neuro-Cells), which can be intrathecally 
injected into the disease environment.  
By depleting the erythrocytes and the majority of the lymphocytes of the original bone 
marrow-derived stem cell preparation, Neuro-Cells is suitable to be injected straight into the 
cerebrospinal fluid without eliciting an inflammatory reaction (rejection) (58,59). The 
advantage of Neuro-Cells over similar products is the fact that the HSCs and MSCs are not 
labelled or expanded, but are kept in their original state until intrathecally administered, 
allowing the exposure to the disease specific signaling environment and thus activating the 
release of paracrine factors by the stem cells to better control the neuron hostile 
environment (60-63). 
 
Both bone-marrow- and adipose-tissue-derived stem cells seem to improve motor 
dysfunction, though the exact mechanisms remain unclear. In this study, the human bone-
marrow derived stem cells (Neuro-Cells) offer the advantage that they were not labelled nor 
expanded when infused directly into the cerebrospinal fluid in SCI-treated rats, they interact 
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with the disease specific signaling environment (64-67). We speculate that the beneficial 
effects of Neuro-Cells during the first days after its intervention in acute SCI might be 
induced by its anti-inflammatory properties, as evidenced by histological findings and 
differences in serum interleukin concentrations at day 4 of the study. 56 Days after this 
intervention, histological analysis did not reveal any signs of anti-inflammatory properties 
anymore, though proteomics then provided enough insights in regulons and pathways to 
suggest that the improvement in locomotor activity at that time was rather associated with 
neurogenesis and axonal regeneration. Further research, though, is needed to indeed get 
proof of stem cell-exerted dedicated apocrine effects (maybe through extracellular vesicles), 
induced by the specific pathological environment. 
 
Several studies have shown that the therapeutic activity of MSCs is mainly mediated by MSC-
secreted factors, suggesting the possible involvement of extracellular vesicles (EVs) as 
important players mediating the therapeutic effects of cells being used as therapeutics (such 
as MSCs and endothelial cells) via regenerative and anti-inflammatory modes of action (64-
67). For instance, MSC-EVs were found to exert immune-suppressive effects, by enforcing 
M2 macrophage polarization and stimulating T cell induction (68). 
 
Early-onset effects of Neuro-Cells in SCI 
Treatment with Neuro-Cells 24h after surgery did not induce serious side effects or mortality 
in SCI-lesioned and sham-lesioned rats. Apart from a higher incidence of a temporary Baycal-
responsive cystitis in the NC-treated animals (P < 0.12), their ‘well-being’, body weight, and 
bladder control recovery during the entire study was comparable to that in Vehicle-treated 
rats (S5, Table 2, and S6, Figure 3). Importantly, not only SCI-related survival (serious adverse 
events leading to human end points) reached significance, NC-treated animals also reached 
(significant) better BBB scores.  
Considering the histological analyses, rats treated with Neuro-Cells initially showed a 
significant reduction in GFAP+ expression at CE, indicative for a lower number of reactive 
astrocytes. These glial cells are, amongst others, one of the key players in scar tissue 
formation following an insult to the spinal cord. Previously, it has been suggested that the 
improved motor function is associated with a reduction in astrogliosis (69). This question, 
though, is beyond the scope of the current study. 
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Furthermore, we showed that an early intervention with Neuro-Cells significantly increased 
the CD68+ cells, caudal of the lesion, 5 days after the acute injury. Several studies testing 
cell-based therapies in SCI have reported a decrease in inflammation, however it must be 
noted that different markers have been used to assess inflammation in SCI rats. In our study, 
we used CD68, which is frequently used as a marker for microglia and peripheral-derived 
macrophages, two cell types that are morphologically indistinguishable from each other. The 
primary role of microglia/macrophages is to remove tissue and cellular debris, thereby 
enabling the resolution of inflammation and tissue repair (70). Since blood-derived 
macrophages enter the site of injury after approximately 3 days, we speculate that our 
results mainly reflect the activation, and possibly the proliferation of resident microglia at 
the lesion and caudal site of the lesion following SCI and the rapid injection of viscous Neuro-
Cells (71). The residual presence of human macrophages in Neuro-Cells may be another 
factor explaining the increased CD68+ cells caudal to the lesion site in the rats treated with 
the xenotransplant. The anti-CD68 antibody used for immunostaining was specific for rat as 
well as for human proteins, thus possibly reflecting an immune reaction to the 
xenotransplant. It has also been reported that subpopulations of HSCs and MSCs do express 
CD68, which could explain the increased expression of CD68+ we observed caudal to the 
lesion and the lesion itself. Over time, due to migration and differentiation, the number of 
the CD68+ cells will eventually increase at all levels.  
Interestingly, we found significantly less apoptotic cells in the same anatomical regions 
(central and caudal part of the SCI-induced lesion) in the Neuro-Cells-treated SCI rats 
compared to the vehicle-treated rats. We found that 4 days after infusion with Neuro-Cells, 
rats in those parts of the lesion had significantly less caspase-3+ cells. The latter is in line with 
a recent study indicating that transplantation of bone-marrow stem cells in SCI mice 
downregulated the caspase-3+ cells after SCI (72). 
Importantly, cells that stained positive for the human mitochondria antibody were detected 
at CA and only few at CE in NC-treated rats, 4 days after administration (Figure 6). These 
results may suggest that Neuro-Cells migrated from the intrathecal space to the lesion and 
are able to integrate into the spinal cord tissue. Since only a few positive cells were detected 
at the lesion, these data also may suggest that the majority of the Neuro-Cells remained in 
the intrathecal space. Urdzikova et al. studying the immunomodulatory effects of human-
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derived MSCs administered in immune-competent rats with SCI have reported similar 
observations (73). 
 
Late-onset effects of Neuro-Cells in SCI 
Neuro-Cells continued to improve motor recovery during the 35 days post-injury 
observation. No effects though were found in GFAP+, CD68+ cells as well as the number of 
cleaved caspase-3+ cells in Neuro-Cells-treated as compared to vehicle-treated T-cell 
deficient SCI rats at any site of the lesion, at 56 days after administration. We speculate that 
the recovery has already happened during the study period resulting in no detectable 
difference in GFAP and CD68 positive cells. Moreover, it appears that Neuro-Cells-treated SCI 
rats had a higher number of cleaved caspase-3+ cells at the lesion 57 days post-injury, which 
may be explained by a recently demonstrated role of caspase-3 in mediating the 
differentiation of HSCs (74,75). Since Neuro-Cells also contains HSCs, we speculate that HSCs 
pass on their immunomodulatory effect to resident cells. However, it must be noted that 
small changes in long tracts can result in a significant improvement of locomotor functions 
and are not always related to the extent of the lesion (76).  
The regulation of spinal cord injury is possibly a function of complex pathway interactions of 
cellular and biochemical reactions to trauma-induced primary and secondary inflammatory 
processes and a dense scar formation.  Protein expression profiling in SCI rats injected with 
Neuro-Cells 56 days after treatment clearly demonstrated a distinct spatial localization at the 
rostral and caudal sites of the lesion, which is in agreement with literature (77,78). Our 
clustering analysis revealed upregulated regulons at the lesion that are involved in positive 
regulation of differentiation (e.g. astrocyte differentiation, neuron differentiation). Our 
analysis took into account the spatial distribution of proteins between Neuro-Cells- and 
vehicle-treated rats. To a certain extent, the same pattern was observed at CA but not at RO. 
Among the regulons that are significantly upregulated at CA are the LMO4, which is involved 
in ATP signaling that promotes neuron survival after hypoxia (79), and Olig1 and Olig2, which 
are linked to the development and maturation of oligodendrocytes (80,81). Both for CA and 
CE, NKX2.2, a regulon that has a critically important role in the differentiation of adult 
oligodendrocyte progenitor cells (OPCs) into remyelinating oligodendrocytes was 
significantly upregulated (82). Moreover, upregulation of HIF1A in the lesion itself is linked 
to regeneration of lost or damaged tissue in mammals that have a repair response (83). 
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Interestingly, in CE and CA, regulons of human origin could be identified (e.g. UBE2L3, 
ANXA7, ENO1, MYH11, HNRNPA0, TPD52), regulons which role is still obscure, thus providing 
a novel protein list through which NC might exert its recovery effects. This result may 
support previous evidence, suggesting that MSCs rapidly pass on their effect to resident 
cells, which may substantially mediate the NC-induced immunomodulatory and regenerative 
effects (84). SCI regulation might be the result of complex cellular and biochemical pathway 
interactions during primary and secondary inflammatory processes and scar formation.  
In the context of reactome pathways, we found a cluster enriched in glycosylation, keratan 
and collagen metabolism related proteins that appeared to be downregulated at the caudal 
site of the lesion and at the lesion but upregulated at the rostral site of the lesion.  It has 
been reported, that increased N-glycosylation correlates in vivo with increased astrogliosis 
(85). Down regulation of glycosylation in Neuro-Cells-treated rats may be responsible for the 
reduced astrogliosis we observed at all sites of the lesion. Interestingly, inhibition of collagen 
matrix formation in spinal cord lesions have also been associated with axonal regeneration 
and motor function recovery (86). An upregulation in ion movements across membrane (for 
instance the Ion transport by P-type_ATPases) and semaphorins was identified at all three 
sites of the lesion. P-type ATPases is a protein family that plays an important role in the ATP-
dependent flipping of phospholipids across the cell membranes, a biological process that is 
vital in vesicle trafficking. Semaphorins are expressed in the adult nervous system and have 
been implicated in controlling axon guidance (87-89). However, contrary to netrins, the role 
of semaphorins in regeneration has not been studied extensively. At the lesion, Netrin-1 and 
L1CAM related proteins are found to be significantly upregulated. In a rat model of nerve 
injury, Ke et al. have shown that overexpression of Netrin-1 in bone-marrow-derived MSCs 
improves functional recovery (90). The LICAM immunoglobulin family has been involved in 
the promotion of regenerative axon sprouting and functional improvement after CNS injury 
as well as neuronal migration and synapse formation (91-93). The significant upregulation of 
platelet activation observed at the rostral site of the lesion has previously shown to be 
associated with inflammation, angiogenesis, and tissue regeneration. Platelets-derived 
microparticles were found to trigger endogenous stem cell repair mechanisms after middle 
cerebral artery occlusion in rats (94). Our proteomic analysis revealed both a signal of 
plasma-membrane and extracellular space restructuring processes at the lesion and 
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unfolded another two ion transport gene sets at all three sites of the lesion (S7, Table 5), 
suggesting a paracrine effect of Neuro-Cells in SCI rats. 
 
Several studies have shown that the therapeutic activity of MSCs is mainly mediated by MSC-
secreted factors, suggesting the possible involvement of extracellular vesicles (EVs) as 
important players mediating the therapeutic effects of cells being used as therapeutics (such 
as MSCs and endothelial cells) via anti-inflammatory and apocrine modes of action (63-66)). 
For instance, MSC-EVs were found to exert immune-suppressive effects, by enforcing M2 
macrophage polarization and stimulating T cell induction (67). Extracellular vesicles (EVs), 
which include micro-vesicles, play an important role in intercellular communication both 
under physiological as well as pathophysiological conditions (95,96). EVs are carriers of 
active molecules regulating in a paracrine or endocrine manner the recipient cells (97,98).  
 
Taken together, in this particular experimental setting, Neuro-Cells did induce a beneficial 
effect over Vehicle in the treatment of acute balloon compression–induced immune-
deficient SCI-rats, significantly reducing SCI-related mortality and improving locomotor 
recovery. The advantage of applying low-immunogenic stem cells into T-cell derived 
immune-deficient rats is the prevention for rejection of the graft and/or host-versus-graft 
disease, without the co-application of immunosuppressive drugs, which may interfere with 
stem cell activities (33,34). Therefore, the significant acceleration of the natural, 
spontaneous recovery after SCI-lesioning in these rats, as shown in this research project, 
indeed, might be interpreted as a main effect of the stem cell transplant. The disadvantage 
in those immune-deficient rats, though, is that due to the reduced secondary posttraumatic 
inflammation in these animals, final balloon compression-induced damage with consequent 
sensorimotor and neurovegetative symptoms is significantly less when compared to 
immune-competent rats. As stem cells are supposed to reach their effects in acute lesions by 
suppressing (secondary) inflammation, it is thus realistic to expect a lower magnitude of 
their eventual beneficial effect in SCI-lesioned T-cell deficient rats. Another disadvantage is 
that those animals, indeed, especially after an intervention with inflammation-reducing stem 
cells, are more prone to infections (35). Most probably, this trend (p < 0.12) to a higher 
frequency of bladder infections in our NC-treated SCI-lesioned rats (as compared to the 
placebo-treated rats) might be explained in this way.  
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Conclusion 
Our study provided the first proof of concept that Neuro-Cells improved the survival and 
accelerated natural motor recovery after SCI. The effects of Neuro-Cells on pathological 
processes related to acute SCI are multiple. We speculate that an intrathecal injection of 
Neuro-Cells in spinal cord-injured rats, after some days, improved motor function initially, 
but not later on, in combination with a decrease of interleukins concentrations confirmed by 
histological established reduction of astrogliosis and apoptosis. The continued motor 
recovery may suggest that Neuro-Cells exert their effects on a dual role: 1) at an early stage 
via their anti-inflammatory properties and 2) resulting at a later stage in a modulation of the 
injury environment. Overall, by targeting multiple mechanistic pathways, the infused Neuro-
Cells may induce or pass on certain aspects of their regenerative properties, providing 
plausible biological mechanisms involved in the regenerative process. Therefore, this 
treatment holds great promise as a neuroregenerative treatment including functional 
recovery in a clinical setting with (sub)acute SCI patients. 
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Supplementary Material S1 
 
Figure 1: An example of a longitudinal section of the spinal cord, in which the fluorescence density 
was measured. Fluorescence intensity was measured using ImageJ at 2 points (the rectangles):  2 at 
the outer surface of the spinal cord and at the middle part of the section at the caudal and rostral 
part of the lesion and 2 points at the border of the lesion.
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S2.  
Table 1. DIA windows 
window start_mz end_mz center width 
1 350 366 358 16 
2 365 380 372,5 15 
3 379 392 385,5 13 
4 391 403 397 12 
5 402 414 408 12 
6 413 423 418 10 
7 422 432 427 10 
8 431 440 435,5 9 
9 439 449 444 10 
10 448 458 453 10 
11 457 466 461,5 9 
12 465 473 469 8 
13 472 481 476,5 9 
14 480 490 485 10 
15 489 497 493 8 
16 496 506 501 10 
17 505 514 509,5 9 
18 513 522 517,5 9 
19 521 530 525,5 9 
20 529 539 534 10 
21 538 547 542,5 9 
22 546 554 550 8 
23 553 562 557,5 9 
24 561 571 566 10 
25 570 579 574,5 9 
26 578 588 583 10 
27 587 596 591,5 9 
28 595 606 600,5 11 
29 605 614 609,5 9 
30 613 623 618 10 
31 622 632 627 10 
32 631 642 636,5 11 
33 641 651 646 10 
34 650 661 655,5 11 
35 660 671 665,5 11 
36 670 681 675,5 11 
37 680 691 685,5 11 
38 690 701 695,5 11 
39 700 713 706,5 13 
40 712 724 718 12 
41 723 737 730 14 
42 736 750 743 14 
43 749 764 756,5 15 
44 763 779 771 16 
45 778 793 785,5 15 
46 792 809 800,5 17 
47 808 825 816,5 17 
48 824 842 833 18 
49 841 861 851 20 
50 860 882 871 22 
51 881 906 893,5 25 
52 905 932 918,5 27 
53 931 961 946 30 
54 960 995 977,5 35 
55 994 1039 1016,5 45 
56 1038 1089 1063,5 51 
57 1088 1166 1127 78 
58 1165 1650 1407,5 485 
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S3 
Level of the Lesion Regulon P-value 
Caudal part of the Lesion TWIST1 
SOX2 
POU3F2 
HOXD10 
OLIG1 
NKX2-2 
OSR2 
PAX6 
LMO4 
ARHGAP35 
RORB 
ZNF536 
CHD5 
RFX4 
TBX3 
OLIG2 
FOXG1 
SRA1 
ZHX3 
SOX8 
0.005 
0.005 
0.008 
0.014 
0.016 
0.019 
0.020 
0.021 
0.024 
0.026 
0.027 
0.029 
0.029 
0.031 
0.032 
0.035 
0.036 
0.039 
0.,040 
0.043 
Central part of the Lesion TWIST1 
ARNT2 
LMO4 
JUN 
ZNF536 
PAX6 
RUNX2 
OLIG1 
THRA 
SOX10 
NKX2-2 
HIF1A 
ANKRD1 
ST18 
LHX2 
FOXG1 
INSM2 
RORB 
CSRNP2 
SPZ1 
NPAS3 
NFATC3 
POU3F2 
ATF1 
FEZF2 
INSM1 
NPAS2 
SOX8 
NR3C2 
TBR1 
FOXQ1 
ZNF529 
0.005 
0.004 
0.006 
0.007 
0.009 
0.010 
0.012 
0.013 
0.013 
0.017 
0.017 
0.019 
0.019 
0.021 
0.022 
0.023 
0.026 
0.027 
0.028 
0.033 
0.033 
0.037 
0.037 
0.039 
0.040 
0.041 
0.041 
0.043 
0.044 
0.044 
0.045 
0.045 
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Table 2: Upregulated regulons at the three levels of the lesion (caudal, lesion, rostral) in  
NC-treated SCI rats compared to vehicle-injected SCI rats.  
 
  
E2F6 
NAT14 
0.045 
0.045 
Rostral part of the Lesion SCMH1 
AR 
KLF4 
DMRT2 
RBMX 
TBX5 
KLF13 
EBF2 
FOXP3 
TFCP2L1 
CREB3L2 
CSDE1 
POU2F2 
MEOX1 
ZNF238 
FOXC2 
RNF10 
0.004 
0.004 
0.008 
0.012 
0.016 
0.020 
0.021 
0.030 
0.032 
0.033 
0.034 
0.035 
0.042 
0.042 
0.043 
0.044 
0.044 
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S4 
 
Lesion Site Cellular Compartment P-value 
 
Caudal part 
 
Plasma_Membrane 
Endoplasmic Reticulum Membrane 
Membrane 
Integral To Membrane 
Intrinsic_To_Membrane 
Ruffle 
Integral To Endoplasmic Reticulum Membrane 
Intrinsic To Endoplasmic Reticulum Membrane 
Integral_To_Plasma_Membrane 
Growth Cone 
Site_Of_Polarized_Growth 
 
0.024 
0.031 
0.035 
0.036 
0.036 
0.039 
0.044 
0.044 
0.044 
0.045 
0.045 
 
Central part 
 
Plasma Membrane  
Endoplasmic Reticulum Membrane  
Membrane  
Integral To Membrane  
Intrinsic To Membrane  
Ruffle  
Integral To Endoplasmic Reticulum Membrane 
Intrinsic To Endoplasmic Reticulum Membrane 
Integral To Plasma Membrane 
Intrinsic To Plasma Membrane 
Growth Cone 
 
0.024 
0.031 
0.035 
0.036 
0.036 
0.039 
0.044 
0.044 
0.044 
0.044 
0.045 
 
Rostral part 
 
Site Of Polarized Growth 
Heterogeneous Nuclear ribonucleoprotein Complex  
Cytoskeletal Part 
Actin Cytoskeleton 
Plasma Membrane 
Sarcomere  
Actin Filament  
Cell Projection 
 
0.009 
0.009 
0.015 
0.030 
0.044 
0.045 
0,.047 
0.048 
 
Table 3: Identified upregulated GO cellular compartment (GOCC) at the lesion, caudally  
and rostrally  to the lesion in Neuro-Cells-treated SCI rats. 
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S5 
 
Day post-surgery Experimental group Mean [g] SEM 
day1  SCI Vehicle 271 4.85 
  SCI Neuro-Cells 274 3.87 
day35 SCI Vehicle 279 9.00 
  SCI Neuro-Cells 272 6.72 
 
Table 4: Absolute body weight recorded at day1 and day 35 post-injury. Animals that underwent 
spinal cord injury and treated with Neuro-Cells did not differ in body weight compared to vehicle-
treated group at day 1 and day 35 post-surgery. 
 
 
 
 
S6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Bladder function. After SCI surgery, all animals needed assistance with bladder voiding. 
Treatment with Neuro-Cells did not affect the recovery of bladder control as seen in SCI-lesioned rats 
treated with vehicle throughout a 14 day observation period (repeated-measurement ANOVA, p = 
0.916; Figure 5B).  
 
 
  
STEM CELLS & SPINAL CORD INJURY 111
4
S7 
Reactome Pathway P-Value 
Gluconeogenesis____R-HSA-70263 3.86E-06
Glucose_Metabolism____R-HSA-70326 3.4E-05
Netrin-1_Signaling____R-HSA-373752 0.001
Glycolysis____R-HSA-70171
0.001
Post-Chaperonin_Tubulin_Folding_Pathway____R-HSA-389977
0.001
Advanced_Glycosylation_Endproduct_Receptor_Signaling____R-HSA-879415
0.001
Response_To_Metal_Ions____R-HSA-5660526
0.001
Semaphorin_Interactions____R-HSA-373755
0.002
Cardiac_Conduction____R-HSA-5576891
0.004
Ion_Homeostasis____R-HSA-5578775
0.004
RAF-Independent_MAPK1/3_Activation____R-HSA-112409
0.004
Nuclear_Signaling_By_ERBB4____R-HSA-1251985
0.006
Metallothioneins_Bind_Metals____R-HSA-5661231
0.006
Metabolism_Of_Carbohydrates____R-HSA-71387
0.009
Recycling_Pathway_Of_L1____R-HSA-437239
0.009
Crmps_In_Sema3A_Signaling____R-HSA-399956
0.010
Signal_Transduction_By_L1____R-HSA-445144
0.011
Carboxyterminal_Post-Translational_Modifications_Of_Tubulin____R-HSA-8955332
0.012
Ion_Transport_By_P-Type_Atpases____R-HSA-936837
0.012
L1CAM_Interactions____R-HSA-373760
0.013
Ion_Channel_Transport____R-HSA-983712
0.018
Activated_TLR4_Signalling____R-HSA-166054
0.020
Myd88-Independent_TLR3/TLR4_Cascade____R-HSA-166166
0.020
Toll_Like_Receptor_3_(Tlr3)_Cascade____R-Hsa-168164
0.020
Toll_Like_Receptor_4_(Tlr4)_Cascade____R-Hsa-166016
0.020
TRIF-Mediated_TLR3/TLR4_Signaling____R-HSA-937061
0.020
Dex/Hbox_Helicases_Activate_Type_I_IFN_And_Inflammatory_Cytokines_Production____R-HSA-3134963
0.030
RIP-Mediated_Nfkb_Activation_Via_ZBP1____R-HSA-1810476
0.030
TAK1_Activates_Nfkb_By_Phosphorylation_And_Activation_Of_Ikks_Complex____R-HSA-445989
0.030
ZBP1(DAI)_Mediated_Induction_Of_Type_I_Ifns____R-HSA-1606322
0.030
DSCAM_Interactions____R-HSA-376172
0.031
MAPK1_(ERK2)_Activation____R-HSA-112411
0.031
Activation_Of_The_AP-1_Family_Of_Transcription_Factors____R-HSA-450341
0.032
Negative_Feedback_Regulation_Of_MAPK_Pathway____R-HSA-5674499
0.032
Acyl_Chain_Remodeling_Of_CL____R-HSA-1482798
0.032
Beta_Oxidation_Of_Palmitoyl-Coa_To_Myristoyl-Coa____R-HSA-77305
0.032
PRC2_Methylates_Histones_And_DNA____R-HSA-212300
0.033
Myd88:Mal_Cascade_Initiated_On_Plasma_Membrane____R-HSA-166058
0.038
Myd88_Cascade_Initiated_On_Plasma_Membrane____R-HSA-975871
0.038
Myd88_Dependent_Cascade_Initiated_On_Endosome____R-HSA-975155
0.038
Toll_Like_Receptor_10_(Tlr10)_Cascade____R-Hsa-168142
0.038
Toll_Like_Receptor_2_(Tlr2)_Cascade____R-Hsa-181438
0.038
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Toll_Like_Receptor_5_(Tlr5)_Cascade____R-Hsa-168176 
0.038 
Toll_Like_Receptor_7/8_(Tlr7/8)_Cascade____R-Hsa-168181 
0.038 
Toll_Like_Receptor_9_(Tlr9)_Cascade____R-Hsa-168138 
0.038 
Toll_Like_Receptor_Tlr1:Tlr2_Cascade____R-Hsa-168179 
0.038 
Toll_Like_Receptor_Tlr6:Tlr2_Cascade____R-Hsa-168188 
0.038 
TRAF6_Mediated_Induction_Of_Nfkb_And_MAP_Kinases_Upon_TLR7/8_Or_9_Activation____R-HSA-975138 
0.038 
TRAF6_Mediated_Induction_Of_Proinflammatory_Cytokines____R-HSA-168180 
0.038 
Mitochondrial_Fatty_Acid_Beta-Oxidation____R-Hsa-77289 
0.039 
Pyruvate_Metabolism____R-HSA-70268 
0.040 
RHO_Gtpases_Activate_KTN1____R-HSA-5625970 
0.043 
Senescence-Associated_Secretory_Phenotype_(Sasp)____R-Hsa-2559582 
0.043 
Cargo_Concentration_In_The_ER____R-HSA-5694530 
0.044 
Oxidative_Stress_Induced_Senescence____R-Hsa-2559580 
0.044 
Mitochondrial_Calcium_Ion_Transport____R-HSA-8949215 
0.044 
Toll-Like_Receptors_Cascades____R-Hsa-168898 
0.047 
Formation_Of_Tubulin_Folding_Intermediates_By_CCT/Tric____R-HSA-389960 
0.049 
Table 5: Reactome pathways identified in Neuro-Cells-treated SCI rats at the lesion. 
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Efficacy of different doses of human 
adult bone marrow stem cell 
transplantation on angiogenesis  
in a rat model with hind limb ischemia 
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Abstract  
Background 
Stem cell transplantation has been implied to facilitate angiogenesis by direct paracrine 
effects on signaling pathways. There are many different sources, types, dosages and routes 
of administration of stem cells under investigation. In this study we tested the concomitant 
intramuscular and intravenous administration of human mesenchymal and hematopoietic 
stem cells from bone marrow aspirates in three different dosages in order to establish an 
optimal dose for angiogenesis. For this purpose a nude T cell deficient rat model with hind 
limb ischemia was used as a model for angiogenesis which did not warrant 
immunosuppressive drugs.  
Methods and Results 
Seven days after a surgical occlusion of the A. iliaca externa in the right hind limb, a baseline 
digital subtraction angiography (DSA) was performed, and animals were intra-arterially and 
intramuscularly injected with low, medium or high concentrations of human mesenchymal 
stem cells or with a saline 0.9% solution (vehicle). At day 35, DSA was repeated, and the 
images of both registrations were compared between the different concentration groups 
and the vehicle group.  
DSA clearly demonstrated the presence of occlusions, resulting in moderate to severe 
ischemia 7 days after ligation. Comparing Mean Gray Values at day 35 DSA versus day 7 DSA, 
the difference did show a natural decrease in the Vehicle-treated group, whereas low- and 
medium human mesenchymal stem cell doses established a significant increase. High dose 
had a tendency to decreased values resulting in muscle damage and further occlusions. A 
dose response could not be detected. 
 
Conclusions 
This study showed that the centrifuged human bone marrow suspension containing low and 
medium concentrations of mesenchymal and hematopoietic stem cells significantly 
improved the hind limb ischemia as compared to vehicle-treated group in T-cell deficient 
rats, and that this effect is almost lost with higher doses, maybe due to hyper viscosity.  
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Introduction 
Angiogenesis is essential for the function of most organs. The angiogenesis after organ injury 
or transplantation is key to the survival, regeneration and functioning of the affected organ. 
Stem cell transplantation was established to induce promotion of repair of ischemic tissue 
partially through angiogenesis which has been shown in models of hind limb ischemia for 
example (1). Stem cell therapies differ with respect to the origin of the cells, cell numbers 
and route of application (2) (3) (4, 5). Studies were for example performed with 
unfractionated bone marrow cells, endothelial progenitor cells and/or peripheral blood 
mononuclear cells which make comparison very difficult (3) (4, 5). In addition, the different 
cell types have different properties and functions. A recent meta-analysis could not identify 
an approach that is clinically established neither with respect to cell type , dose route of 
application (6). Mesenchymal stem cells offer a unique combination of anti-inflammatory 
and regenerative effects whereas endothelial stem cells may directly promote angiogenesis 
(7). In animals with subacute ligated femoral arteries, neo-angiogenesis with restoration of 
the blood flow to the ischemic limb was reported to develop after injection of different kinds 
of stem cells (8-15). These findings are considered to be the effect of both cell presence and 
the paracrine secretion of growth factors and cytokines. The role of the various cell types of 
the transplants (mesenchymal cells, hematopoietic cells, etc.), however, remains unclear, 
although after transplantation, both the number of circulating endothelial progenitor cells 
increases (16, 17). Some cells of the transplant were found to be incorporated into newly 
formed collaterals in ischemic areas (18). However, the intra-arterial versus the 
intramuscular route was found to be equivalent (6) which raises questions about the 
mechanisms since no direct initial contact of the transplanted cells with the injured tissue 
was apparently necessary (2). Although a systemic effect may be suspected, there was 
however a dose dependency in response (2).  
We asked in this study whether we can determine an optimal dose for the administration of 
unfractionated human bone marrow derived cells, containing a mixture of mesenchymal, 
hematopoietic stem cells and angiotrophic factors after centrifugation, in an 
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immunodeficient animal model in order to promote angiogenesis after hind limb ischemia. 
We combined intraarterial with intramuscular administration of human cells to test for 
enhanced revascularization after 35 days in a dose dependent manner.  
 
Methods 
The animal experiments were executed after animal approval was obtained. We chose an 
immunodeficient animal model which does not mandate the concomitant administration of 
immunosuppressive drugs in order to avoid confounding. 
After clinical examination, 35 female animals were anesthetized and the right A. iliaca 
externa was proximally occluded to establish a right hind limb ischemia. Rats were 
anesthetized with isoflurane, and the right hind limb was shaved with an electric clipper, and 
disinfected with ethanol. The animals then were subcutaneously injected with tramadol 2 
mg/kg body weight (BW) for analgesia. After an incision in the right hind limb, the A. iliaca 
externa was exposed and proximally occluded with Vycril 5-0. Subcutaneous tissue was then 
sutured with Vycril 3-0 and the skin was closed with Michel clamps. After the occlusion, the 
animals were kept one week in their cages for recovery before digital subtraction 
angiography. 
Seven days after the occlusion, the animals were again anesthetized with isoflurane and 
then the ventral region of the neck was clipped and disinfected with ethanol. The animals 
received Tramadol 2mg/kg BW subcutaneously for analgesia. First, a conventional X-Ray was 
performed to document the anatomic locations for further analysis. Secondly, the Arteria 
carotis communis sinistra (ACCS - left common carotid artery) was prepared and a catheter 
(1270.02 Umbilical Catheter, Vygon, 2,5 French 30 cm) was inserted into the ACCS and 
guided into the aorta, with the catheter tip ending directly in front of the bifurcation of the 
A. iliaca interna. Finally, a Digital Subtraction Angiography (DSA) was performed with a GE 
OEC 7700 X-ray device and using 0.3 to 0.5 ml of Ultravist® in a fast bolus to visualize the 
vessels of the rats. The complete DSA procedures were repeated at day 35 after the 
occlusion with the difference that the catheters were then inserted directly in the abdominal 
aorta. The DSA device (GE, OEC 7700) settings were 2 images per second at 1,1 – 1,2 mA and 
52 – 54mV. The analysis of the angiography was performed using ImageJ® software.  
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Cell preparation 
Six healthy volunteers were recruited for iliac crest-bone marrow collection, after giving 
written informed consents. Bone marrow samples were processed under good 
manufacturing practice (GMP) conditions by centrifugation according to standard operating 
protocols to obtain the buffy coat (internal product name ASCT01). The samples were 
analyzed to assess the total number of viable CD34+ cells. Within 48 hours after the bone 
marrow procurement, the samples were administered to the rats. During the whole 
procedure, bone marrow cells were kept between 2-8 degrees Celsius, which ensured a 
cellular viability greater than 95% (data not shown). Directly before administration to the 
rats, bone marrow cell suspensions were carefully resuspended and adjusted with sodium 
chloride 0.9% (vehicle) solution to the needed concentrations. Table 1 gives for each group 
the mean number of administrated viable CD34+ cells per kg. Study drugs (bone marrow cell 
suspension and vehicle) were injected both intraarterial (through the DSA catheter over a 
period of 10 min) and intramuscular through syringes, warmed in the water bath at 37°C 
prior to injection. The ratio of cells injected intraarterially and intramuscularly were 2:1. Cell 
concentrations for intraarterial injections are given in Table 1. 
 
The primary outcome of this study was the change in the vascular density of the blood 
vessels as an indicator of angiogenesis in the ischemic limbs after treatment with various 
doses of bone marrow cells versus treatment with the vehicle. Therefore, regions of interest 
(ROI) were set by conventional X-ray from the head of the femur to the distal end of the 
fibula of both the vascular occluded right and the intact left hind limbs of the individual rats. 
In these regions, the mean gray value (MGV) was visualized in the digital images taken 
during the subtraction angiography (DSA) at day 7 and day 35 (MGV-7 and MGV-35). MGV 
was calculated using the pixel calculator of the ImageJ® Software.  
The effect of the unilateral ligation of the (right) iliac artery was studied by comparing MGV-
7 of both legs. Then, the effect of the vehicle on vascularization in the right hind limb after 
ligation was studied by comparing Vehicle MGV-7 and MGV-35 calculations in the right hind 
limb. The effect of bone marrow cells on the vascularization in the ischemic legs was studied 
by comparing their MGV-7 and MGV-35 calculations in the ligated right hind limbs with the 
vehicle MGVs.  
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Statistical Analysis 
The changes in MGV for the different bone marrow cells treated groups were tested to the 
changes in the MGV for the Vehicle group using analysis of variance (ANOVA).  
The individual changes between the MGV at day 35 and day 7 for every group were tested 
within the group using a pair wise T-test. At last, the positive changes in the MGV ratio’s for 
the occluded legs are grouped as 1. No changes or negative changes are grouped as 0. With 
a Chi-square non parametric test the bone marrow treated group was compared with the 
Vehicle group and tested for significance.  Statistical significance was assumed with p<0.05 
levels. 
 
Results 
The surgery was successfully performed in all animals. There was no difference in body 
weight between the different treatment groups and the vehicle group before the surgery 
(data not shown). In the treatment group treated with the high bone marrow cell dose, two 
animals died during the application of this dose, and another one had to be sacrificed during 
follow-up. During the follow-up of the treated animals, all remaining animals showed an 
uncomplicated and expected body weight development (data not shown). During the study 
the limb temperatures were measured. The temperature of the limb was stable over time 
(data not shown). 
The MGV-7 and MGV-35 for both vascular occluded right and intact left legs were calculated 
for each animal. There was a significant decrease in MGV-7 in the occluded right legs as 
compared with the intact left legs in MGV-7 (figure 1a), which showed about 40% loss of 
calculated vascular density as compared to the left MGV. During the follow-up, vehicle-
treated animals showed significant progression up to roughly 60 % of the MGV at day 35 
(figure 1 b) which is in line with results in immunocompetent animal models (8).  
At day 35, a significant increase of vascular density was found in all other bone marrow cells 
treated groups compared to the vehicle treated group (figure 1b) except in the high dose 
group. To set these changes into proportion to each other, figure 1c presents the 
percentages of change in MGV at day 35 for the occluded leg for the different ASCT01 and 
vehicle treated groups. Low and medium dose of unfractionated bone marrow cells 
improved mean gray values significantly which high dose treatment did not. The 
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proportional improvement was highest in the low dose bone marrow cells group. We then 
asked the question whether there was a correlation between the number of CD34+ cells and 
the MGV improvement. Figure 2 represents the dose response curve which showed no clear 
correlation between the absolute number of CD34+ cells administered intra-arterially and 
intramuscularly and the absolute change in MGV at day 35 compared with day 7. 
The concomitant application of cells intra-arterially and intramuscularly into the affected 
limb was done to optimize the re-vascularisation. Angiographical data, as obtained during 
this study, illustrated that the newly formed vessels were still very small. A representative 
study is shown in Figure 3. 
 
Discussion 
We used for our study a T cell deficient rat model in order to avoid confounding effects of 
immunosuppressive drugs. The critical limb ischemia did deteriorate in the vehicle group, 
which is in line with the natural course of the disease. In order to promote the effects of the 
unfractionated bone marrow preparation we tested the combined intraarterial/intra-
muscular treatment with human bone marrow-derived stem cells in the ischemic leg, at day 
35 in a dose dependent manner. We found no dose dependency but a profound clinical 
improvement after the lower and medium cell concentrations with a significant increase of 
vascular density, if compared with the reduced vascular density at day 7. This significant 
repair of vascular density, though, was not seen in the animals treated with higher bone 
marrow cell concentrations. Treating the ligated legs with these high doses, on the contrary, 
had a non-significant tendency to further loss of vascular density as compared to the MGV-7 
situation was established. We tested in 5 animals the highest possible cell concentration of 
bone marrow cells which resulted in the death of 2 out of 5 rats during administration of this 
preparation. Although in general, bone marrow cell treatment was well tolerated in the low 
and medium dose groups, in the higher dose groups there were some difficulties with the 
intra-arterial administration, due to the high viscosity of the solutions, probably resulting in 
physical obstruction in these vessels despite the rather long infusion period.  
 
Angiographic data illustrated that the newly perfused vessels were still very small (Figure 4). 
This could indicate that our intra-arterial and intramuscular approach did not generate an 
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expedition of the underlying angiogenesis. The process of angiogenesis is starting up slowly, 
making the clinical improvements initially difficult to detect. Therefore, a longer follow up 
period after treatment would probably result in more and longer blood vessels formation 
and diameter in the treatment groups. This is most likely not possible in the placebo group 
due to the natural deterioration of the hind limb occlusion.  
Our approach of intra-arterial plus intramuscular administration was very different from 
currently clinically tested intramuscular or intra-arterial approaches (7) (6). We chose the 
combined approach to bring the cells to the circulation and allow access from the 
endothelial side for cell to cell interaction and secretion of paracrine factors (19) (20). In 
addition, the allogenic cells have a short half-life irrespective of the immunosuppression of 
the animals (21). The chosen xenograft model, in which T-cell deficient rats were treated 
with human bone marrow stem cells without any further immune suppression, is useful in 
order to avoid the confounding effects of immunosuppression (22). It has the advantages, 
such as better animal treatment conditions, and better mimicking the human clinical 
situation when compared with studies were immune suppressive drugs were used.  
It would be interesting to also assess the effect of individual treatments (intra-arterial and 
intra-muscular administration) to clarify the contribution of each route of stem cells 
administration. Since clinical trials have shown an equipoise between the two administration 
routes we did not include these groups in order to reduce the number of experimental 
animals.  
  
 
We faced serious limitation due to the high viscosity which makes this approach less 
promising (4). Our study has additional limitations with respect to the time period of follow 
up and the mode of administration. The approach to test cell-based or cell-derived 
preparations in T-cell deficient rats is however possible and allows the assessment of cell-
based or cell-derived preparations without additional drugs administration since the quest 
for the best cell preparation is still ongoing (21). The different properties of the cell mixture 
of bone marrow versus mesenchymal stromal cells offers opportunities in particular with 
respect to immunomodulation and/or regeneration (23). Despite the evolving evidence for 
clinical effectiveness of autologous bone marrow derived treatment (7), the preparation of 
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bone marrow and the selection of subgroups of cells from bone marrow warrants further 
studies (4).  
 
Conclusion 
This study reports that T cell deficient rats can be used as a model for angiogenesis after 
critical limb ischemia. We used the immunosuppressed animals to test centrifuged human 
bone marrow suspension containing mesenchymal and hematopoietic stem cells  which 
significantly improved hind limb perfusion in T cell deficient rats. This study did show that 
the centrifuged human bone marrow suspension containing low and medium doses of bone 
marrow cells significantly improved the hind limb ischemia as compared to vehicle-treated 
group in T-cell deficient rats, and that this effect was lost with higher doses, most likely due 
to hyper viscosity.  
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Overview MGV-7 and MGV-35 values in the ischemic right hind leg (left) and in the intact left hind leg. 
(a) MGV in intact left leg for Vehicle, low dose, medium dose and high dose group.  (b) MGV in occluded right 
leg for vehicle, low dose, medium dose and high dose group. Significance compared to MGV-7 with ANOVA 
marked with * p<0.01. (c):  Percentage of change between the MGV at day 7 and 35 for the occluded leg and 
the different groups. (*1) Deterioration of the limb ischemia in vehicle treated animals (Pair wise T-Test p = 
0.003);  (*2) Difference after low dose cell therapy to the vehicle treated group (ANOVA p < 0.001); (*3) 
Difference after medium dose cell therapy to the vehicle treated group (ANOVA p < 0.01). No improvement 
after high dose therapy. 
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Figure 2: The dose-response graph describes the relationship between the total number of CD34+
cells in low and medium dose ASCT01 and the improvement on day 35 in Mean Gray Value (MGV). 
The values are weighted by dividing the expected value by the measured value for each point. The R2
is 0,216, which means that no correlation between the total CD34+ and the Mean Gray Value was 
found.
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Figure 3  
 
 
Figure 3: Example of a set of angiographic images of a with human bone marrow cells (ASCT01) 
treated T cell deficient rat. The left image is taken at day 7 (before treatment) and the right image is 
taken at day 35 after the treatment with low dose of human bone marrow cells. Despite concomitant 
application of cells intramuscularly and intravenously, the newly formed vessels are very small.  
 
 
STEM CELLS & HIND LIMB ISCHEMIA 127
5
 
 
 
Table 1 Overview mean number of CD34+ Cells per treatment group 
Concentration group Mean number of viable CD34+ 
Cells administered intraarterially 
(I.A.) and intramuscularly (I.M.) 
per animal  
Total number of rats 
Low Concentration 
 
I.A.: 327,600 CD34+ Cells/kg 
I.M.: 163,800 CD34+ Cells/kg 
7  
Medium Concentration 
 
I.A.: 688,800 CD34+ Cells/kg 
I.M.: 344,400 CD34+ Cells/kg 
6  
High Concentration 
 
I.A.: 1,308,000 CD34+ Cells/kg 
I.M.: 654,000 CD34+ Cells/kg 
5 
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Abstract 
Autologous fat transfer (AFT) is limited by post-operative volume loss due to ischemia-
induced cell death in the fat graft. Previous studies have demonstrated that electrical 
stimulation (ES) promotes angiogenesis in a variety of tissues and cell types. In this study we 
investigated the effects of ES on the angiogenic potential of adipose-derived stem cells 
(ASC), important progenitor cells in fat grafts with proven angiogenic potential. Cultured 
human ASC were electrically stimulated for 72 hours after which the medium of stimulated 
(ES) and non-stimulated (control) ASC was analysed for angiogenesis-related proteins by 
protein array and ELISA. The functional effect of ES on angiogenesis was then assessed in an 
in vivo model.  
Nine angiogenesis-related proteins were detected in the medium of electrically (non-) 
stimulated ASC and were quantified by ELISA. The pro-angiogenic proteins VEGF and MCP-1 
were significantly increased following ES compared to controls, while the anti-angiogenic 
factor Serpin E1/PAI-1 was significantly decreased. Despite increased levels of anti-
angiogenic TSP-1 and TIMP-1, medium of ES-treated ASC significantly increased vessel 
density, total vessel network length and branching points in chorio-allantoic membrane 
assays. In conclusion, our proof-of-concept study showed that ES increased the angiogenic 
potential of ASC both in vitro and in vivo.  
 
Introduction 
Autologous fat transfer (AFT; also called fat grafting or lipofilling) is a widely used 
reconstructive and aesthetic procedure, wherein fat is harvested as an injectable filler to 
augment or reconstruct tissue in all regions of the body 1. Currently, post-operative volume 
loss, described to be ranging from 40 to 80% of the initial graft volume 2-4, is a significant 
limitation of AFT, and often requires additional grafting procedures. A lack of blood flow 
through the graft necessitates the transplanted  cells to fully rely on the diffusion of oxygen 
and nutrients from surrounding tissue for their survival 5. In an experimental mouse model, 
Kato et al 6 have shown that only adipocytes in the outermost layer of the transferred fat 
tissue survive the first week post-operative, while adipocytes present inwards of the 
diffusion limit  of approximately 300 µm quickly die.  
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Numerous studies have focused on revascularization of the graft by stimulating angiogenesis 
in order to improve graft survival and maximize the retained graft volume. Approaches 
primarily focused on increasing the vascularization of the recipient site pre- and post-
operatively 7,8 or on modifying the pro-angiogenic potential of the adipose graft itself by 
adding single growth factors (i.e. FGF-2, PDGF and IL-8) 9-11, platelet-rich plasma 12,13, by 
adding regenerative cells from stromal vascular fractions 3,4 or by adding isolated adipose-
derived stem cells 14,15. While administration of angiogenic growth factors has been proven 
to stimulate angiogenesis 16, clinical implementation is hampered by the short serum half-
life and adverse effects associated with continuous administration 17. Others have suggested 
to enrich fat grafts with a heterogeneous population of regenerative cells, called the stromal 
vascular fraction, which is normally present in adipose tissue 18,19. This procedure has been 
dubbed cell-assisted lipotransfer (CAL) 19. However, Peltoniemi et al. 20, did not find CAL to 
be superior to non-enriched fat grafts in respect to graft volume retention and for this 
reason concluded that regular AFT is cheaper, faster and has a lower risk of contamination. 
Adipose-derived stem cells (ASC) being abundantly present in adipose tissue are part of this 
stromal vascular fraction and have been studied for their angiogenic properties under 
numerous conditions 14,15,21-25. In the only human clinical trial so far applying pure ASC, the 
authors isolated ASC from aspirated fat and expanded them in vitro for enriching the fat 
grafts that were injected in a second procedure 26. Although ASC-enriched fat grafts 
remarkably retained 80.9% of the original graft volume (versus 16.3% for the controls), 
incorporating ex vivo expansion in daily clinical practice remains difficult because of its time 
and labour intensiveness, associated high costs and regulatory issues. Taking above 
mentioned limitations into account, a potential treatment which increases graft volume 
retention by stimulating revascularization in a cost-effective, non-invasive way is therefore 
essential to improve clinical care. 
Previous in vitro and in vivo studies have demonstrated that electrical stimulation (ES) is able 
to stimulate angiogenesis in a variety of tissues and cell types 27-32. Sheikh et al 
demonstrated for example that ES of ischemic rabbit hind limbs significantly induced both 
arteriogenesis and angiogenesis 27. The exact mechanisms remain to be elucidated, although 
in endothelial cells the enhanced release of VEGF and activation of VEGF receptors (VEGFRs), 
phosphatidylinositol-3-kinase (PI3K)-Akt and Rho-ROCK elements of the VEGFR signalling 
pathway play a significant role 29. A major advantage of ES is that by influencing the 
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secretion profile of stimulated cells it can induce autologous cells to secrete a myriad of 
important factors, in contrast of having to inject specific exogenous factors 30. In light of 
these findings, we hypothesized that ES would enhance the secretion of paracrine 
angiogenic factors by ASC, leading to increased angiogenesis. In this study we aim to 
determine whether ES of ASC can stimulate in vivo parameters of angiogenesis. 
 
Results 
 
Determination of the electrical stimulus parameters  
A titration experiment was performed to analyse the effect of different electrical stimulation 
parameters (i.e. voltage, pulse duration and frequency) on the viability and detachment of 
the ASC after 72 hours of continuous stimulation. Starting with 4 V/cm, 6 ms pulses at a 
frequency of 2 Hz, one parameter per experiment was increased or decreased (n=3). High 
viability of the cells was detected for a maximum voltage of 4 V/cm and maximum pulse 
duration of 6 ms. Thereafter viability decreased versus unstimulated control (Fig. 1). The 
decrease in viability was paralleled by cell detachment in culture. Frequency had a lower 
impact on viability and a decreased viability was only seen when the frequency was set to 
the device’s maximum (25 Hz).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Determination of relative cell viability after electrical stimulation. Relative cell viability of 
electrically stimulated ASC for 72 hours versus unstimulated controls (CTRL set at 100%). Starting 
with a protocol of 4 V/cm, 6 ms pulses and 2 Hz, one parameter was changed per experiment while 
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the other two parameters were kept at the original level. (A): Voltage was increased and decreased 
twofold. 4 V/cm had no effect on cell viability, whereas 2 V/cm increased viability and 8 V/cm 
decreased viability. (B): Pulse duration was set at 6 ms, 3ms and 12 ms. Where 6 and 3 ms had no 
effect on cell viability, 12 ms decreased cell viability. (C): Only frequencies of more than tenfold the 
starting value showed a decrease in viability. Values are expressed as the mean percentage of 
relative viability (of ES vs. CTRL) +SD. n=3 per parameter.    
 
 
An additional experiment was conducted to investigate the effect of different electrical 
stimulation parameters on the concentration of VEGF A in the conditioned medium as a key 
component of angiogenic process (Fig. 2). Using  4V/cm, 6ms pulse duration and 2 Hz we 
found a 1.85 times increase in VEGF concentration compared to non-stimulated control. 
Elevated levels of VEGF were also found when we increased voltage (factor 1.48 at 8V/cm), 
pulse duration (factor 2.59 at 12ms) and frequency (factor 10.41 at 25Hz). However, in case 
of the elevated voltage and pulse duration groups, cells were substantially detached which 
was even in part reflected by increased cell death. This phenomenon was especially 
prevalent when ASC were exposed to the highest frequency, explaining the relatively high 
VEGF concentration in this group. When the pulse duration was decreased to 3ms, a 1.92 
times higher VEGF concentration was found when compared to unstimulated cells. However, 
the inter group variation between concentrations was higher when compared to the cells 
exposed to 4V/cm, 6ms, 2Hz. Importantly this latter protocol was also used as preferred 
setting in a previous publication.33 Based on the group homogeneity and historical data, the 
parameters 4V/cm, 6 ms and 2 Hz were used as standard setting for the study. 
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Figure 2. Three stimulation runs, each containing two ES groups and a control, were 
performed to analyse the effect of different treatment settings. Using  4V/cm, 6ms pulse 
duration and 2 Hz a 1.85 times increase in VEGF concentration was found compared to non-
stimulated control. Elevated levels of VEGF were also found when we increased/decreased 
voltage. In the elevated pulse duration and frequency groups, cells were substantially 
detached which was in part reflected by increased cell death, especially in the 25Hz group, 
explaining the highly increased VEGF A expression. Values are expressed as the mean VEGF 
expression relative to control. N=3 per stimulation protocol.
Conditioned medium of electrically stimulated adipose-derived stem cells contains 
multiple pro- and anti-angiogenic factors. 
Medium of both ES and CTRL ASC cultures for time points 0h (baseline) and 72h were 
screened for the presence of pro- and anti-angiogenic factors using a human angiogenesis 
proteome profiler array (Fig. 3A), which has been used for ASC before 34. The presence of 13 
separate proteins was detected in the conditioned medium of ES and CTRL 72h, of which 9 
proteins (IGFBP-3, IL-8, MCP-1, PTX-3, SERPIN-E1, SERPIN-F1, TIMP-1, TSP-1 and VEGF-A) 
were above the pixel density threshold of 1x103 arbitrary units (Fig. 3B). No difference 
between control and ES group in terms of baseline medium was found. Regarding the typical 
semi-quantitative nature of the protein profiler array, no conclusions were drawn for 
differential signal between the groups. Rather, the proteins above threshold were assigned 
for further quantitative analysis.
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Figure 3. Screening of conditioned medium using a human angiogenesis proteome profiler 
array. (A): the respective membranes are depicted for CTRL and ES 0h and 72h, respectively. 
Next to the positive array controls in upper left, upper right and lower left corners, the in 
duplo spots for a total of 13 proteins were visible after scanning.  (B): Mean pixel density 
was calculated for each spot, after normalization to the background. Nine proteins reached a 
minimum mean pixel density of 1x103 arbitrary units (a.u.; dotted line). For each group a 
single medium sample was analysed. 
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Electrical stimulation increases both pro- and anti-angiogenic proteins in ASC medium 
To confirm and quantify differential expression of the identified proteins, ELISA were 
performed on baseline 0h medium and on the CM of 4h-72h for each of the 9 proteins. 
Protein levels in the CM showed an increase parallel to post-stimulation time, with no 
apparent differences between CTRL and ES for the first 48h (Fig. 4A; depicted for VEGF-A). 
All secreted proteins analysed revealed a similar pattern with a gradual increase in 
concentration over time. At 72h significant differences between ES and CTRL were detected 
for several proteins (Fig. 4B); VEGF A (1.99 vs. 1.30 ng/mL; p=0.04), TSP-1 (1,93 v. 2,59 
ng/mL; p=0.03), TIMP-1 (356.50 vs. 512.90 ng/mL; p=0.04), and MCP-1 (3.26 vs. 5.38 ng/mL; 
p=0.04) were significantly increased in the ES group vs CTRL, whereas Serpin-E1 was 
significantly decreased in the ES group vs CTRL (59.6 vs 88.3 ng/mL; p=0.03). PTX-3 was 
increased in the ES group vs. control (7.90 vs. 12.77 ng/mL), however the difference did not 
reach statistical significance (p=0.08). Since only the 72h medium showed significant 
differences in protein secretion between groups, medium of this time point was used in 
subsequent functional assays.  
 
 
Figure 4. Quantification of the identified proteins with ELISA. (A): Concentrations of VEGF in the CM 
over time, ES vs. CTRL. The concentration at 72h was significantly different for ES compared to CTRL 
(p=0.04). The gradual rise in concentration visible in the time curve was representative for that of the 
other proteins. (B): MCP-1 was significantly increased in ES vs CTRL (p=0.04), whereas the increase in 
PTX-3 did not reach statistical significance (p=0.08). (C): Serpin-E1 was significantly decreased in ES vs 
CTRL (p=0.03), whereas IGFBP-3, IL-8 and Serpin-F1 were not statistically different. (D): TSP-1 and 
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TIMP-1 were both significantly increased in ES vs. CTRL (p=0.03 and p=0.04, respectively). Values 
displayed are mean+SD. * p<0.05. n=4 per group. 
 
 
Conditioned medium of electrically stimulated ASC induced angiogenesis in vivo.  
To determine whether the observed changes in angiogenesis-related proteins after electrical 
stimulation induced an angiogenic effect in vivo, a CAM assay was performed. In the ES 
group compared to controls, a significant increase in density of the vessels within the ring 
was detected (34.7 vs 30.3%; p<0.05), as well as an increased total vessel network length 
(18,541 vs. 16,621 px; p<0.01) and a higher total number of branching points (447 vs. 380; 
p<0.05) (Fig. 5). Representative images of the control and ES-treated CAMS, including their 
analysis, can be found in Supplementary Figure S1 online.  
 
 
Figure 5. Conditioned medium of electrically stimulated ASC induced angiogenesis in vivo. ES CM 
significantly increased vessel density (A), total vessel network length (B) and total number of 
branching points (C) compared to CTRL CM in a chorioallantoic membrane (CAM) assay. * p<0.05; ** 
p<0.01; **** p<0.0001. n=4-7 CAMs per group. px = pixel, ns = not significant, NaCl = 0.09% sodium 
chloride as negative control, nCM = non-conditioned baseline medium, CTRL 72h = non-stimulated 
conditioned medium after 72h of incubation, ES 72h = electrically stimulated conditioned medium 
after 72 hours, VEGF = positive control. 
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Supplementary figure S1. Representative images of the ES and CTRL CAM at day 14. (A): 
contrast agent was injected under the CAM to enhance the identification of capillaries 
before photographs were made. (B): lower panels reflect the computer analyzed overlays, 
wherein all vessels are tracked by automated Wimasis image analysis service.  
 
Discussion 
This proof-of-concept study demonstrates that ES of ASC improves in vitro and in vivo 
parameters of angiogenesis. Using a protocol of continuous stimulation with a biphasic 
electrical current of 4 V/cm, 6 ms pulse duration with a frequency of 2 Hz, we detected 
significant differences in ASC secreted protein level for several pro- and anti-angiogenic 
proteins after 72 hours of ES. ES of ASC significantly augmented the concentrations of the 
pro-angiogenic proteins VEGF-A 35 and MCP-1 36, whereas the anti-angiogenic protein Serpin 
E1/PAI-1 37 was significantly decreased compared to non-stimulated controls. The elevated 
level of VEGF confirms and extends previous work from Tandon et al. 38, showing increased 
VEGF-A mRNA expression after ES of ASC. The concentrations of VEGF found in the 
conditioned medium range from an average of 1.30 ng/mL for the control group to an 
average of 1.99 ng/mL for the ES group, representing a 153% increase in VEGF. This increase 
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seems biologically relevant since the concentrations of 1.30 and 1.99 ng/ml fit exactly in the 
biologically relevant range of concentrations, reported to stimulate endothelial cells in vitro 
39. A robust increase of VEGF-A mRNA expression and/or VEGF-A protein level in response to 
ES is also supported by studies focusing on various other human cell types, such as 
endothelial cells 29, bone marrow-derived mesenchymal stromal cells 30, cardiomyocytes 40, 
osteoblasts 41 and skeletal muscle cells42. Although an influence of ES on the secretion of 
MCP-1 was shown for macrophages 43, no reports have been made on a similar effect for 
ASC. Only for ASC stimulated with the pro-inflammatory stimulus TNF-α an increase of MCP-
1 secretion has been shown 44,45. Comparably, TNF-α-induced upregulation has been 
reported for Serpin E1/PAI-1 44,45, whereas we provide data showing the opposite to occur 
after ES. Taken together, these findings suggest that ES is not the equivalent of a pro-
inflammatory stimulus, a finding which is important for clinical translation where the 
amplification of the pro-inflammatory environment post-operative must be avoided. In 
addition to the pro-angiogenic factors described above, ES significantly induced the release 
of two anti-angiogenic factors, namely TSP-1 46 and TIMP-1 47. Under physiological 
circumstances pro- and anti-angiogenic stimuli are well balanced and related feedback 
mechanisms are considered to prevent unrestricted growth of blood vessels 48. In this study, 
we found a positive pro-angiogenic effect in vivo using the conditioned medium, even 
though two inhibitors of angiogenesis were upregulated in the ES medium. Inhibition of TSP-
1 and TIMP-1 secretion in future experiments might induce an even more profound pro-
angiogenic response.  
Using the CAM assay we found a pro-angiogenic effect, as net result of the altered pro- and 
anti-angiogenic factors. The CAM assay allows analysis of the full blown angiogenic potential 
of stimuli, ranging from tubulogenesis up to stabilization of the vessel over a longer period of 
time. The higher cellular complexity of the CAM assay (i.e. endothelial cells and pericytes) 
together with the options to test the angiogenic capacity of stimuli for the different phases 
of angiogenesis provides in depth information on the angiogenic potential. Reviewing the 
results of Kim et al 30 who reported a small but statistically significant increase of VEGF after 
electrical stimulation of BM-MSC after 1 day and a more profound effect after 2 days, we can 
conclude that several factors (e.g. cell type or ES protocol) influence the timeframe in which 
statistically significant differences between control and ES can be detected. This has 
important clinical implications since the majority of transplanted adipocytes in the hypoxic 
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region of the graft die within the first 24 hours after transplantation 5. Starting with ES of the 
donor and recipient site several days pre-operative in order to create a pro-angiogenic 
environment at the time of surgery is one way to utilize the effect of ES in the short window-
of-opportunity. Alternatively, future studies should evaluate the effect of altering key 
stimulus parameters such as wave form, voltage, pulse duration and frequency to assess 
which ES protocol provides the earliest pro-angiogenic response. More precisely, Zhao et al 
49 found significantly elevated levels of VEGF as early as 5 minutes after ES of endothelial 
cells using their custom built ES set-up. Rackauskas et al 40 evaluated different ES regimes for 
cardiomyocytes and found a frequency-dependent effect, both on the level of secreted VEGF 
protein in the medium and on the growth of cultured human coronary artery endothelial 
cells treated with CM from stimulated cells.  
While various forms of ES, such as direct or alternating current (DC or AC) 38,50-52, capacitive 
coupling (CC) 53, and pulsed electromagnetic fields (PEMF) 54,55 have been used to stimulate 
ASC, each have their advantages and disadvantages. In case of DC stimulation, treatments 
can be separated in two main groups: constant or pulsed electric stimulation. Whereas the 
former leads to a build-up of charge causing electrolysis and hence changes in pH and 
oxygen tension around the cathode, accumulation of proteins and necrosis in vivo 30,56, we 
chose biphasic current to circumvent these side effects due to charge balance resulting from 
the bidirectional wave consisting of a positive and negative phase. In addition, biphasic 
waveforms are often referred to as most comfortable to the patient with the least skin 
reaction 57.  
With the establishment of proof-of-concept for increased angiogenesis after stimulation of 
ASC, the question arises what the influence of ES would be on other angiogenic cells 
contained within fat. We envision a non-invasive, cost-effective and easy clinical approach to 
electrically stimulate adipose tissue in vivo by applying biphasic electric current from a 
portable stimulator through electrodes attached to the skin. Multiple treatments such as 
electrical muscle stimulation (EMS) and transcutaneous electrical nerve stimulation (TENS) 
have already used this set-up for years. Using these devices it is possible to choose from a 
wide range of stimuli and create an optimal treatment schedule that can include both pre- 
and post-operative stimulation, without the need to isolate cells and treat them in vitro.  
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In conclusion, our proof-of-concept study showed that ES increased the angiogenic potential 
of ASC as demonstrated with in vitro and in vivo parameters. The results provide a valid basis 
for a translational study in which the effect of a non-invasive ES intervention will be analysed 
in a pre-clinical model of AFT.  
 
Materials and Methods 
 
Cells 
Human ASC were purchased from Lonza (Basel, Switzerland. Single donor: 52Y female, BMI 
24). After thawing, ASC were seeded at a density of 5,000 cells/cm2 in culture medium 
consisting of low glucose Glutamax Dulbecco’s modified Eagle medium (DMEM, Thermo 
Fisher Scientific, MA, USA), supplemented with 10% MSC-qualified fetal bovine serum (FBS, 
Thermo Fisher Scientific) and 1% penicillin/streptomycin. ASC were subcultured according to 
the manufacturer’s protocol until reaching 90% confluence, and used at passage 5 in all 
experiments.  
 
Electrical stimulation 
Cells were stimulated using the C-pace EP Cell culture stimulator (Ion-Optics Co., MA, USA) 
to generate a biphasic electrical current. As described previously 33 cells were electrically 
stimulated using a protocol of 4V/cm with 6ms pulses at a frequency of 2Hz. However, 
considering this study focused on ES of a different cell type (i.e. ASC), a dose-response curve 
was performed to determine the effect of different stimulation protocols on cell viability and 
Vascular Endothelial Growth Factor (VEGF A) release. Starting with the above mentioned 
parameters of 4V/cm, 6ms pulses and 2Hz in each subsequent stimulation round, one of the 
parameters (i.e. voltage) was increased or decreased, while the other two parameters were 
kept at the original setting.  The investigated settings were as follows:  
1. 2V/cm, 6ms and 2 HZ 
2. 4V/cm, 6ms and 2 Hz 
3. 8V/cm, 6ms and 2 Hz 
4. 4V/cm, 3ms and 2 Hz 
5. 4V/cm, 12ms and 2 Hz 
6. 4V/cm, 6ms and 25 Hz 
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ASC were cultured in 6-well plates (TC treated, Greiner bio one, Kremsmünster, Austria) at 
15,000 cells/cm2. Stimulated cell cultures were checked for cell adherence and overall 
morphology. After 72 hours of continuous stimulation, cell number and viability were 
assessed using a cell counter with integrated Trypan Blue detection (Bio-rad, CA, USA).  
 
Conditioned Medium 
Baseline medium (t0) and conditioned medium (CM) were collected each from a different 
well at the following time points: 4, 8, 24, 48 and 72 hours (t4-t72). To this end, ASC were 
seeded at 15,000 cells/cm2 in 6 well plates in culture medium and allowed to adhere to the 
plate for 12 hours. Next, cells were starved by culturing them in medium with 5% serum for 
12 hours and before stimulation “starvation” medium was refreshed completely. After 
centrifugation for 5 minutes at 300g the CM was aliquoted and stored at -20°C before use in 
subsequent experiments.  
 
Angiogenesis array 
To determine the production of angiogenesis-related proteins of stimulated and control 
samples, a human angiogenesis proteome profiler array which enables detection of 55 
angiogenesis-related proteins per sample was used according to the manufacturer’s 
instructions (R&D Systems Inc., MN, USA). Near infrared fluorescence detection with IRDye 
800CW (Li-cor, NE, USA) was applied and signals were visualized by using an Odyssey CLx 
imager (Li-cor). After normalization to the background, average pixel intensity of each of the 
spots’ pixels within a fixed circular boundary was determined using image analysis software 
(Odyssey v1.2, Li-cor).  
 
Enzyme-linked immunosorbent assays 
For data confirmation of the array and quantification of the angiogenesis-related proteins 
with an average pixel intensity of ≥ 1.03 arbitrary intensity units 58 as defined with the 
angiogenesis array, enzyme-linked immunosorbent assays (ELISA) were performed. Levels of 
Vascular Endothelial Growth Factor A (VEGF A), urokinase-type Plasminogen Activator (uPA), 
Insuline-like Growth Factor Binding Protein (IGFBP-3), Interleukin 8 (IL-8), Monocyte 
Chemoattractant Protein 1 (MCP-1), Pentraxin-3 (PTX-3, also known as TSG-14), Plasminogen 
Activator Inhibitor 1 (PAI-1 also known as Serpin E1), Pigment Epithelium-derived Factor 
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(PEDF, also known as Serpin F1), Thrombospondin-1 (TSP-1) and TIMP Metallopeptidase 
Inhibitor (TIMP-1) were measured in the CM of ES and Control groups for each respective 
time point, using Duoset ELISA kits (R&D Systems Inc.) according to the manufacturer’s 
instructions. The OD’s were measured at a wavelength of 450 nm using a Thermo Multiskan 
Spectrum plate reader and SkanIt software (Thermo Fisher Scientific).  
 
Chorioallantoic membrane assay 
The protocol for the chorioallantoic membrane (CAM) assay was based on the procedure 
described by Le Noble et al 59. Fertilized White Leghorn eggs were incubated in an egg 
incubator for 3 days at 37.8°C and a relative air humidity of 55%, while being rotated every 
hour.  At day 3 a rectangular window measuring 1x1.5cm was cut into the eggshell. Initially, 
the eggshell membrane was left intact to prevent any debris from the shell falling into the 
egg. After making a small hole in the eggshell membrane, two milliliters of albumin were 
withdrawn from the blunt end of the egg, using a 21G needle at an angle of 45 degrees. Care 
was taken to prevent sticking of the embryo against the membrane. Next, the membrane 
was removed to expose the embryo. Subsequently, the window was covered with adhesive 
tape to prevent dehydration. The eggs were placed back in the incubator without rotation 
until day 7 when a small silicon ring, measuring 1cm and weighing 17mg was placed on the 
developing CAM. Sixty-five microliters of each respective test solution was injected inside 
the ring on the membrane of each egg after filtering of the solution with a 0.2 micrometer 
syringe filter. The test solutions consisted of sodium chloride 0.9% (negative control), non-
conditioned medium (nCM, consisting of DMEM, 5% FCS and 1% PS), conditioned medium 
from the control group that was incubated for 72 hours (CM CTRL), conditioned medium 
after 72 hours of stimulation (CM ES) and VEGF (positive control, dissolved in DMEM, at a 
total daily dose of 20 ng/mL of VEGF). Test solutions were applied daily until day 14. At day 
14 the shell was opened to expose the CAM. In order to increase the contrast and to isolate 
the blood vessels in the CAM from vessels running over the yolk, a suspension of zinc oxide 
in vegetable oil was injected right underneath the ring and its surroundings. A Leica MS5 
stereomicroscope, Leica IC A camera and VideoVelocity software (Candylabs, Vancouver, 
Canada) was then used to photograph the area within the ring at a magnification of 4x. The 
images were then analysed using the objective and completely automated Wimasis image 
analysis service (WimCAM, OnImagin Technoglogies SCA, Cordoba, Spain) 60. Only eggs with 
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no major blood vessels inside the ring were included, to decrease intra- and inter-group 
variation. Total vessel density (in %), total vessel network length (in px) and total branching 
points were extracted from the analysed data.  
 
Statistical analyses 
Data are expressed as the mean ± standard deviation (SD). ELISAs were performed in 
duplicate over four independent CM samples (n=4). In the tube assay the n value ranged 
from 3-5. For the CAM assay at least four eggs per condition were included (n=4-7). The 
ELISA results were analysed by unpaired Student t-test, whereas one-way ANOVA with 
Bonferroni’s multiple comparisons test was used to analyse the tube assay and CAM assay 
data (GraphPad Prism 6, GraphPad Software Inc., San Diego, USA). A p-value <0.05 was 
considered statistically significant.  
 
Data availability 
All data generated or analysed during this study are included in this published article.  
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General discussion 
 
With today’s detailed anatomical knowledge and the sophistication of surgical tools and 
techniques, we have reached to some extent the border of the technical feasibility to 
optimize surgical outcome. Even with more advanced surgical techniques, the procedure will 
still evoke an inflammatory response in the operated area, which is beneficial at first, but 
negatively impacts the outcome if this inflammatory response persists. Surgical procedures 
such as AFT, keep relying heavily on the capability of the surrounding tissue to revascularize 
the graft through angiogenesis. For this reason cell-based therapeutics and modification 
hereof holds so much promise to keep on improving surgical procedures in the future since 
they modify these processes in order to optimize form and function. The aim of this thesis 
was therefore to investigate the effect of stem cells on inflammation and angiogenesis in 
different (extreme) models of neuro-injury and angiogenesis.  
 
Autologous Fat Transfer 
In chapter 2 we performed a systematic review and meta-analysis regarding AFT in facial 
reconstructive surgery. The extensive meta-analysis showed that AFT is a safe procedure 
with a high rate of patient (91%) and surgeon (89%) satisfaction. Complications occurred in 
5% of procedures, of which when asymmetry and overcorrection were left out, 0.8% was a 
‘true’ surgery related complication (1755 AFT procedures: 2 infections, 2 cases of fat necrosis 
and 10 hematomas). The wide variation in ‘graft take’ mentioned in the introduction was 
also visible in this study as retention varied between 40% to over 80% with a pooled effect 
estimate of 59% at one year in patients with congenital facial deformities. In HIV-
lipodystrophy patients this value ranged from 51% at one year, to 238%, a major increase 
which could be due to the commonly reported adverse event lipohypertrophy after AFT in 
HIV-patients. These findings were similar in meta-analyses of AFT in other areas, such as 
breast reconstruction1 and imply that AFT is a safe and well received treatment, yet a 
significant part of the graft volume is lost after time which has led to an ongoing quest to 
improve retained graft volume.  
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In chapter 3 we investigated whether patients with chronic neuropathic pain without 
apparent cause (such as a neuroma) and who were non responders to conventional 
treatment could benefit from AFT in the area around the affected nerve. No complications 
were registered, patient satisfaction was high (86%) after more than one year follow-up and 
the level of pain scored on a VAS scale decreased from 7.4 pre-operative to 3.8 directly post-
operative (p<0.0001) and 4.3 (p=0.0017) at long-term follow-up. This study proves that AFT 
can also be used to improve function, irrespective of form. Although we did not gather data 
on the mechanisms leading to this neuropathic pain-reducing effect of AFT, nor looked into 
the cell populations responsible for the effect, Vaienti et al speculated that both a 
mechanical effect (“cushioning” the affected nerve) and a biological effect that is mainly 
based on immunomodulation and angiogenesis by regenerative cells in the graft lead to a 
favorable environment for correct axonal repair.2 These regenerative cells may very well be 
ASC. Lin et al found that autologous ASC transplantation in rats with burn injuries attenuate 
local inflammation and central neuroinflammation and ameliorated autophagy and 
apoptosis in the spinal cord.3 For definitive clinical evidence on the use of AFT for 
neuropathic pain, prospective controlled studies with a larger study population and 
control/sham groups as well as mechanistic studies are warranted.  
 
Immunomodulation  
When a surgical incision is made, contact between platelets and the extracellular matrix 
induces the release of granules containing clotting factors and inflammatory cytokines. In 
response, neutrophils find their way to the injured site, followed by macrophages and 
leucocytes in an organized effort to clear foreign antigens and (cellular) debris.4 Chemotaxis 
of regenerative cells such as MSCs occurs through signaling by a variety of cytokines. Both 
resident and recruited MSCs are triggered by pro-inflammatory cytokines like TNF-α, INF-ɣ 
and IL-1β which in turn activate regulatory functions that lead to an inhibition of the 
recruitment, proliferation and activity of pro-inflammatory immune cells.5,6  
In chapter 4 we administered a cocktail of minimally manipulated human bone-marrow 
derived MSCs, HSCs and other mononuclear cells called Neuro-Cells (NC) to both sham and 
SCI-lesioned T-cell deficient rats. At day 4 the early immune response was investigated by 
quantifying serum levels of key inflammatory proteins. There was a significant increase in 
serum concentration of IL-1β and TNF-α in SCI-lesioned versus sham-lesioned animals 
156 CHAPTER 7
 
 
 
(P<0.05). However, this was not true for NC-treated SCI animals, possibly indicating 
attenuation by the added stem cells. A similar effect, revealing decreased levels of IL-1β and 
TNF-α, was found after intrathecal application of human MSCs in rats by Urdzikova et al.7 
While in our study IL-6 was lower in the NC treated SCI-lesioned animals compared to their 
vehicle-treated counterparts both were still significantly higher as compared to the sham 
groups. In addition, immunohistochemical analyses were performed of the sampled spinal 
cords at day 4 focusing on the marker CD68, which is found on microglia and macrophages. 
Interestingly, a significant increase of CD68+ cells was found caudal to the lesion site in NC-
treated SCI-lesioned animals versus vehicle-treated SCI-lesioned animals, with a moderate 
increase at the lesion site itself and no difference rostral to the lesion site. Explanations as to 
why there were more microglia/macrophages in the NC treated group include a more 
profound damage-response reaction to the injection of rather viscous Neuro-Cells and 
detection of possibly human and rat macrophages since the anti-CD68 antibody was both 
specific for rat as for human CD68. With more CD68+ cells present in NC treated SCI rats, 
knowing they are a prime source for IL-1β and TNF-α, it is even more surprising that the 
levels of inflammatory cytokines in the serum are lower and potentially highlights the 
immunomodulatory effect of MSC and HSC. The subsequent steps are therefore to 
characterize the function M1 or M2 of the recruited cells over time.  Is a macrophage 
beneficial or detrimental after surgery? 
We found in this model of SCI that the administration of NC not only reduced 
inflammation but also improved function. This functional outcome is paramount since only 
improved function means an improvement in quality of life for the patient.  The basic lesson 
in this experiment was that even central nervous function can be protected/regenerated by 
the administration of local NC. We have not conducted detailed mechanistic analysis but the 
available data point towards anti-inflammatory effects which in the long run result in better 
cell survival and function.8  
   
Angiogenesis 
Tissue perfusion is key to the success of every surgical procedure. This aspect is easily 
visualized in free-flap reconstruction in plastic surgery. Blood flow is re-established through 
the flap after surgical anastomosis of the blood vessels. However, if the blood flow is 
insufficient (usually in the most distal part of the flap), ischemic necrosis occurs. In non-
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vascularized tissue transfer, such as AFT, early revascularization is of paramount importance. 
Without it, all cells that are out of diffusion range undergo the same process of ischemic 
necrosis. Fat grafts are revascularized by formation of a new vascular network through the 
process of angiogenesis. Angiogenesis starts in the remodeling phase of healing around 3 
days after the initial tissue trauma, stimulated by factors in the microenvironment such as 
hypoxia and by angiogenic factors produced in the prior days by surrounding cells such as 
macrophages, (mesenchymal) stem cells, fibroblasts and endothelial cells.9 However, in fat 
grafts the majority of adipocytes perish within the first 24 hours, well before the onset of 
angiogenesis.10,11 Since stem cells tolerate hypoxia for several days and are a prime source of 
pro-angiogenic factors, many studies have investigated the effect on angiogenesis and tissue 
survival by adding all kinds of stem cells to the affected site in different models of 
angiogenesis.12-15    
 
In chapter 5 different dosages of human unfractionated bone marrow-derived cells 
(containing mesenchymal and hematopoietic stem cells) were intramuscularly and 
intravenously administered to T-cell deficient rats who had undergone unilateral ligation of 
the arteria iliaca externa 7 days prior. At day 35 differences in vascular density between 
animals who had received cell preparations and the control group (which received only 
carrier, NaCl) were compared using Mean Gray Values (MGV) established through Digital 
Subtraction Angiography (DSA). Three different dosages were standardized by the number of 
CD34+ cells: low, medium and high. Whereas the low and medium group showed a 
statistically significant increase in vascular density, the high concentration group did not. 
There was no correlation between the total number of CD34+ cells and the MGV in this study 
so we were unable to make a statement on dose-dependency. This is in line with other 
studies in both animal models and clinical trials, in which the total cell number, the site of 
administration and the regime (single vs multiple injections and IV vs IM administration) 
appeared not to affect efficacy.16 However, the high dose group actually led to the death of 
2/5 animals during administration (most likely due to hyper viscosity of the cell preparation) 
highlighting the importance of a refined and standardized application of cell preparations in 
order to avoid such complications.  
The two different cell preparations in chapter 4 and 5 highlight the general problem of cell 
processing and conditioning. These cell preparations were unfractionated and processed 
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with Neuroplast’s Rapid Interventional Stem Cells Platform, which is a GMP-compliant closed 
system that generates NC within 6 hours of aspirating crude bone marrow. It would be 
interesting to find out which subpopulation of the NC has the highest impact on vascular 
density. However, this mandates isolation and at least some form of manipulation or 
labeling of cells in the lab, before administering the cells to the patient. This approach faces 
huge regulatory hurdles in Europe and the US regarding the safety of ex vivo manipulated 
cells and the agents/chemicals that have been in contact with the cells and thus may be 
transferred into the body.17  
The same hurdle is described in the scientific literature regarding AFT. In an effort to 
enrich fat grafts with regenerative cells, Cytori therapeutics has developed the Celution® 
system that isolates the stromal vascular fraction (containing ASC) from the patient’s own fat 
in the same procedure.18 However, regulatory issues still persist since the system uses 
collagenase to digest the fat. In addition, the system itself is relatively costly to use and 
extends surgery and anesthesia time by at least 90 minutes, meaning higher risks, costs and 
less patients operated per day.19  
The approach of manipulating or expanding cell populations ex vivo is thus not a 
simple solution to the underlying problem. Angiogenesis is mandatory for the survival of 
transplanted cells in AFT. We envisioned therefore manipulation/conditioning of the 
patient’s own cell in vivo by a method that is neither invasive nor harmful to the patient. 
Instead of administering exogenous cells whose primary function is to secrete pro-
angiogenic/immunomodulatory cytokines and growth factors, an alternative approach 
would be to use an external stimulus to influence native cells to upregulate their own 
secretion instead.  Electrical stimulation is one of those stimuli, is rather inexpensive, non-
invasive, safe, and clinically approved. In a rabbit ischemic hind limb model it stimulated 
both arteriogenesis and angiogenesis20, but a potential pro-angiogenic effect on ASC had 
never been investigated. Therefore, we performed a proof-of-principle study to determine 
whether ES of ASC can stimulate in vitro and in vivo parameters of angiogenesis in chapter 6.   
Cultured human ASC were electrically stimulated for 72 hours after which the 
medium of stimulated (ES) and non-stimulated (control) ASC was analyzed for angiogenesis-
related proteins and then tested for a functional effect in an in vivo model of angiogenesis. 
Two pro-angiogenic proteins (VEGF and MCP-1) were significantly increased while the anti-
angiogenic growth factor Serpin E1/PAI-1 was significantly decreased. Despite the fact that 
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the levels of two anti-angiogenic growth factors TSP-1 and TIMP-1 were also increased, 
medium of ES-treated ASC significantly increased vessel density, total vessel network length 
and branching points in a chorio-allantoic membrane assay. So even though two inhibitors of 
angiogenesis were upregulated, we found an overall proangiogenic effect in an in vivo 
model, hinting at the possibility that ES might leave feedback mechanisms in place that 
prevent unrestricted angiogenesis.  
Furthermore, it is interesting that secretion of MCP-1 was increased because 
monocyte chemoattractant protein-1 recruits monocytes to the site of injury. At first glance 
this might imply a pro-inflammatory effect of ES, however other studies21,22 have shown that 
treatment of ASC with the pro-inflammatory stimulus TNF-α also increased levels of Serpin-
E1/PAI-1 whiles ES caused the opposite to happen in our study, suggesting that ES is not the 
equivalent of a general pro-inflammatory stimulus. On the other hand, macrophages play an 
important role in regeneration. They comprise the majority of immune cells present in the 
SVF of adipose tissue, ranging from 5% of the SVF cells in lean mice and humans to about 
50% in obese individuals23,24 and have been shown to produce a great number of pro- (and 
anti-) angiogenic factors, such as VEGF-A, FGF-2 and PDGF-BB.25 Navarro and colleagues 
even report a greater influence of macrophages on angiogenesis than that of ASC.26 Phipps 
et al found a stimulatory effect of added M2 macrophages on the volume retention of a fat 
graft in mice.27 
In addition, the timeframe, in which significant elevation of pro-angiogenic factors 
can be reached, has important clinical applications. To put our findings into perspective: 
most adipocytes in the inner layers of the fat graft die within 24 hours of ischemia.10,11 
Whereas in our study, involving ASC, ES induced a significantly higher concentration of VEGF 
after 3 days, in BM-MSC, Kim et al found a small but statistically significant increase of VEGF 
after electrical stimulation of BM-MSC after 1 day and a more profound effect after 2 days.28  
This finding implies that it could be beneficial to already start treatment of the recipient site 
before AFT, in order to capitalize on a better vascular network and already activated 
angiogenesis. Another possibility, even in conjunction with the latter, would be to pretreat 
the donor site in order to already prime and activate the resident (stem) cells that soon after 
will be transferred.  Subsequent studies have to determine this. 
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Summary 
Chapter 1. General introduction 
In plastic and reconstructive surgery many surgical procedures have been developed to 
restore form and/or function. Autologous fat transfer (AFT), in which adipose tissue is 
relocated from one place to the other is a recent example that is safe and versatile. An 
important aspect in the final outcome for the patient is the state of the local 
microenvironment in the regenerating tissue. However great the surgeon or surgical 
technique may be, they have no direct way of modifying the local microenvironment to 
promote healing. Great potential herein lies with the use of (adult) stem cells. This thesis 
investigated the effect of stem cells on two important cellular processes, occurring after 
(surgical) tissue trauma: inflammation and angiogenesis. Ideally we would have a technique 
to directly “activate” tissue resident stem cells and guide them towards promoting 
angiogenesis or modulating inflammation. A technique called electrical stimulation is 
promising in this area. 
Chapter 2. Efficacy and safety of autologous fat transfer in facial reconstructive surgery: a 
systematic review and meta-analysis. 
In chapter 2, we focused specifically on AFT through analysis of the efficacy and safety of 
performing AFT in plastic surgery. We compiled the available clinical data from 52 relevant 
studies consisting of 1568 unique patients in a systematic review and meta-analysis. It 
showed a very high overall satisfaction rate of 91.1% in patients, together with a 88.6% 
satisfaction rate in surgeons. In facial reconstructive surgery the mean number of sessions to 
achieve the desired end result was 1.5, with a retention rate of 50-60% of the grafted 
material. Less than 5% of the procedures resulted in minor complications, deeming it a safe 
procedure.   
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Chapter 3. Autologous fat transfer as a treatment for peripheral neuropathic pain without 
apparent cause. 
In chapter 3, we tested in a clinical trial whether patients in a chronic neuropathic pain 
setting without a cause such as a neuroma, and who had exhausted all other treatment 
options, would benefit from AFT with respect to their pain perception. Fourteen patients 
received AFT in the area of the affected nerve. Outcome parameters included patient 
satisfaction, pain scored on a visual analogue scale (VAS) and quality of sleep. Patient 
satisfaction was 93% at the follow-up after two weeks and 86% after a follow-up of more 
than one year. The mean VAS score decreased significantly from 7.4 before surgery to 3.8 
directly after AFT and 4.3 at long-term follow-up visit. The quality of sleep improved in 50% 
of the patients, whereas the remainder indicated no difference. No complications were 
registered. This study shows that AFT can be a suitable option for patients suffering from 
debilitating neuropathic pain that is refractory to other treatments. A potential mechanism 
of action lies in the regenerative capabilities of cells within the transplant.  
Chapter 4. Standardized human bone marrow-derived stem cells infusion improves 
survival and recovery in a rat model of spinal cord injury. 
In chapter 4, we set out to investigate the immunomodulatory properties of a refined bone-
marrow derived preparation of mesenchymal and hematopoietic stem cells in an acute 
model of spinal cord injury.  Our focus lay towards researching the anti-inflammatory 
properties and the effect on nerve regeneration in the context of improved functional 
outcome. To this end T-cell deficient rats, in which a spinal cord lesion (SCI) was induced by 
balloon-compression of the spinal cord, received an intrathecal injection of bone marrow-
derived stem cells (called Neuro-Cells; NC) the day after SCI. During the first 5 weeks after 
this intervention, NC significantly improved locomotor recovery and induced less injury-
associated adverse events compared to the vehicle-treated control group. Histological 
analyses showed that NC reduced astrogliosis and apoptosis primarily in the first days after 
administration. Proteomic studies of the sampled spinal cords at the study endpoint (56 
days) pointed to the release of paracrine factors and identified proteins involved in 
regenerative processes.  
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Chapter 5. Efficacy of different doses of human adult bone marrow stem cell 
transplantation on angiogenesis in a rat model with hind limb ischemia. 
In chapter 5, we surgically ligated the external iliac artery of T-cell deficient rats to develop a 
hind limb ischemia model. The surgical ligation of arterial blood vessels lead to an acute-
onset moderate to severe traumatic ischemia in the affected hind limbs.  After 7 days a 
baseline digital subtraction angiography (DSA) was made. Then, different doses of human 
bone marrow-derived stem cells, or vehicle alone were administered intramuscularly and 
intra-arterially. At day 35, DSA was repeated and images were compared between the 
groups at the different time points to directly visualize the angiogenic effects of the 
administered stem cells. Comparison of DSA Mean Gray Values at day 35 versus day 7 
showed a significant increase in the low and medium dose groups, pointing towards 
improved vascularization, whereas the vehicle group displayed a natural decrease. 
Surprisingly, the high dose stem cell group also had a decreased Mean Gray Value at day 35 
and more tissue damage, possibly due to hyperviscosity. A dose response could not be 
detected. 
Chapter 6. Electrical stimulation promotes the angiogenic potential of adipose-derived 
stem cells. 
In chapter 6, we electrically stimulated adipose tissue-derived stem cells (ASC) in vitro to 
determine the effects of electrical stimulation (ES) on the angiogenic potential of ASC. 
Cultured human ASC were electrically stimulated for 72 hours after which the medium of 
stimulated (ES) and non-stimulated (control) ASC was analyzed for angiogenesis-related 
proteins by protein array and ELISA. Nine angiogenesis-related proteins were detected in the 
medium of electrically stimulated ASC. The pro-angiogenic proteins VEGF and MCP-1 were 
significantly increased following ES compared to controls, while the anti-angiogenic factor 
Serpin E1/PAI-1 was significantly decreased. Despite increased levels of anti-angiogenic TSP-
1 and TIMP-1, medium of ES-treated ASC significantly increased vessel density, total vessel 
network length and branching points in a functional in vivo model of angiogenesis, called a 
chorio-allantoic membrane assay. This proof-of-concept study showed that ES increased the 
angiogenic potential of ASC both in vitro and in vivo and lays the foundation for further 
translational studies.  
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Chapter 7. General discussion 
The general discussion reflects on the findings of the individual studies included in this 
thesis, starting with autologous fat transfer. Next chapters 4 through 6 were discussed in 
light of the topics immunomodulation and angiogenesis. Gaps in current knowledge are 
identified and proposals for future studies are provided.  
  
CHAPTER 9
Nederlandse samenvatting
9
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Summary in Dutch - Nederlandse samenvatting 
Hoofdstuk 1. Algemene introductie 
In plastische en reconstructieve chirurgie zijn een groot aantal chirurgische procedures 
ontwikkeld om vorm en/of functie te herstellen. Autologe vet transfer (AFT), waarbij vet van 
de ene locatie naar de andere wordt gebracht is een recent voorbeeld dat zowel veilig als 
veelzijdig is. Een belangrijk aspect voor het uiteindelijke resultaat is de status van het lokale 
micromilieu in het regenererende weefsel. Hoe fantastisch de chirurg of de chirurgische 
techniek ook is, zij hebben geen directe mogelijkheid om het lokale micromilieu zodanig te 
beïnvloeden dat het de genezing bevordert. Het inzetten van stamcellen vertoont op dit vlak 
grote potentie. Deze thesis onderzocht het effect van stamcellen op twee belangrijke 
cellulaire processen die optreden na (chirurgisch) trauma: inflammatie en angiogenese. 
Idealiter zouden we een techniek wensen om direct de reeds aanwezige stamcellen in het 
weefsel te “activeren” en ze te stimuleren om angiogenese te bevorderen of inflammatie te 
moduleren. Een techniek genaamd elektrische stimulatie is veelbelovend voor deze 
indicatie.    
Hoofdstuk 2. Effectiviteit en veiligheid van autologe vet transfer in faciale plastische 
chirurgie: een systematische review en meta-analyse.  
In hoofdstuk 2 focusten we specifiek op AFT door een grondige analyse van de effectiviteit 
en veiligheid van AFT in plastische chirurgie. We compileerden de beschikbare klinische data 
van 52 relevante studies die in totaal bestonden uit 1568 unieke patiënten in een 
systematische review en meta-analyse. Het tevredenheidsniveau bleek algemeen erg hoog 
te zijn met 91.1% in de patiëntengroep en 88.6% bij de chirurgen. Het gemiddeld aantal 
sessies om het gewenste eindresultaat te bereiken was 1.5, met een retentiepercentage van 
50-60% van het ingebrachte vetweefsel. Lichte complicaties traden op in minder dan 5% van 
de gevallen, waaruit geconcludeerd werd dat AFT in het gelaat een veilige ingreep is.   
Hoofdstuk 3. Autologe vet transfer als een behandeling voor perifere neuropathische pijn 
zonder duidelijke oorzaak.  
In hoofdstuk 3 onderzochten we in een klinische trial of patiënten met chronische 
neuropathische pijn zonder oorzaak zoals een neuroom, en die reeds alle andere 
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mogelijkheden voor behandeling hadden geprobeerd, effect zouden hebben van AFT op het 
verminderen van de pijn. Veertien patiënten ontvingen AFT in het gebied van de aangedane 
zenuw. Tot de uitkomstparameters behoorden patiënttevredenheid, pijn gescoord op een 
visuele analoge schaal (VAS) en de kwaliteit van slaap. De patiënttevredenheid bedroeg 93% 
bij de controle na 2 weken en 86% na een follow-up van meer dan één jaar. De gemiddelde 
VAS score daalde significant van 7.4 voor de ingreep tot 3.8 direct na AFT en 4.3 bij de 
controle op lange termijn. De kwaliteit van slaap verbeterde in 50% van de patiënten, 
waarbij de rest aangaf geen verschil te merken. Er werden geen complicaties geregistreerd. 
Deze studie toont dat AFT een mogelijke optie kan zijn in de behandeling van patiënten die 
lijden aan therapieresistente neuropathische pijn. Een potentieel werkingsmechanisme 
hiervan kan liggen in de regeneratieve eigenschappen van cellen in het vettransplantaat.  
Hoofdstuk 4. Infusie met gestandaardiseerde uit beenmerg verkregen stamcellen verbetert 
de overleving en het herstel in een ratmodel van dwarslaesie.  
In hoofdstuk 4 hebben we de immunomodulatoire eigenschappen van een geraffineerd 
preparaat met mesenchymale en hematopoïetische stamcellen uit beenmerg onderzocht in 
een acuut model van dwarslaesie. Onze focus lag bij het onderzoeken van de anti-
inflammatoire eigenschappen en het effect op zenuwregeneratie in de context van een 
verbeterde functionele uitkomst. Hiervoor kregen T-cel deficiënte ratten, bij wie een 
dwarslaesie was aangebracht door middel van balloncompressie, een intrathecale injectie 
met uit beenmerg verkregen stamcellen (genaamd Neuro-Cells; NC) de dag na de 
dwarslaesie. Gedurende de eerste 5 weken na de interventie verbeterden NC het motorische 
herstel significant en veroorzaakten zij minder trauma gerelateerde complicaties in 
vergelijking met de controle groep die behandeld was met alleen oplosvloeistof. 
Histologische analyses toonden aan dat NC astrogliose en apoptose vooral in de eerste 
dagen na toediening verminderden. Proteomisch onderzoek van het verzamelde 
ruggenmerg aan het einde van de studie (na 56 dagen) wees op vrijgelaten paracriene 
factoren en identificeerde eiwitten betrokken bij regeneratieve processen.  
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Hoofdstuk 5. Effectiviteit van de transplantatie van verschillende doseringen van humane 
uit beenmerg verkregen stamcellen op angiogenese in een ratmodel met ischemie van de 
achterpoot.  
In hoofdstuk 5 werd bij T-cel deficiënte ratten operatief de a. iliaca externa geligeerd om een 
diermodel met ischemie van de achterpoot te ontwikkelen. De chirurgische ligatie van 
arteriële bloedvaten leidde tot de acute ontwikkeling van middelmatige tot ernstige 
traumatische ischemie van de betrokken achterpoten.  Na 7 dagen werd er een baseline 
digitale subtractie angiografie (DSA) gemaakt. Daarna werden er verschillende doseringen 
van humane uit beenmerg verkregen stamcellen, of alleen oplosvloeistof intramusculair en 
intra-arterieel toegediend. Op dag 35 werd de DSA herhaald en werden afbeeldingen 
vergeleken tussen de groepen op de verschillende tijdpunten om direct de angiogene 
effecten van de toegediende stamcellen te visualiseren. Vergelijking van de DSA Mean Gray 
Values op dag 35 versus dag 7 toonde een significante stijging in de lage en medium dosis 
groep, wijzende op verbeterde vascularisatie, terwijl de groep met alleen oplosvloeistof een 
natuurlijke daling liet zien. Verassend was dat de groep met een hoge dosis stamcellen ook 
een verminderde Mean Gray Value had op dag 35 met meer weefselschade, mogelijk door 
hyperviscositeit van het toegediende product. Een dosis-responscurve kon niet worden 
gedetecteerd.  
Hoofdstuk 6. Elektrische stimulatie bevordert de angiogene potentie van stamcellen uit 
vetweefsel.  
In hoofdstuk 6 hebben we stamcellen uit vetweefsel (adipose tissue-derived stem cells; ASC) 
in vitro gestimuleerd met elektrische stroom (ES) om het effect hiervan op de angiogene 
potentie van ASC te testen. Gekweekte humane ASC werden 72 uur elektrisch gestimuleerd 
waarna het kweekmedium van gestimuleerde en niet-gestimuleerde ASC werd onderzocht 
op angiogenese-gerelateerde eiwitten middels protein array en ELISA. Negen angiogenese-
gerelateerde eiwitten werden gedetecteerd in het medium van elektrisch gestimuleerde 
ASC. De proangiogene factoren VEGF en MCP-1 waren significant verhoogd na ES in 
vergelijking met de controlegroep, terwijl de anti-angiogene factor Serpin E1/PAI-1 
significant was gedaald. Ondanks verhoogde niveaus van de anti-angiogene factoren TSP-1 
en TIMP-1, vergrootte medium van gestimuleerde ASC significant de vaatdichtheid, totale 
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lengte van het vaatnetwerk en het aantal vaatvertakkingen in een functioneel in vivo model 
van angiogenese, genaamd een chorioallantoïsch membraan onderzoek. Deze proof-of-
concept studie toonde aan dat ES de angiogene potentie van ASC zowel in vitro als in vivo 
bevordert en legt hiermee het fundament voor toekomstige translationele studies.  
Hoofdstuk 7. Algemene discussie 
In de algemene discussie worden de bevindingen van de individuele studies in deze thesis 
besproken, beginnend met autologe vet transfer. Daarna worden hoofdstukken 4 tot en met 
6 besproken in het kader van de onderwerpen immunomodulatie en angiogenese. Hiaten in 
de huidige kennis worden geïdentificeerd en er worden voorstellen voor toekomstige studies 
gegeven.  
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Valorization 
Stem cell technology is thought by many medical professionals in the field to bring about the 
next era in medicine. Countless research groups are working towards harnessing the body’s 
own regenerative capabilities in endogenous or isolated cells, and tailoring the therapy to a 
specific disease, condition, request or person. At the moment we still rely largely on 
medication to treat diseases, but businesswise as well as socially this is a horrible model, 
according to Dr. Susan Solomon in her 2012 TED talk: “Currently, developing a drug takes an 
average of 13 years, costs $4 billion, and has a 99% failure rate.”, and: “The way we’ve been 
developing drugs is essentially like going into a shoe store and no one asking what size you 
are … They just say, ‘Well, you have feet. Here are shoes.’” This thesis was meant to explore 
new approaches to improve outcome in a variety of clinical conditions  involving stem cells. 
This chapter focuses on discussing the societal and economic impact, as well as future 
implementation possibilities of the findings.  
In Chapter 4, an animal study was carried out to assess the efficacy and safety of Neuro-cells, 
a standardized GMP-compliant and minimally manipulated product containing autologous 
stem cells from a patient’s own bone marrow (derived from initial experiments in Chapter 3), 
on spinal cord injury. The prevalence of spinal cord injury (SCI) worldwide is estimated at 2.5 
million cases and the financial burden per case is calculated to be between 200,000 - 
260,000 Euros/year, aside from the tremendous impact on the quality of life for the patient 
and surrounding people.1  The preclinical work in this chapter was part of a data set that has 
been used by the company Neuroplast to obtain an Orphan Drug Designation from the 
European Medicines Agency, allowing a fast track procedure for clinical trials. Currently 
phase I/II trials are being carried out. Neuroplast has raised €4 million in 2020 to proceed 
with a phase II/III study in 2021 and, if successful, obtain conditional market approval for 
treatment of patients suffering from spinal cord injury.  
The proof-of-principle study in chapter 6, involving electrical stimulation (ES) of ASC in order 
to enhance their angiogenic properties, can pave the way for a non-invasive, painless 
procedure for the patient to optimize the results of AFT. Several subsequent steps can be 
taken based on the information that was obtained. These steps include a proof of principle 
in animals in which the effect of ES on AFT is investigated with a focus towards volume 
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retention, graft composition and immunomodulation. Multiple groups can be included to 
determine whether it could be beneficial to pre-operatively treat the donor site (“priming 
the graft”), or the acceptor site (“pretreating the soil”). In addition, the effect of altering key 
stimulus parameters such as wave form, voltage, pulse duration and frequency needs to be 
studied to assess which ES protocol provides the best response. A basic problem however, 
may be the size of the graft when using small animals as this is not representative for 
humans. Graft survival due to plasmatic diffusion plays a bigger role and penetration of ES 
into the graft could be drastically different.  Therefore, a choice has to be made to either go 
for a big animal model where also the penetration of the ES into the tissue can be assessed, 
or go straight into a clinical trial. ES devices for use in humans have been on the market for 
years. However, the safety of applying ES after breast cancer has to be established, 
especially when the therapy is aimed at stimulating angiogenesis. Today, on average 3-4 
sessions of AFT are needed for a complete breast reconstruction after mastectomy. Every 
AFT is an operation with inherent risks, costs and recovery period. The reduction of the 
number of surgical procedures may therefore prove a valuable goal both financially and for 
the patient’s wellbeing and safety.   
This thesis further identified AFT as a potential treatment for neuropathic pain in Chapter 3. 
Neuropathic pain has a major influence on patients’ lives and the people around them, not 
to mention the economic burden for society when debilitating pain leads to chronic 
unemployment. Our clinical proof of principle study provides the basis for a subsequent 
clinical study in which the effects of AFT are analyzed more in depth. The effect of adding ES 
to the treatment protocol is another avenue that is of interest and could be investigated in a 
randomized, controlled clinical trial. Non-responders to established treatments of 
neuropathic pain could be ideal patients for this clinical trial.  
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Professor Barker, John, thank you for the opportunity to join the Frankfurt Initiative for 
Regenerative Medicine as a research fellow. Thanks to everyone in the team for teaching me 
different lab techniques, including electrical stimulation. Vincent, I enjoyed your fascinating 
views and our conversations on LARPing. Zach, bedankt voor de tijd die we samen hebben 
doorgebracht in Frankfurt, hopelijk lukt het je snel ertussen te komen bij de plastische 
chirurgie! 
And last but certainly not least, een zeer oprecht en gemeend dankjewel aan familie en 
vrienden. Een promotietraject verloopt slechts zelden van een leien dakje, en dat was bij mij 
ook zeker niet het geval. Het heeft een aardige tijd geduurd en in die periode zijn er 
natuurlijk ook wat minder leuke momenten geweest. Het zijn juist die momenten waarop ik 
altijd bij jullie terecht kon. Of het nu gaat om een glaasje wijn of een desperados, barbecue, 
feestje of vakantie naar waar dan ook, dit zijn de momenten die tellen. Voor iedereen die ik 
tot mijn vriendengroep mag rekenen, het volgende: “…is everybody happyyyyyy?” En proost 
op nog veel meer mooie momenten in de toekomst.  
Lieve mam, wat heb jij het toch maar fantastisch voor elkaar gekregen voor mij en Jop. We 
zijn nooit iets tekort gekomen en altijd stond je voor ons klaar. Dikwijls heb je jezelf hierbij 
weggecijferd, terwijl jij zelf ook keihard aan de weg timmerde. Met veel trots heb je de 
ontwikkeling van onze (school)carrières gevolgd, en soms maakte je je misschien een beetje 
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zorgen, maar nu is het moment daar dat beide zoons gepromoveerd zullen zijn. Moeder 
bedankt voor alles, ik ben trots op jou.  
Beste Pap en Suus, bedankt voor alle support door de jaren heen. Het doorzettingsvermogen 
en harde werken komt gelukkig van geen vreemde. Ook jullie toonden veel interesse in de 
stand van zaken en waren niet vies van een hapje of drankje om bij te kletsen met 
bijbehorende gezelligheid. Maar pap, nu met het afmaken van dit boekje gaat een scala aan 
smoesjes verdwijnen en wordt het wel tijd dat we echt gaan sporten.  
Mijn kleine grote broertje Jop. Beetje jammer dat je mijn idee hebt gekopieerd om plastisch 
chirurg te worden en het dan ook nog voor elkaar krijgt eerder te promoveren en aan je 
opleidingstraject te beginnen. Grapje natuurlijk, al hebben wel veel mensen hier naar 
gevraagd. Ik ben juist enorm trots op wat je bereikt hebt en zeer zeker nog gaat bereiken. Je 
doorzettingsvermogen, gecombineerd met precisie, top 3% attitude, humor en social skills 
gaan je nog ver brengen. Oh, en je fameuze danspasjes. Het is erg fijn om iemand dichtbij te 
hebben die dezelfde weg bewandelt, zodat we vaak en makkelijk kunnen sparren. Bij onze 
bruiloft was je “best man” en dat blijf je ook. Ik kijk uit naar onze toekomstige samenwerking 
bro! 
Opa Harry en oma Ietje, opa Jos en oma Truus. Hartelijk dank voor de talloze fijne 
momenten die Jop en ik bij jullie hebben mogen doorbrengen. Altijd stonden jullie voor ons 
klaar. Het is zeer spijtig dat onze beide opa’s onze promoties hebben moeten missen, want 
wat waren ze altijd trots, en iedereen mocht dat horen.  
Beste Frans, ik kan je niet genoeg bedanken voor de mooie tijden en vrolijke herinneringen. 
Van spaarpot vol kleingeld voor de kermis tot mijn eerste (en volgende) auto’s. Je hebt me 
veel geleerd over allerlei facetten van het leven en hebt me meer dan eens uit de brand 
geholpen. Jop zei het al, maar ook ik meen het als ik zeg dat ik hoop ooit eens wat terug te 
kunnen betekenen.  
Lieve schoonfamilie, John, Shireen, Mitchell, Jordy, oma Riet en oma Poemie. Bedankt voor 
jullie warmte, support en dat jullie altijd voor ons klaar staan, no matter what. Naast alle 
gezelligheid en klushulp zijn jullie er ook voor onze kids. Ik kan geen betere schoonfamilie 
wensen! 
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Mees en Miles, mijn lieve kids. Wat hou ik ontzettend veel van jullie en wat doet een 
glimlach soms goed na een drukke dag. Mees, ik ben enorm trots op je, zelfs als we weleens 
mopperen. Je doet het fantastisch op school, bent erg begaan met de medemens, hebt een 
heerlijk karakter en zorgt heeeel goed voor je broertje Miles. Miles, lekker mannetje, wat is 
het een genot om je te zien opgroeien. Je bent een kleine boef. Al sta je nu net pas op het 
moment om zelfstandig te gaan lopen, ik kan niet wachten om samen echte mannendingen 
te gaan doen.  
Lieve lieve Djin, het zit er eindelijk op! Jij bent van allen de grootste motivator geweest, die 
altijd achter me heeft gestaan, maar die in de loop van het promotietraject ook het meeste 
heeft moeten verduren. De LAT-relatie toen ik in Frankfurt zat, de piekmomenten voor 
deadlines, frustraties bij misgelopen experimenten, alle momenten waar rekening mee 
gehouden moest worden zoals de tripjes naar het lab voor tijdspecifieke experimenten en ga 
zo maar door. Het lastige aan onderzoek is dat je werkdag nooit echt af is, er is altijd nog wel 
iets dat kan gebeuren of in mijn geval dat in mijn hoofd rond speelde. Dat heeft de nodige 
quality time gekost en die wil ik toch nu wel echt weer gaan inhalen. Dat heet, als jij in het 
vervolg tijd hebt, want met je nieuwe baan staat je een grote uitdaging te wachten en voor 
mij begint ook weer een nieuw avontuur. Maar, zoals je er voor mij bent geweest zo wil ik 
jou ook steunen. Je bent een top moeder en een fantastische echtgenote. Lieverd, ik hou 
van je en ben trots op je. Cheers to the future, op nog vele vele mooie jaren samen! 
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